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ABSTRACT OF THE DISSERTATION
THE ROLE OF ID3 AND PCB153 IN THE HYPERPROLIFERATION AND
DYSREGULATION OF LUNG ENDOTHELIAL CELLS
by
Mayur Doke
Florida International University, 2018
Miami, Florida
Professor Quentin Felty, Co-Major Professor
Professor Deodutta Roy, Co-Major Professor
Uncontrolled growth of vascular stem cells as a result of endothelial-mesenchymal
transition is considered to cause hyper-proliferative vascular remodeling in severe
pulmonary arterial hypertension (PAH) patients. Hyperplastic intimal growth is one of
the causes of closure of the lumen of pulmonary arterioles. This abnormal vessel
remodeling leads to the progressive increase in pressure of the pulmonary arterioles
causing severe PAH. Environmental factors, including polychlorinated biphenyls (PCBs),
are considered to be involved in hyper-proliferative vascular remodeling because genetic
makeup can only explain about 10% of severe PAH cases. PCB involvement in lung
toxicity has received attention because (i) they have been reported to accumulate in the
lung; (ii) PCBs produce pathological vascular remodeling in the experimental model;
high levels of PCBs are found in human lung tissue; and (iii) epidemiological studies
show the association between lung toxicity and PCBs; and prevalence of hypertension
and elevated concentrations of particularly PCB153. ID3 is an important determinant of
mitogen and reactive oxygen species-induced G1→S phase cell cycle progression.
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Although there is, still there is a critical gap in understanding the molecular
mechanism(s) of pulmonary proliferative vascular remodeling associated with PCB
exposure in humans and the role of the transcription regulator ID3. Our overall objective
was to investigate ID3 mediated transcriptional reprogramming as a driver of PCB153induced pathological proliferative vascular remodeling. Stable ectopic expression of ID3
in lung endothelial cells contributed to endothelial-mesenchymal transition (EndMT), cell
proliferation, and cell migration. To determine the molecular mechanism by which ID3
contributes to hyper-proliferative endothelial cells, we investigated ID3 transcriptional
reprogramming using ChIP-Seq and RNA-Seq technology. We show here for the first
time that ID3 is part of a more general mechanism of transcriptional regulation. We
identified 19 genes whose RNA was differentially expressed in ID3 overexpressing cells.
In summary, our data demonstrated that PCB153 and/or ID3 induces proliferation of lung
endothelial cells via transcriptional reprogramming. Discoveries from these findings will
lay the necessary groundbreaking work for testing the efficacy of ID3 antagonists for the
prevention and treatment of pathological vascular remodeling as well as provide a new
paradigm by which PCBs may contribute to lung vascular toxicity.
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CHAPTER 1 Literature Review
This chapter has been partially published:
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1

Introduction

The overwhelming increase in the global incidence of pulmonary disease and its
associated complications such as insulin resistance, atherosclerosis, obesity, and
degenerative disorders including dementia constitutes a serious public health problem.
Since some of the endocrine disruptors are lipophilic chemicals with long half-lives, they
tend to bioaccumulate in the lipid rich tissue of exposed populations. Elevated exposure
to these chemicals may predispose susceptible individuals to metabolic perturbative
disorders by increasing the proliferation of the cells. The Inhibitor of DNA
Binding/Differentiation-3, a member of the ID family of transcriptional regulators, has
been shown to play a role in adipogenesis, angiogenesis and vasculogenesis. Therefore,
ID3 may influence obesity and vascular dysfunction in response to environmental factors.
This literature review will highlight the current understanding of how ID3 may contribute
to complex chronic diseases like pulmonary artery hypertension via metabolic
perturbations. Based on the increasing number of reports that suggest chronic exposure
and accumulation of endocrine disrupting chemicals (EDCs) within the human body are
associated with vascular disorders, we will also consider the impact of these chemicals on
ID3. Improved understanding of the ID3 pathways by which exposure to EDCs can
potentiate complex chronic diseases in populations with vascular disorders and metabolic
disorders (obesity, metabolic syndrome, and glucose intolerance) will likely provide
useful knowledge in the prevention and control of complex chronic diseases associated
with exposure to environmental pollutants.

2

Toxic EEDs exposure to humans
Estrogenic endocrine disruptors (EEDs) are compounds that alter hormone
production or function including phytoestrogens, heavy metals, and anthropogenic
chemicals. More specifically, EEDs include compounds such as genistein, arsenic, DES,
PCBs, phthalates, and Bisphenol A (BPA). Polychlorinated biphenyls (PCBs) are manmade aromatic chlorinated hydrocarbons. PCBs have been used commercially since 1930
in various industrial applications like transformers, capacitors, plasticizers, paints,
lubricants, and surface coatings because of their distinct physicochemical properties like
low electrical conductance, fire resistance, and chemical inertness. PCBs consists of 209
congeners (Ballschmiter & Zell, 1980; Rigaudy, Klesney, & International Union of Pure
and Applied Chemistry, 1979), which have been manufactured as complex, and multiple
mixtures of congeners by the progressive chlorination of batches of biphenyl until a
particular PCB congener was achieved. As PCBs are lipophilic, they tend to
bioaccumulate in nature. Moreover, the half-life of PCBs is about 2–6 years (Shiraia &
Kissel, 1996). PCBs can able to accumulate in lipid-rich tissues of living organisms
(ASTDR, 2000a; Matthews & Dedrick, 1984a). In humans, half of dry weight of the
brain consist of lipids which make the brain lipid-rich organ after adipose tissue
(Betsholtz, 2015). Moreover, lungs also harbor surfactant lipid composition, mainly disaturated phosphatidylcholine and cholesterol (Veldhuizen, Nag, Orgeig, & Possmayer,
1998). PCBs being lipophilic in nature, conjugate with lipoproteins in plasma and cell
membrane lipids and then eventually accumulate in the tissues of liver and lung (ASTDR,
2000a; Elabbas et al., 2014; European Food Safety Authority, 2005). PCBs are lipophilic
and chemically stable in nature so they can pass through any cell membranes and enter
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into the nuclear compartment to bind estrogen receptors (Kimbrough & Krouskas, 2003;
Safe, 1994). Although Stockholm Convention on Persistent Organic Pollutants has
banned the production of PCBs in 2001, researchers have shown many evidences of
bioaccumulation of PCBs in the ecosystem and food chain. Low chlorinated (1-4Cl)
PCBs are volatilized into air, and highly chlorinated (5–9Cl) PCBs accumulate in food,
soil, sediments, and humans (Dobson et al., 1993; Selene & Chou, 2003). Aquatic
sediments are main reservoirs of high chlorinated PCBs and concentration of PCBs
increases in the air due to evaporation from water to air which is always greater in
summer than in winter, because these parameters increase with temperature (Per &
Anderss, 1987). Lungs are a highly vascularized organ and receives chemicals from
blood through food and air; hence, it is vulnerable to chemical toxicants.
Bioaccumulation of PCBs can increase the inflammation in vascular injury which has
been shown to promote crosstalk between different organ systems, leading to
inflammatory disease pathologies (Achour et al., 2017; He et al., 2017; Lasserre et al.,
2009; Wahlang et al., 2017). Moreover, several studies have shown higher levels of
PCBs in breast, lung, and liver tissues (ASTDR, 2000a; Chao, Wang, Lin, & Chung,
2006; Elabbas et al., 2014; European Food Safety Authority, 2005; Grimm et al., 2015;
Polder et al., 2003). In addition to this, our secondary analysis of The National Health
and Nutrition Examination Survey (NHANES) data from 1999-2004, we found that
exposure to PCBs increases the risk of PAH in the U.S. population ≥ 20 years old. The
concern over adverse health effects from human exposure to PCBs has led to
investigations of non-dioxin-like polychlorinated biphenyls (NDL-PCBs), dioxin-like
PCBs (DL-PCBs), together with polychlorinated dibenzo-p-dioxins (PCDDs) and
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polychlorinated dibenzofurans (PCDFs) in foods and the effects of the consumption of
these contaminated foods. The Joint FAO/WHO Expert Committee on Food Additives
(JECFA) committee has identified seven PCBs called as “indicator PCBs” (JECFA,
2007). These PCBs are divided into two groups of NDL-PCBs and DL-PCBs depending
on the site of chlorine substitution on the phenyl rings. Six out of these seven are NDLPCBs (PCB 28, PCB 52, PCB 101, PCB 138, PCB153, and PCB 180), and one is a DLPCB (PCB 118). DL-PCBs bind strongly to the aryl hydrocarbon receptor (AhR) due to
their planar structure (Bjermo et al., 2013). The higher chlorinated NDL-PCBs congeners
are more stable and tend to bioaccumulate in greater concentration within the food- chain
and particularly foods of animal origin like fish and fish products, milk, eggs, and meat
products (Albro & Fishbein, 1972; ASTDR, 2000a; Elabbas et al., 2014; European Food
Safety Authority, 2005; JECFA, 2007). Out of six NDL-PCBs, PCB153 showed higher
half-life compared to other five PCBs which is about 14.4 years and has a very slow rate
of biotransformation (Chen, Luo, Wong, & Chen, 1982; Matthews & Dedrick, 1984b;
Ritter et al., 2011a). It has already been shown by epidemiological and experimental
studies the association of PCB153 with metabolic disorders (Mullerova et al., 2008;
Wahlang et al., 2013). We and others have shown that PCB153 increases oxidative stress
or reactive oxygen species (ROS) that mediate hyper-proliferation of endothelial cells
(Felty & Porther, 2008a; Mueller, Baudler, Welzel, Böhm, & Nickenig, 2002). However,
ubiquitous exposure to weaker endocrine disruptors such as PCBs and BPA are more
likely to occur in humans. NHANES data provide information about the U.S population
in demographic, dietary, physical examination, laboratory, and questionnaire data (
Centers for Disease Control and Prevention, 2017). The analysis of NHANES survey data
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showed that there is strong association between exposures to EDCs and risk of PAH.
Moreover, meta-analysis of Gene Expression Omnibus (GEO) and NHANES data
demonstrated PCB geometric mean concentrations found higher levels in people at risk of
PAH than people not at risk of PAH (Assaggaf, 2017). Interestingly, the limits of
detection (LODs) of PCB153 showed higher risk of PAH than other PCBs based on
Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL
Registry) scoring methods (Benza et al., 2012) (Assaggaf, 2017).
EEDs signaling mechanism
Epidemiological studies have reported that women who received hormone
replacement therapy (HRT) show higher risk to PAH when compared to women with no
HRT (Irey, pathology, & 1973, ; Kleiger, Boxer, Ingham, Chest, & 1976, ; Morse, Horn,
& Barst, 1999). Researchers have shown the involvement of estrogen in vascular and
pulmonary disorders (Khalil, 2013). 17β-estradiol (E2) signaling occurs through both
genomic (nuclear) and non-genomic (extra-nuclear) pathways (Heldring et al., 2007;
Shanle & Xu, 2010). Nuclear estrogen receptors consist of ERα and ERβ while
membrane estrogen receptors (mERs: GPER, GPR30, ER-X, and Gq-mER) are mostly G
protein-coupled receptors (Bondar, Kuo, Hamid, & Micevych, 2009; Filardo, Quinn,
Bland, & Frackelton, 2000; Gorosito, Lorenzo, & Cambiasso, 2008; Lagrange,
Ronnekleiv, & Kelly, 1997; Qiu et al., 2003; Skipper et al., 1993; Toran-Allerand et al.,
2002). Relative binding affinities of ortho, para-DDE, hydroxylated PCB, BPA, and DES
have been shown to be significantly weaker than E2 in binding to nuclear ERs and mERs
like GPR30 (Bonefeld-Jorgensen, Andersen, Rasmussen, & Vinggaard, 2001; Korach,
Sarver, Chae, McLachlan, & McKinney, 1988; Nadal et al., 2000; P. Thomas & Dong,
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2006; Watson, Bulayeva, Wozniak, & Finnerty, 2005). Moreover, EEDs have been
shown to mimic estrogenic activity and interfere with the endocrine system through these
receptor signaling pathways (Diamanti-Kandarakis et al., 2009; Rasier, Parent, Gérard,
Lebrethon, & Bourguignon, 2007; Zsarnovszky, Le, Wang, & Belcher, 2005). This has
been suggested to be a result of the higher exposure to estrogen (Austin et al., 2009).
Moreover, many idiopathic pulmonary arterial hypertension (IPAH) registries reported
that females are more prone to PAH than men (Badesch et al., 2010b; Humbert et al.,
2006). Estrogen causes multiple effects through ERα and/or ERβ in PAH-associated
pathways (Massaro, Clerch, & Massaro, 2007; Patrone et al., 2003).
Pulmonary arterial hypertension
Pulmonary artery hypertension is complex and a multifactorial disease characterized by
the multifactorial interaction of genetic, behavioral, and environmental factors. PAH is a
progressive disease caused by narrowing or tightening of the pulmonary arteries. The
right side of the heart becomes enlarged due to the increased strain of pumping blood
through the lungs which leads to the common symptoms of PAH (breathlessness, fatigue,
weakness, angina) (Genetic and Rare Diseases Information Center (GARD), 2009). In
addition to this, hypertension and elevated triglyceride levels, obesity also constitute the
metabolic and biochemical risk factors of vascular dysfunction (Kopeć et al., 2017). PAH
is characterized by endothelial damage, increased pulmonary vascular resistance, and
right heart failure. The estimated prevalence of PAH is 15–50 cases per million (Peacock,
Murphy, McMurray, Caballero, & Stewart, 2007) and has an annual incidence of 1–2
cases per million people in the US and Europe (Gaine & Rubin, 1998). Interestingly, it is
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2-4 times more prone in women than men (Badesch et al., 2010a). Researchers have
shown molecular level interactions associated with PAH pathogenesis include:
inflammation, uncontrolled vascular growth, and formation of obliterative vascular
lesions (Irey & Norris, 1973). Epidemiological studies have shown that the incidence of
PAH is more common in overweight and obese individuals with a BMI greater than 30
kg/m2 (Badesch et al., 2010a). PAH mainly occurs in pulmonary artery which carries the
blood from the right ventricle of the heart to the lungs for oxygenation. The pulmonary
artery is divided into three layers- the outermost layer is known as the tunica externa, is
mainly made of collagen fibers. Underneath that, the artery is lined by the tunica media,
which is made up of smooth muscle cells. The innermost layer is called as the tunica
intima. This layer is mainly made up of endothelial cells. These endothelial cells maintain
a balance between vasodilation and vasoconstriction. The hollow internal cavity through
which the blood flows is called the lumen. Increased proliferation and progressive
migration of endothelial cells further results in intimal fibrosis. In the late stage of disease
progression, the formation of plexiform lesions as shown in Figure 1. Progressive
reduction of the blood flow leads to high pulmonary arterial pressure defined to be at
least 25 mm Hg at rest or 30 mm Hg with exertion measured by right heart
catheterization. According to the Dana Point classification system, PAH is classified into
five groups. Group 1- Pulmonary arterial hypertension, Idiopathic (“primary pulmonary
hypertension”) and secondary to systemic disorders.
Group 2- Pulmonary hypertension due to left heart disease (pulmonary venous
hypertension)
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Group 3- Pulmonary hypertension associated with respiratory disease and/or hypoxia
COPD, Interstitial lung disease, OSA
Group 4- Chronic thromboembolic/embolic pulmonary hypertension
Group 5- Pulmonary hypertension from unclear mechanisms.
The Mayo clinic in Florida did retrospective chart review study of patients from January
1990 to October 2013 with PAH characterized by right heart catheterization (N = 640).
The study revealed that 39% of PAH patients were associated with some form of
metabolic risk factors like diabetes mellitus and obesity (Ussavarungsi, Thomas, &
Burger, 2015). Researchers studied the PAH patients lung tissues sample and microarray
data of those samples revealed decreased expression or mutation of bone morphogenetic
protein receptor type II (BMPR2) (Du et al., 2003; Hamid et al., 2009; Machado et al.,
2001). BMPR2 is associated with TGF-beta superfamily of ligands which regulates
signaling of downstream genes like the transcription factor peroxisome proliferatoractivated receptor γ (PPARγ) and its downstream effectors, apolipoprotein E (ApoE) and
adiponectin (Yang et al., 2002). PPARγ is best known for its role in glucose metabolism
and adipogenesis (He et al., 2003; Hevener et al., 2003; Lehrke & Lazar, 2005). Earlier
studies have also shown that patients with metabolic syndrome are associated with
defective BMPR2 signaling. Together these studies help connect PAH with metabolic
syndrome through dysregulated BMPR2 pathway. BMPR2 is known to regulate multiple
important pathways like endothelin-1, MCP-1, and eNOS (Farber & Loscalzo, 2004;
ITOH et al., 2006).
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Figure 1. Pathological pulmonary arterial remodeling. (Revised from Gaine S.
JAMA 2000;284:3160-3168).
A mechanism of pulmonary arterial hypertension development. Sequence of events that
leads from endothelial cell initial proliferation give rise to intimal and medial
hypertrophy, neo vascularization of arterioles and complex vascular lesions.
Transcription regulator ID3
Transcriptional regulation by ID3 ultimately functions to increase cell
proliferation and preserve multipotency. ID3 mediated gene regulation governing these
processes in endothelial stem cells provide a possible explanation for how ID3 promotes
vascular perturbations (Kaplan et al., 2015). ID3 protein-protein interactions occur via the
helix loop helix (HLH)-motif. ID3 protein interactions block the DNA binding activity of
basic HLH (bHLH) transcription factors encoded by the genes TCF3, TCF4, and TCF12.
TCF3 gene encodes for E12, E47 proteins. TCF4 gene encodes for E2-2, and TCF12
gene encodes for HEB proteins in humans (Murre, McCaw, & Baltimore, 1989). E12,
E47, E2-2 and HEB proteins are class I bHLH proteins that possess the basic DNA
binding domain. These E proteins specifically recognize and bind to Ephrussi-box (Ebox) sequences (CANNTG) on the DNA (Lazorchak, Jones, & Zhuang, 2005; Sun,
2004). ID3 has been most often reported to interact with proteins encoded by the TCF3
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gene (Benezra, Davis, Lockshon, Turner, & Weintraub, 1990). ID3 protein-protein
interactions can regulate transcription by E-proteins preventing their binding and
subsequent activation of target gene promoters (Benezra et al., 1990). ID3 has frequently
been described throughout the literature as an inhibitor of gene expression. For example,
ID3 promotes cells to pass through cell cycle checkpoints by inhibiting the expression of
cell cycle inhibitor gene p21Cip1 as shown in Figure 2 (Taylor et al., 2006a). However,
ID3 can also act as a positive transcriptional regulator depending on the cellular context.
E-proteins suppress the expression of embryonic genes OCT4, SOX2, and NANOG
leading to cell differentiation (Bensellam, Montgomery, Luzuriaga, Chan, & Laybutt,
2015). As shown in Figure 2, ID3 can increase the expression of these embryonic genes
by repressing TCF3. We have demonstrated that ectopic overexpression of ID3 in
endothelial cells increased OCT4 and SOX2 expression and the acquisition of the
vascular stem cell signature: CD133+ VEGFR3+ CD34+ (Das, Voelkel, & Felty, 2015).
Based on these findings, ID3 can maintain undifferentiated cells by increasing the
expression of embryonic pluripotency factors via repression of TCF3. Since ID3 is a
transcription regulator of genes involved in both cell proliferation and stemness, EEDs
may facilitate the uncontrolled proliferation of adipocytes through ID3 contributing to
pulmonary or metabolic disorders.
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Figure 2 - ID3 regulates a variety of cellular processes
This includes cellular growth, senescence, apoptosis, differentiation, angiogenesis,
and neoplastic transformation. This Figure illustrates the ID3 interaction with E
proteins. The ID3 protein controls transcription of genes like p21Cip1, OCT4, SOX2,
and NANOG by binding to the E-proteins and preventing them from interacting with
the E-box sequence on the DNA.

ID3 and EEDs
The molecular factors that contribute to endocrine disruption have yet to be
fully elucidated. The ID (inhibitor of differentiation) family of small proteins consists of
four proteins (ID1-ID4). ID1 and ID3 have been shown to regulate cell growth, selfrenewal, senescence, angiogenesis, and neurogenesis (Benezra et al., 1990; Lasorella,
Benezra, & Iavarone, 2014; Zebedee & Hara, 2001) (Duncan, DiCicco-Bloom, Xiang,
Benezra, & Chada, 1992; Ellmeier & Weith, 1995; Jen, Manova, & Benezra, 1997).
Depending on the cellular context, ID1 and ID3 have been shown to exhibit overlapping
functions as dual gene knockout combinations have demonstrated redundancy (Lyden et
al., 1999a). ID1 and ID3 have been shown to be co-expressed in early development of
cell cycle progression, angiogenesis, and neurogenesis in the mouse model (Duncan et
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al., 1992; Ellmeier & Weith, 1995; Jen et al., 1997). Amongst PCB congeners, PCB153
has been found to be one of the largest contributors to total PCB body burden in humans
(Mullerova et al., 2008; Wahlang et al., 2013). We have previously demonstrated that
PCB153 modulates ID3 expression and phosphorylation (Das & Felty, 2014c). ID3 is
highly expressed in the embryonic tissue and highly proliferating and undifferentiated
adult cells (Lyden et al., 1999b). We and others have shown that PCB153 increases
oxidative stress or ROS that mediate ID3 expression (Felty & Porther, 2008b; Mueller et
al., 2002). Exposure to estrogenic chemicals have been shown to increase ROS in the
nucleus in which they modify the surrounding DNA necessary for transcriptional
activation of cell growth genes (Okoh, Felty, Parkash, Poppiti, & Roy, 2013; Parkash,
Felty, & Roy, 2006c; Perillo et al., 2008). In other words, ROS that we have already
shown to be induced by treatment with PCB153 may be involved in ID3 mediated
transcription regulation. EEDs have been shown to increase ROS production in
adipocytes. Di-(2-ethyl hexyl)phthalate (DEHP) increased ROS in rat adipocytes (Rajesh,
Sathish, Srinivasan, Selvaraj, & Balasubramanian, 2013). Mitochondria are a major
source of ROS production in mammalian cells (Wang, Zhang, Lu, & Liu, 2015).
Although other endogenous ROS sources besides mitochondria such as NADPH oxidase
exist, we have shown that estrogenic chemicals increase mitochondrial ROS (Felty et al.,
2005). Furthermore, the presence of ERα and ERβ in mitochondria may potentially be
targets of EEDs contributing to oxidative stress (Chen, Delannoy, Cooke, & Yager, 2004;
Chen, Eshete, Alworth, & Yager, 2004; Monje & Boland, 2001). Although there is
evidence linking EEDs exposure to increased mitochondrial ROS, it is unclear whether it
is responsible for redox sensitive phosphorylation of ID3 upon exposure to PCB153.
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Exposure to EEDs may also exert negative health effects by altering epigenetic
marks including DNA methylation and histone acetylation ultimately influencing gene
expression in lung tissues. Epigenetic transgenerational effects has been demonstrated in
animals exposed to EEDs: BPA and phthalates (Manikkam, Tracey, Guerrero-Bosagna,
& Skinner, 2013). Early life exposures to EEDs like DES and PCB153 are known to alter
DNA methyltransferase activity (Wu, Zhou, & Ohsako, 2006). Since altered DNA
methylation have been found in PCB153 exposed cells (Sales et al., 2013), it is
biologically plausible that chromatin modifications including acetylation/deacetylation of
histones are another way for ID3 to regulate transcription. ID proteins have been shown
to promote acetylation and transcriptional activity by recruiting histone acetyltransferase
(HATs): i) CREB-binding protein (CBP), ii) p300 (E1A binding protein p300), and/or
P300/CBP-associated factor (PCAF) to the chromatin (Knowell et al., 2013). Moreover,
ID proteins interact with another chromatin modifying protein, ZRF1 (Aloia, Gutierrez,
Caballero, & Di Croce, 2015). These evidences suggest that ID3 may regulate
transcription through interactions with both transcription factors and chromatin
modifying proteins.
ID3 and Vascular Diseases
ID3 involvement in vascular disease has been studied together with the
lipoxygenase (12/15-LO) which is known to generate pro-inflammatory changes in blood
vessels that precede the development of atherosclerosis (Chakrabarti, Cole, Wen, Keller,
& Nadler, 2009). 12/15-LO is an important mediator of vascular smooth muscle cells
(VSMC) growth and its growth-promoting effects were shown to be mediated by ID3
transcription (Butany, Ahluwalia, Nair, & David, 2004). Increased expression of 12/15-
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LO in the vessel wall enhanced ID3-dependent cell proliferation, fibronectin deposition,
and neointimal formation. Population-based studies have found SNP (single nucleotide
polymorphisms) rs11574 in the coding region of the human ID3 gene associated with
subclinical atherosclerosis in the Diabetes Heart Study (Doran et al., 2010). ID3 SNP
rs11574 showed a significant association of coronary artery disease for Caucasians and to
a lesser extent African Americans and Hispanics (Manichaikul et al., 2014). Ectopic
expression of ID3 in VSMC regulates the cell cycle (Yang et al., 2013). ID3 has also
been shown to play a complex role with atherosclerosis. ID3 expression is increased by
hyperlipidemia and oxidized LDL (Taylor et al., 2006b). ID3 regulates angiotensin II and
carotid intima-media thickness. Angiotensin

II promotes hyperplasia through

upregulating ID3 (Phillip & Iii, 2009). The ID3 SNP could be a potential loss of function
mutation if it inhibits the functioning of E proteins, thus being an atheroprotective factor.
As shown in Figure 3, ID3 may impact vascular cell dysfunction leading to intimal
lesions. ID3 stimulates visceral adipose vascular endothelial growth factor A (VEGFA)
expression, depot expansion, and microvascular blood volume (Cutchins et al., 2012).
ID3 promotes angiogenesis in high fat diet - (HFD -) induced visceral adiposity (Cutchins
et al., 2012). ID3 KO shows a protective effect from HFD induced visceral fat depot
expansion. Furthermore, HFD-induced VEGFA expression in visceral adipose tissue was
completely abolished by loss of ID3. BMP9 induces both ID1 and ID3 which are
necessary for induction of Ephrin B2 (Kim, Peacock, George, & Hughes, 2012). A
summary in Figure 4 shows an ID3 signaling pathway involved in vascular
malformations. Similar to adipocytes, ID3 induced VEGF overexpression and Ephrin B2
downregulation may be involved in endothelial cells.
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Epigenetic imprinting of vascular progenitor or endothelial stem cells by ID3 in
individuals exposed to EEDs is another plausible mechanism based on the following
evidence. Specifically, we postulate that EEDs can induce ROS-mediated ID3
phosphorylation and acetylation, histone acetylation, and DNA base oxidation
collectively that control expression of ID3 target genes involved in vascular cells
programming. This in turn controls the fate and epigenetic footprints of vascular
progenitor cells. Reactive oxygen species like H2O2 are highly diffusible molecules. In
addition to affecting ID3 signaling pathways, ROS can also facilitate histone acetylation
and oxidize nuclear DNA resulting in chromatin modification. These modifications are
significant because transcription in eukaryotes occurs in the context of DNA, packaged
into chromatin. The basic unit of chromatin is the nucleosome, in which DNA is wrapped
around the core histones H2A, H2B, H3, and H4. Acetylation of lysine in the histone tails
can facilitate the opening of repressive chromatin structures in promoter regions to
provide access for the transcription regulator ID3. In support of our concept that both
histone acetylation and ROS-mediated DNA oxidation control the transcription of EEDinduced genes, we and others have shown that E2 and PCB153-induced ROS in the
nucleus, particularly H2O2, modify the surrounding DNA (Okoh, Deoraj, & Roy, 2011;
Parkash, Felty, & Roy, 2006a; Perillo et al., 2008). It has been recently shown that DNA
oxidation through recruiting 8-oxoguanine–DNA glycosylase triggers chromatin and
DNA conformational changes that are essential for estrogen-mediated transcription of
genes (Perillo et al., 2008). ROS generating agents and inflammation have been shown to
modulate chromatin-bound hSirT1 deacetylase activity on the promoters of several genes
(Adcock, Cosio, Tsaprouni, Barnes, & Ito, 2005; Brunet et al., 2004; Moodie et al., 2004;
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Pediconi et al., 2009). Taken together, EEDs through induction of ROS may increase
histone acetylations by post-translational activation of acetylases and oxidation of DNA
bases, which are necessary for ID3-mediated transcription regulation of target genes
involved in vascular and metabolic complications.
Given the significant role of ID3 in stemness, it is possible that EEDs exposure
may contribute to an increase in vascular progenitor cells. Epigenetic changes mediated
by ID3 in the stem cells may ultimately increase the total number of endothelial cells that
can be produced by an individual. Subsequent environmental exposures of these
susceptible individuals who have a higher number of endothelial stem cells, to begin
with, may potentially lead to pathological vascular remodeling including plexiform
lesions.

Figure 3- ID3 molecular mechanism and vascular diseases.
Summary illustration of ID3 signaling involved in vascular disease pathogenesis. ID3
signaling can lead to neointimal lesions or vascular remodeling by transcriptional
regulation of the target genes described above (up- and down regulated genes by ID3).
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Figure 4 - ID3 involvement in arteriovenous malformation.
Summary of experimental studies showing impact of ID3 in vascular cell dysfunction.
ID3 involved in VEGFR higher expression by inducing BMP9 and downregulation of
Ephrin B.
Interaction of ID3 and EEDs
In order to investigate how environmental exposures, affect human health at
genetic and protein level, we used the Comparative Toxicogenomic Database (CTD).
CTD is a public website, and research tool that consists of scientific data illustrating
chemical-gene interactions and chemical-disease associations. CTD includes in vitro and
in vivo data studies describing relationships between chemicals, genes, and diseases. The
database was used to manually curates information about EEDs–gene/protein
interactions, EEDs–disease and gene-disease associations. We used these public
databases to investigate the role of ID3, especially in various metabolic pathways. This
tool can be used to decipher gene-environment or gene-EEDs interactions involved in the
generation of vascular diseases.
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We initially selected PCB as a chemical and chose hypertension as the disease.
Our search results showed 29 genes associated with both the hypertension and PCBs.
Because ID3 is our candidate gene, we created a list of genes related to ID3 and PCBs.
We established that 38 genes are associated with this group in Table 1. Furthermore, we
show an interaction between these genes, we additionally inputted them into STRING, a
database of recognized and predicted protein-protein interactions. The interactions
contain direct (physical) and indirect (functional) associations which stem from
computational prediction, interactions aggregated from other (primary) databases, and
from knowledge transfer between organisms. As seen in Figure 5 STRING provides a
network of these proteins and furthermore provides a pathway description for the
mutually represented proteins (Szklarczyk et al., 2015a). We created Table 2 with the
help of STRING network, and it shows that the involvement of the ID3 protein in the
various pathway.
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PCBs and Hypertension related
genes

ID3 and PCBs related genes

ABCA3
BMPR2
CAV1
CBLN2
CCL1
CCL2
CXCL8
EDN1
EIF2AK4
FBLN5
FOXO1
GUCY1A1
HDAC1
HDAC4
HDAC5
HIF1A
HTR2B
KCNMA1
LOX
NOS3
NPPB
PRKG1
RETNLA
SLC31A1
SLC6A4
SMAD9
SOD2
TGFA
TNF

ATF3
CDK2
CNOT3
CSK
E2F4
ELSPBP1
EMX1
FHL2
GATA4
GNB2
ID3
MLX
MYOD1
NPHP4
PUF60
RND1
SMURF2
SREBF1
TCF3
TCF4
UNK
ZNF3
ZNF408
ZNF626
FAM74A1
ID4
IKBKG
NKX2-5
PAX5
PRDM14
SAP30
TCF12
VHL
CBFA2T2
COPS5
COPS6
COPS7A
ELOC

Table 1- Genes involved ID3 -PCBs and PCBs -hypertension.
CTD network curated information about genes involved in PCBs–ID3 protein
interactions, PCBs–hypertension and ID3- hypertension associations.
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Figure 5 - STRING network illustration of proteins involved in ID3 - PCBs
and PCBs -hypertension.
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Table 2- Summary of functional enrichments involved in the genes related to ID3 PCBs and PCBs - hypertension

Figure 6 - Central Hypothesis of study
The diagram represents central hypothesis, which is based on background information
Conclusion and Rationale of the Study
and earlier studies. We hypothesize that the exposure of PCB153 increases ID3
expression. ID3 may be involved in vascular reprogramming and hyperproliferation of
endothelial cells.
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ID3 has been shown to promote vascular disorders in experimental models.
Studies have reported associations between endothelial or vascular dysfunction in PAH
and exposure to EEDs: BPA, DES, and PCBs. Based on the evidence discussed in this
review, elevated exposure to EEDs or unopposed increase in the body burden of
estrogens may increase the expression of the transcription regulator ID3. We propose that
ID3 may be an additional molecular risk factor for vascular perturbations or PAH from
environmental exposure to estrogenic chemicals. Emerging evidence demonstrated that
ID3 can regulate mitochondrial function and morphology associated with changes in the
expression of electron transport chain complex components and transcription factor A,
mitochondrial (TFAM) (Bensellam, Montgomery, Luzuriaga, Chan, & Laybutt, 2015b).
We have previously shown that ER independent mitochondrial ROS signaling contributes
to the growth of cells treated with 17β-estradiol (Felty et al., 2005; Felty & Roy, 2005;
Parkash, Felty, & Roy, 2006b). Therefore, ID3 mediated vascular programming of
mitochondria may be dysregulated by exposure to EEDs and increase susceptibility to
PAH or vascular disorder. In addition, the ID3 dependent production of cytokines and
recruitment of macrophages in lung tissue are suggested to play an important role in the
inflammatory process to enhance susceptibility to complications.
In closing, we have systematically reviewed the existing evidence to illustrate the
association between ID3, EEDs, & PAH. Furthermore, we extended this understanding of
how ID3 and vascular perturbations by environmental factors such as EEDs can increase
the risk of PAH. Research is warranted to better define the influence of EEDs and ID3
alongside gene-environment interactions on PAH. A better understanding of how ID3 &
EEDs affect the risk of PAH may open up new avenues for prevention and treatment of
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diseases. We have shown previously that PCB153 and natural estrogen 17β-estradiol
increase ID3 expression in endothelial cells. Based on our findings, we postulate that ID3
is a molecular target of EEDs like PCB153 in lung tissue and a better understanding of
this relationship may help to explain how EEDs can lead to the transcriptional
programming of deviant endothelial cells. Thus, the purpose of this dissertation will be to
discuss the current understanding of ID3 in vascular reprogramming and to consider the
potential for PCB153 to influence susceptibility to pulmonary or vascular disorders via
ID3 signaling as shown in Figure 6.
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CHAPTER 2

Lung endothelial cell dysfunction from exposure to polychlorinated biphenyl 153
(PCB153) contributes to lung toxicity.
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Abstract
ID3, a transcription regulator, has been shown to contribute to the aggressive spread of
endothelial cells by facilitating the generation of tumor blood vessels. Tumor vascular
cells characterized as CD133+ endothelial stem/progenitor cells are associated with poor
prognosis in lung cancer and pulmonary artery hypertension. Previously, we have shown
that ID3 overexpression reprograms adult endothelial cells to acquire vascular stem
markers including CD133. However, little is known regarding the molecular contribution
of ID3 to tumor vascular reprogramming and how this may impact the aggressive growth
of lung cancer. In the current project, we evaluated ID3 mediated vascular
reprogramming upon PCB exposure. This idea is consistent with the literature, which
shows that PCBs accumulate in the human lung; PCBs produce pathological vascular
remodeling; high levels of PCBs are found in human lung tissue; and epidemiological
studies associating lung toxicity with PCBs. Recent studies identify PCB153 as one of the
largest contributors for total PCB body burden in humans. Using human lung endothelial
and smooth muscle cells, we exposed ID3 overexpressing and vector control cells to
PCB153. We observed a significant increase in cell proliferation as determined by the
BrdU incorporation assay and Fluorescence activated cell sorting (FACS) analysis.
Similarly, a 3D HuBiogel model, which mimics in vivo conditions, showed a significant
increase in size and number of vascular spheres upon PCB153 treatment. Pluripotent
vascular stem cells showed the loss of VE-cadherin and gain of MMP9, N-cadherin, and
vimentin, which are markers of endothelial-mesenchymal transition. In summary, our
findings show that persistent environmental pollutant PCB153 induces ID3 expression
that plays a critical role in regulating survival and hyper-proliferation of lung endothelial
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cells. Implications of our research include a new paradigm by which PCBs may
contribute to lung vascular toxicity through pathological vascular remodeling and/or
angiogenesis.
Key words- ID3, endocrine disruptors, Lung endothelial cells, plexiform lesions.
IntroductionPCBs are ubiquitous man-made aromatic chlorinated hydrocarbons considered as an
organic persistent pollutants. Being lipophilic in nature, PCBs have been shown to bioaccumulate in the food chain and tissues of living organisms. High levels of PCBs are
found in human lung tissue and epidemiological studies have shown the association of
lung toxicity by chronic exposure to PCBs. PCB153 is one of the 209 congeners of the
PCBs most often found in human foods and lipid-rich human tissues. PCB153 has been
shown to be involved in pathological vascular remodeling and selective bioaccumulation
in lung in the experimental models. Our earlier study on investigation of the effects of
exposure of PCB153 to primary cells, human umbilical vein endothelial cells (HUVECs)
and normal human dermal fibroblasts (NHDF) demonstrated PCB-induced ROS
contributed to neovascularization in endothelial cells dysfunction (Das & Felty, 2015;
Doke, Felty, & Das, 2017). Epidemiological studies have reported that women who
received hormone replacement therapy (HRT) show higher risk to PAH when compared
to women with no HRT (Irey et al., 1973 ; Kleiger et al., 1976; Morse et al., 1999). In
addition to this, women are 2-4 times more prone to pulmonary disorder or PAH than
men (Badesch et al., 2010a). So, the extra estrogen or synthetic estrogen present in the
form environmental pollutants maybe responsible for pulmonary vascular disease in
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humans. Since, the aerosols or vapors containing highly lipophilic PCBs may enter
through inhalation and tend to accumulate in lipid rich tissues like lungs, brain and breast
(ASTDR, 2000b). Epidemiological studies have associated PCBs with cardiovascular
disease (Perkins, Petriello, Newsome, & Hennig, 2016). Therefore, the present study
aims to investigate the effect of environmental pollutants on neo-vascularization in
human pulmonary lung endothelial cells, which are exposed to environmentally relevant
concentrations (ppb) of PCB153, and physiological concentrations of 17β-estradiol.

Materials and Methods
Cell culture and treatment conditions
Primary cells, Human pulmonary microvascular endothelial cells or human lung
endothelial cells (HPMEC-ST1.6R). HPMEC cells were maintained in DMEM-F12
medium supplemented with 5% FBS. Cells were cultured at 37 ºC in a humidified
atmosphere with 5% CO2. We also used pulmonary smooth muscle cell line (SMC)
purchased from Lonza Inc.
Estrogenic chemical treatments
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB
blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in
occupationally exposed individuals (Wassermann, Cucos, & Miller, 1979). Our
unpublished data showed a significant increase in PCB- induced vascularization with
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PCB153 concentrations of 10–100 ng/mL. Based on known PCB blood levels from
occupational exposure and our preliminary results; we chose a PCB dose of 100 ng/mL
(∼0.3 µM) to expose endothelial cells. Our previous studies also showed endothelial cell
proliferation and vascular tube formation at physiological doses of 17β-estradiol (Das &
Felty, 2014a; Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+
were exposed to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′hexachlorobiphenyl (PCB153) were purchased from AccuStandard (NewHaven, CT) and
dissolved in dimethyl sulfoxide (DMSO). All other chemicals and reagents were
purchased from Sigma (St. Louis, MO).
ID3 overexpression
The HPMEC cells were stably transfected with either Precision LentiORF for ID3
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and
selected cells that overexpressed ID3 with blasticidin S (5 mg/mL) as per manufacturer’s
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy.
Cell migration assay
The cell migration assay was performed to quantify and compare the rate of migration of
cells between wild-type lung endothelial cells and ID3 overexpressing lung endothelial
cells. Lung EC and lung EC ID3+ cells were cultured in DMEM-F12 media with 5% fetal
bovine serum in six-well plates to create a confluent monolayer, and an equal size scratch
was created by manually scraping the cell monolayer with a sterile plastic p200-pipette
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tip in the middle area of the well as a line. Then lung EC and lung EC ID3+ cells were
treated with 0.1% DMSO as a control, E2 (100 ng/mL), PCB153 (100 ng/mL) and
combination treatment of E2 + PCB153 in separate wells and incubated in growth
medium for 12h. The initial cell migration quantification was performed on images
collected 0h after scratching when the scratch size had stabilized. Additional images were
collected randomly from the scratched areas at 6 and 12h after scratching. Pictures were
taken under a microscope at 40X magnification and the results were analyzed using
ImageJ Launcher. This experiment was carried out in triplicate.
Endothelial spheroid assay
HPMEC and HPMEC ID3+ cells were suspended in serum-free DMEM/F12 (1:1) culture
medium supplemented with B27. For EC spheroid formation, approximately 100–150
HPMEC and HPMEC ID3+ cells were seeded separate well in an ultra-low attachment
96-well plate (Corning Inc. Lowell, MA) followed the published protocol of our
laboratory (Das & Felty, 2014a). The effect of estrogenic chemical PCB153 was
determined by pre-treating the cells with 100 ng/mL E2 2h prior to exposure with 100
ng/mL (∼0.3 µM) PCB153 on the day of seeding cells. Endothelial spheroids were grown
for 10 days in liquid culture in the absence or presence of PCB153. A total of 15
endothelial spheroids with a minimum diameter of 50 µm were counted in each
experimental group. Pictures were taken on 5d and 10d after seeding. We counted
number and size of spheroids on 5d and 10d. Data were analyzed by ANOVA; Turkey
HSD test for multiple comparisons.
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MTT assay
To determine the effect of E2 and extra estrogen environmental pollutant PCB153 on the
metabolic activity of lung endothelial cells, we performed cell viability and cell
proliferation assays. For cell viability measurement, we performed MTT assay which is
colorimetric assay and measures the metabolic activity of cells. Actually, MTT is a
tetrazolium dye known as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
NAD(P)H-dependent oxidoreductase enzymes present in mitochondria of metabolically
active and dividing cells. This enzyme catalyses tetrazolium dye and converts into
insoluble formazan, which gives a purple colour (Berridge & Tan, 1993; Berridge, Herst,
& Tan, 2005). The intensity of the purple colour that can be measured at an optical
density (OD) of 590 nm and its proportional to a number of metabolic active cells. We
seeded HPMEC and HPMEC ID3+ cells with 50% confluence in 96 well clear walled
plate. We allowed the cells to grow for 24h in 5% FBS culture medium. After 24 hours,
we gave treatments, 0.1% DMSO (control), E2 (100 ng/mL), PCB153 (100 ng/mL) and
combination treatment of E2 + PCB153 to make total volume 100 µL in each well. We
measured the metabolic activity of cells after 48h with the addition of MTT dye and
evaluating the purple colour intensity at 590 nm.
SRB assay
The sulforhodamine B (SRB) assay is used for measurement of the total cellular protein
content of adherent cells in a 96-well format. This assay is useful in the determination of
cellular proliferation and growth. We seeded HPMEC and HPMEC ID3+ cells with 50%
confluence in 96 well clear-walled plate. We allowed the cells to grow for 24h in 5%
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FBS culture medium. After 24 hours, we gave treatments, 0.1% DMSO (control), E2
(100 ng/mL), PCB153 (100 ng/mL) and combination treatment of E2 + PCB153 to make
total volume 100 µL in each well. After an incubation of 48h, cell monolayers were fixed
with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye
is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye
is dissolved in 10 mM Tris base solution for OD determination at 590 nm using a
microplate reader (Vichai & Kirtikara, 2006).
BrdU assay- BrdU assay is a direct method for evaluation of cell proliferation. In this
rapid method, Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) a synthetic
nucleoside that is an analogue of thymidine gets incorporated into DNA synthesis of
proliferating cells. It is a suitable method for detection and quantification of the
stimulatory effect of environmental chemicals (Russo et al., 1984). For BrdU assay, we
used Roche’s kit and followed the manual instructions.
We seeded HPMEC and HPMEC ID3+ cells in 5% FBS DMEM F-12 media with 50%
confluence and cultured with addition of BrdU in 96 well clear-walled plate. After 24
hours, we gave treatments, 0.1% DMSO (control), E2 (100 ng/mL), PCB153 (100
ng/mL) and combination treatment of E2 + PCB153 to make total volume 100 µL in each
well. After an incubation of 48h, cell monolayers fixed with FixDenat. Followed by
fixation we added anti- BrdU-POD, which binds to BrdU in newly synthesized DNA.
This immune complex detected by a plate reader at 450 nm.
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Western blot
Whole cell lysates were prepared with lysis buffer containing 25 mM Tris-HCl buffer
(pH 8.0), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 8 mM b-glycerophosphate, 2.5 mM
sodium pyro- phosphate, 10 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and 10 ml/ml
protease inhibitor cocktail (Sigma-Aldrich) followed the published protocol of our
laboratory (Das & Felty, 2014a). Proteins were quantified using the Bradford assay
reagent (Bio-Rad) according to the manufacturer’s instructions. Proteins (35–75 mg)
were separated by 15%, 7.5% and 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore). Membranes were blocked with 5% nonfat milk and incubated
with the following antibodies: ID3 (Cal BioReagent), VE-cadherin-2 antibody (F-4): sc515467 mouse monoclonal Ab, vimentin antibody (V9): sc-6260 mouse monoclonal Ab,
N-cadherin antibody (H-63): sc-7939 and B-actin (Cell Signaling). Antibody dilutions
used were according to manufacturer’s recommendations for detection by immunoblot.
Membranes were then incubated with horseradish peroxidase-conjugated secondary IgG
antibodies and visualized with ECL plus Western blot reagents (GE Healthcare,
Amersham). The membranes were re-probed for b-actin as a loading control.
Electrochemiluminescence (ECL) intensity of detected target proteins was imaged and
quantified with a Bio-Rad Versa Doc instrument. All immunoblots have completed a
minimum of three times for each experiment.
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Immunofluorescence
We seeded approximately 200–250 HPMEC and HPMEC ID3+ cells in 8 chambered
slide. We allowed the cells to grow for 24h. Then we gave treatment 0.1% DMSO
(control), E2 (100 ng/mL), PCB153 (100 ng/mL) in both the cell lines. Then we fixed
samples in 2% paraformaldehyde made in PBS for 15 minutes at room temperature.
Washed monolayer 2 times in PBS to remove residual paraformaldehyde, store samples
submerged in PBS at 4oC until use. Permeabilized cells with 0.1% Triton X-100 made in
PBS solution for 15 min. Washed monolayer 5 times with a PBS + 0.5% BSA (PBB).
Then blocked with 2% BSA for 45 minutes. Cells were then incubated with primary
antibodies and alexa fluor-conjugated secondary antibodies. The confocal fluorescence
images were scanned on a Nikon TE2000U inverted microscope. The DRAQ-5 was used
to label the nucleus. The confocal images were acquired on a Nikon C1 laser scanning
confocal

microscope

(Melville,

NY,

USA).

MMP-9

was

determined

by

immunofluorescent labelling with rabbit anti-MMP9 polyclonal antibody bs-4593R
(Alexa Fluor 566-conjugated secondary antibody). VE-Cadherin was determined by
immunofluorescent labelling with mouse monoclonal IgG1 sc-9989 (Alexa Fluor 633conjugated secondary antibody). Vimentin was determined by immunofluorescent
labelling with polyclonal goat IgG AF2105.
Zebrafish Xenograft
We purchased xenotransplantation Zebrafish embryos from Zebrafish International
Resource Center (ZIRC), University of Oregon, Eugene. Albino embryos are completely
transparent. Prior to injecting HPMEC and HPMEC ID3+ cells on 2 days post fertilization
(dpf), albino zebrafish were maintained at 28 ºC. During injection, zebrafish were
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anaesthetized with MESAB (0.5 mM 3-aminobenzoic acid ethyl ester, 2 mM Na2HPO)
and then placed in a 15 mm Petri dish on their sides on a ramp comprised of 1% agarose.
Approximately 50 HPMEC and HPMEC ID3+ cells were injected into the yolk sac and
zebrafish were then transferred in fresh fish water to an incubator and maintained at 37 ºC
for up to 7 days post injection (dpi) when the experiments were terminated and animals
were euthanized by overexposure to MESAB.
Assessment of temperature effect on zebrafish development
Normally, zebrafish are incubated at 28 ºC. To accommodate human EC proliferation, an
incubation temperature close to 37 ºC was desirable. We purchased xenotransplantation
Zebrafish embryos from Zebrafish International Resource Center (ZIRC), University of
Oregon, Eugene. Albino embryos are completely transparent. Prior to injecting HPMEC
and HPMEC ID3+ cells on 2 dpf, albino zebrafish were maintained at 28 ºC. During
injection, zebrafish were anaesthetized with MESAB (0.5 mM 3-aminobenzoic acid ethyl
ester, 2 mM Na2HPO) and then placed in a 15 mm Petri dish on their sides on a ramp
comprised of 1% agarose. Approximately 50 HPMEC and HPMEC ID3+ cells were
injected into the yolk sac and zebrafish were then transferred in fresh fish water to an
incubator and maintained at 37 ºC for up to 7 dpi when the experiments were terminated
and animals were euthanized by overexposure to MESAB.
Cell preparation for transplant
Cells were detached from the culture flask by incubating with 2 mL dispase (Invitrogen)
at 37 ºC for 45 min, pelleted by centrifugation at 2500 rpm for 5 min, and resuspended in
2.5 mL HBSS. Cells were labeled with CM-DiI, a lipophilic fluorescent tracking dye
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(Invitrogen). According to manufacturer’s instructions, CM-DiI is transferred from
mother to daughter cells but not between other cells. The cells were incubated with CMDiI dissolved in DMSO (final concentration: CM-DiI: 4.8 lg/mL, DMSO: 0.4%) for 4
min at 37 ºC, followed by 15 min at 4 ºC. CM-DiI labeled cells were loaded into a pulled
glass micropipette that was drawn on an electrode puller and then trimmed to form a
needle with a 15 μm internal and a ~18 μm external diameter. The microneedle was
attached to an air driven Cell Tram micro injector. The tip of the needle was inserted into
the animals and cells were delivered in a single injection. A sharp needle cut in the yolk
will reclose with little to no loss of contents. Any injection site in the yolk is suitable.
Using 30–100 milliseconds pulse time and 8 pounds per square inch (psi) positive
pressure, we optimized the number of cells injected at ~50, which we confirmed by
dispensing cells onto a microscope slide and visually counting. The volume of material
injected is approximately 20–50 nL. After injection, zebrafish were maintained for 1 h at
28 ºC, examined for the presence of a fluorescent cell mass of ~50 cells localized at the
injection site in the yolk sac, and then transferred to an incubator and maintained at 37
ºC. On 1 dpi, zebrafish were examined by fluorescence microscopy (Haldi, Ton, Seng, &
McGrath, 2006).
Flow Cytometry
For cell cycle analysis, cells were harvested, rinsed with PBS, and fixed in suspension in
73% ethanol for 20h at −20 °C. After incubation at −20 °C, the cells were washed with
PBS containing 1% BSA, stained with PI (10 μg/mL) in PBS containing RNase A (250
μg/mL), and incubated at 37 °C for 30 min in the dark before FACS analysis. Cell cycle
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distribution was analyzed with the Guava easyCyte™ using the CytoSoft software
program according to the manufacturer's instructions. The percent DNA content was
determined by FACS analysis using PI staining.
Statistical analysis
All experiments were performed at least three times and data are expressed as mean ±
standard deviation Graphpad prism version 5.01 was used to perform graphics and the
two-tailed student’s t-test was used to compare statistical significance. P<0.05 was set as
a statistical significance. Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
Results:
ID3 overexpression in wild type lung endothelial
We previously demonstrated that E2 treatment increased ID3 phosphorylation and ID3
protein stability; and that E2-induced cell proliferation was dependent on oxidant
sensitive ID3 signalling (Felty & Porther, 2008b). We have also demonstrated that
exogenous estrogen or estrogenic PCBs like PCB153 increases ID3 protein expression
which eventually gives stemness markers to the human cerebral microvascular
endothelial cell line HCMEC/D3 (Das & Felty, 2014c). Given the biological significance
of ID3 proteins for the maintenance of stemness, we asked whether overexpression of
ID3 could induce a molecular stem-cell signature in adult lung ECs HPMEC-ST1.6R cell
line. To direct this question, human HPMECs were transduced using an MOI of 25 with
either the Precision LentiORF for ID3 overexpression or control empty lentiviral vector
pLEX-JRED/TurboGFP according to the manufacturer's instructions. Cells were then
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seeded at clonal density and selected with blasticidin S (5 μg/mL). Cells that overexpress
ID3 will be selected for culture and referred to as HPMEC ID3+ as shown in Figure 7.

Figure 7. ID3 overexpression in Lung EC
HPMEC cells were stably transfected with Precision LentiORF for ID3 (Thermo
Scientific Open Biosystems). Selected cells that overexpressed ID3 with blasticidin S (5
mg/ml) as per manufacturer’s instructions. Cells expressing TurboGFP in HPMEC ID3+
cells were identified by fluorescence microscopy. We also shown phase contrast image of
HPMEC ID3+ cells along with it.

Cell migration (Wound healing) assay
In order to study and distinguish between the wild-type lung endothelial cell line HPMEC
and newly transfected stable ID3 overexpressed HPMEC ID3+ cell line, we did some
experiments to detect the phenotypic behaviour in these two cell lines. We evaluated the
effect of ID3 overexpression had on cell migration using a wound healing or cell
migration assay. A cell monolayer consisting of HPMEC wild type or HPMEC ID3+
overexpressing cell was mechanically scratched to create a wound. Then HPMEC and
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HPMEC ID3+ cells with wound were treated with 0.1% DMSO as a control, E2 (100
ng/mL), PCB153 (100 ng/mL) in separate wells and incubated in growth medium for 12
h, we examined the extent of wound closure up to 12h. We took images of wound healing
at 6h and 12h intervals. We analyzed the cell migration rate by using ImageJ Launcher
software. By measuring the wound area compared with the initial wound area, we
measured the number of cells migrated into scratched area. By measuring the migration
rate of both the cell lines, we found that the ability of HPMEC ID3+ cells to migrate to
the wound area was significantly greater than HPMEC cells. Images were captured after
the wound at the 6h interval. The number of HPMEC ID3+ cells migrated in the scratched
area were significantly (p < 0.0001) higher than HPMEC cells in 0.1% DMSO (control)
itself (Figure 8). Migration of HPMEC ID3+ cells was higher when compared to HPMEC
cells. Likewise, we saw that treatments of E2 (100 ng/mL) and PCB153 (100 ng/mL)
significantly increase the number of HPMEC ID3+ cells migrated in the scratched area (p
< 0.0001) compared to HPMEC cells. At the 12h interval, HPMEC ID3+ cells completely
migrated to the scratched area and filled out the wound in all treatments except
0.1%DMSO (control). In case of HPMEC cells, all treatments E2 (100 ng/mL), PCB153
(100 ng/mL) showed significant (p < 0.0001) results compared to 0.1% DMSO (control)
in terms of cell migration into scratched area (Fig. 8 and 9).
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Figure 8- Wound healing assay
Representative images showing migration of both lung EC & EC ID3+ cells. When both
the cells lines treated with control, E2 and PCB153. E2 and PCB153 increased the
migration rate of cells compared to control in 6h and 12h intervals. Magnification X200
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Figure 9- Cell migration
Higher migration of lung ECs overexpressing ID3. Experimental treatments: vehicle,
E2, PCB153. Treatments with E2 and PCB153 increased the migration of ID3
overexpressing lung ECs compared to control at 6h and 12h intervals. Graph shows
number of cells migrated in 6h and 12h intervals. Error bars represent the mean
number of cells migrated ± SD in 5 wells. E2 & PCB153= 100 ng/mL. **p<0.01
PCB153 & E2 vs DMSO for lung EC ID3+. Data were analyzed by ANOVA; Tukey
HSD test for multiple comparisons.

MTT, SRB and BrdU assay of HPMEC and HPMEC ID3+ cells
We tested the lung endothelial cell proliferation in presence of estrogenic chemicals by
MTT, SRB and BrdU assay. Since researchers have shown that lung endothelial cells
possess estrogen receptors, the HPMEC and HPMEC ID3+ cells were showing a
stimulatory effect in terms of cell proliferation and growth when they treated with E2
(100 ng/mL) and PCB153 (100 ng/mL). Our data revealed that treatments with E2 (100
ng/mL) and PCB153 (100 ng/mL) significantly increased cell growth when compared to
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vehicle control. Cell growth was determined by the MTT and SRB assays and
corroborated by BrdU assay. The data from SRB and BrdU assays reported that
treatments E2 (100 ng/mL), PCB153 (100 ng/mL) showed a significant increase in
numbers of cells compared to control. In terms of SRB assay, the total protein content of
treated cells was significantly higher than control. The BrdU assay data results showed
the synthesis of new DNA in proliferating cells was significantly higher in treatments
than control. These results show that PCB153 (100 ng/mL) drives endothelial cell
proliferation. In addition to this, we determined the contribution of ID3 to endothelial
proliferation upon treatment with E2 (100 ng/mL), PCB153 (100 ng/mL) than HPMEC
cells in the Figures 10, 11, and 12.
Since estrogenic chemicals like PCB153 shows their growth stimulating endothelial cell
survival effects on HPMEC and HPMEC ID3+ cells, we investigated signaling
mechanism action of PCB153. Felty et al. showed that PCB153 increases microvascular
lesions in HUVEC cells through ROS pathway. To address this question we assessed the
effects of ER blocker and ROS scavengers on HPMEC and HPMEC ID3+ cells in
presence of E2 and PCB153 treatment.
To investigate whether ER was involved in the E2 and PCB153-mediated
hyperproliferation of HPMEC ID3+ cell, cells were treated with the known ER
antagonist, tamoxifen. Tamoxifen is a nonsteroidal triphenylethylene derivative that
binds to the estrogen receptor (Jordan, et al., 1980.). It acts as a selective estrogen
receptor modulator. Although tamoxifen prevents the growth of estrogen-sensitive tissue,
the researchers have shown that tamoxifen treatment has been clinically effective in triple
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negative breast cancer patients (Adjuvant Trial Organisation, 1988). We treated HPMEC
and HPMEC ID3+ cells with single treatment of tamoxifen (5 µM) dose as wells as cotreatment with E2 + tamoxifen, PCB153 + tamoxifen. We carried out MTT, SRB and
BrdU assays and analyzed the data. We found that tamoxifen (5 µM) significantly
(P<0.01) inhibit the growth of cells in both the HPMEC and HPMEC ID3+ cell lines
compare to control. In addition to this, our data showed that co-treatment of E2
+tamoxifen and PCB153 + tamoxifen showed significant (P<0.01) reduction in growth of
cells compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively. These data
suggests that tamoxifen may be blocking metabolism and redox cycling of estrogen,
PCB153 and acts as free radical scavengers as previously reported by researchers in
MDA cell line which is triple negative breast cancer cell line (Arteaga, Villaseca,
Bianchi, Rojas, & Marshall, 2003) as shown in Figure 13, 14 and 15.
To determine whether E2 and PCB153 increases the number of HPMEC and HPMEC
ID3+ cells by either estrogen receptor or ROS signaling pathway. Fulvestrant is drug
treatment for hormone receptor-positive metastatic breast cancer in postmenopausal
women with disease progression following anti-estrogen therapy. It is a complete
estrogen receptor antagonist with no agonist effects, which in addition, accelerates the
proteasomal degradation of the estrogen receptor. We found the similar results like
Fulvestrant drug treatment. We carried out MTT, SRB and BrdU assays and analyzed the
data. We found that Fulvestrant (5 µM) significantly (P<0.01) inhibit the growth of cells
in both the HPMEC and HPMEC ID3+ cell lines compare to control. In addition to this,
our data showed that co-treatment of E2 + Fulvestrant, PCB153 + Fulvestrant showed
significant (P<0.01) reduction in growth of cells compared to E2 (100 ng/mL) and
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PCB153 (100 ng/mL) respectively (as shown in Figure 10, 11 and 12).
To investigate the E2 and PCB153 increases number and new DNA synthesis of HPMEC
and HPMEC ID3+ cells through ROS signaling, we used antioxidant like ebselen. It is an
organoselenium compound and acts as a mimic of glutathione peroxidase (Kumar, Bullet,
& Tomar, 2014). Interestingly, we found the similar results like tamoxifen and
Fulvestrant drug treatment. We carried out MTT, SRB and BrdU assays and analyzed the
data. We found that Ebselen (10 µM) significantly (P<0.01) inhibit the growth of cells in
both the HPMEC and HPMEC ID3+ cell lines compare to control. In addition to this, our
data showed that co-treatment of E2 + Ebselen, PCB153+Ebselen showed significant
(P<0.01) reduction in growth of cells compared to E2 (100 ng/mL) and PCB153 (100
ng/mL) (as shown in Figure 16, 17 and 18). ID3 overexpression increased the growth and
DNA synthesis of lung ECs upon exposure to mitogens PCB153 and E2. ID3
overexpression make these cells resistant to Tamoxifen, Ebselen and fulvestrant when
compared to vector alone. ID3 give these cells advantage so they grow or proliferate
more than vector.
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Fulvestrant

Figure 10- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+
cells using MTT assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased cell
growth. HPMEC and HPMEC ID3+ cells exposed to 17β-estradiol and/or PCB153. E2
& PCB153= 100 ng/mL. Graph of cell survival determined by MTT assay 24 h after
exposure. All treatment groups showed significant increase in growth b**p<0.01 for
HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs control. Fulvestrant (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both HPMEC
and HPMEC ID3+ cells compared to control. Co-treatment of E2+Fulvestrant
(c**p<0.01), PCB153+Fulvestrant (d**p<0.01) showed significant reduction in
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in
HPMEC cells. Co-treatment of E2+ Fulvestrant (e**p<0.01), PCB153+Fulvestrant
(f**p<0.01) showed significant reduction in growth of cells compared to E2 (100
ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were analyzed
by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 11- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+
cells using SRB assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by SRB assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Fulvestrant (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment
of E2+ Fulvestrant (c**p<0.01), PCB153 + Fulvestrant (d**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Fulvestrant (e**p<0.01),
PCB153 + Fulvestrant (f**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 12- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+
cells using BrdU assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by BrdU assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Fulvestrant (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Cotreatment of E2 + Fulvestrant (c**p<0.01), PCB153 + Fulvestrant (d**p<0.01)
showed significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153
(100 ng/mL) respectively in HPMEC cells. Co-treatment of E2 + Fulvestrant
(e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed significant reduction in
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in
HPMEC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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Tamoxifen

Figure 13- Measuring the effect of Tamoxifen on HPMEC and HPMEC ID3+
cells using MTT assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by MTT assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Cotreatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01),
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 14- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+
cells using SRB assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by SRB assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Cotreatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01),
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 15- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+
cells using BrdU assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by BrdU assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Cotreatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01),
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Ebselen

Figure 16- Measuring the effect of Ebselen on HPMEC and HPMEC ID3+ cells
using MTT assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by MTT assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL)
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 +
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 17- Measuring the effect of Ebselen on HPMEC and HPMEC ID3 + cells
using SRB assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by SRB assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100ng/mL)
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 +
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 18- Measuring the effect of Ebselen on HPMEC and HPMEC ID3+ cells
using BrdU assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by BrdU assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL)
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 +
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Smooth muscle cells (SMC)
Researchers have shown that presence of ERs in SMC and involvement of SMCs in
plexiform lesions and atherosclerotic plaque along with lung endothelial cells (Bennett,
1999; Doran, Meller, & McNamara, 2008; Rosenthal, 2001). We evaluated the
combination effect of E2 and PCB153 on SMC using MTT, SRB and BrdU assays.
Similar to lung endothelial cells, we seeded SMCs in a 96 well plate and gave treatments
E2 (100 ng/mL), PCB153 (100 ng/mL). The results showed that all treatments induced
significant (P<0.01) increase in numbers of SMCs compared to control. We also checked
the effects of tamoxifen, Ebselen and Fulvestrant treatment SMCs. We found out that
tamoxifen, Ebselen and Fulvestrant treatments significantly (P<0.01) inhibit the growth
of SMCs compare to control as wells as in treatments E2 (100 ng/mL) and PCB153 (100
ng/mL). Given the biological significance of ID3 proteins for the maintenance of
stemness, we questioned whether overexpression of ID3 could induce a molecular stemcell like a signature in adult lung SMCs cell line. To direct this question, human SMCs
were transduced using an MOI of 25 with either the Precision LentiORF for ID3
overexpression or control empty lentiviral vector pLEX-JRED/TurboGFP according to
the manufacturer's instructions. Cells were then seeded at clonal density and selected with
blasticidin S (5 μg/mL). Cells that overexpress ID3 will be selected for culture and
referred to as SMC ID3+ for Ebselen as shown in Figure 20, 21 and 22. Similarly, for
tamoxifen (as shown in Figure 23, 24 and 25) and Fulvestrant (as shown in Figure 26, 27
and 28).
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Figure 19- ID3 overexpression in Lung SMC
SMC cells were stably transfected with Precision LentiORF for ID3 (Thermo Scientific
Open Biosystems). Selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as
per manufacturer’s instructions. Cells expressing TurboGFP in SMC ID3+ cells were
identified by fluorescence microscopy. We also shown phase contrast image of SMC
ID3+ cells along with it.
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Ebselen

Figure 20- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using
MTT assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01
for SMC vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and
SMC ID3+ cells compared to control. Co-treatment of E2 + Ebselen (c**p<0.01),
PCB153 + Ebselen (d**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Cotreatment of E2 + Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey
HSD test for multiple comparisons.
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Figure 21- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using
SRB assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC
vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is estrogen
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+
cells compared to control. Co-treatment of E2 + Ebselen (c**p<0.01), PCB153 +
Ebselen (d**p<0.01) showed significant reduction in growth of cells compared to E2
(100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed significant reduction in
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in
SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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Figure 22- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using
BrdU assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is estrogen
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+
cells compared to control. Co-treatment of E2+ Ebselen (c**p<0.01), PCB153 +
Ebselen (d**p<0.01) showed significant reduction in growth of cells compared to E2
(100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed significant reduction in
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in
SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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Tamoxifen

Figure 23- Measuring the effect of Tamoxifen on SMC and SMC ID3+ cells using
MTT assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and
SMC ID3+ cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01),
PCB153 + Tamoxifen (d**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Cotreatment of E2+ Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD
test for multiple comparisons.
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Figure 24- Measuring the effect of Tamoxifen on SMC and SMC ID3 + cells using
SRB assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC
vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is estrogen
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+
cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01), PCB153 +
Tamoxifen (d**p<0.01) showed significant reduction in growth of cells compared to
E2 (100ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed significant
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL)
respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for
multiple comparisons.
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Figure 25- Measuring the effect of Tamoxifen on SMC and SMC ID3+ cells using
BrdU assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and
SMC ID3+ cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01),
PCB153 + Tamoxifen (d**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Cotreatment of E2+ Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD
test for multiple comparisons.
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Fulvestrant

Figure 26- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using
MTT assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and
SMC ID3+ cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01),
PCB153 + Fulvestrant (d**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Cotreatment of E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD
test for multiple comparisons.

74

Figure 27- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using
SRB assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC
vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is estrogen
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+
cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01), PCB153 +
Fulvestrant (d**p<0.01) showed significant reduction in growth of cells compared to
E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of
E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed significant
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL)
respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for
multiple comparisons.
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Figure 28- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using
BrdU assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and
SMC ID3+ cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01),
PCB153 + Fulvestrant (d**p<0.01) showed significant reduction in growth of cells
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Cotreatment of E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD
test for multiple comparisons.
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SU5416 treatment to HPMEC ID3+ and SMCs
Researchers have shown in vivo and in vitro studies of exposure to SU5416 reported to
produce endothelial stem cell markers in lung endothelial cells which give rise to lung
vascular lesions (Das et al., 2015). In addition to this, many PAH studies showed the
upregulated levels of ID3 protein in plexiform lesions (Yu, Wilson, Taylor, & Polgar,
2015). Therefore, we compared the endothelial types HPMEC and HPMEC ID3+ to
determine the effect of SU5416 exposure which is a chemical inducer of molecular stem
cell-like signature. We tested the lung endothelial cell proliferation in presence of
estrogenic chemicals and SU5416 by MTT, SRB and BrdU assay. We treated HPMEC
and HPMEC ID3+ cells with single treatment of SU5416 (1 µM) dose as wells as cotreatment with E2 + SU5416, PCB153 + SU5416. We carried out MTT, SRB and BrdU
assays and analyzed the data. We found that SU5416 (5µM) significantly (P<0.01)
induce the growth of cells in both the HPMEC and HPMEC ID3+ cell lines compare to
control. In addition to this, our data showed that co-treatment of E2 + SU5416, PCB153
+ SU5416, showed significant (P<0.01) increase in growth of cells compared to E2 (100
ng/mL) and PCB153 (100 ng/mL) respectively as shown in Figure 29, 30 and 31.
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Figure 29- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells
using MTT assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by MTT assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01),
showed significant increase in growth of cells compared to E2 (100 ng/mL) and
PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were analyzed by
ANOVA; Tukey HSD test for multiple comparisons.
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Figure 30- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells
using SRB assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100ng/mL. Graph of cell survival
determined by SRB assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01),
E2+PCB153 + SU5416 (h**p<0.01) showed significant increase in growth of cells
compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 31- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells
using BrdU assay
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17βestradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival
determined by BrdU assay 24 h after exposure. All the treatment showed significant
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01),
E2+PCB153 + SU5416 (h**p<0.01) showed significant increase in growth of cells
compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively in HPMEC ID3+
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.

Similarly, we tested the effect of SU5416 drug effect on SMCs. We found that SU5416
(5 µM) significantly (P<0.01) induce the growth of cells in the SMCs compare to control.
In addition to this, our data showed that co-treatment of E2 + SU5416, PCB153 +
SU5416, showed significant (P<0.01) increase in growth of cells compared to E2 (100
ng/mL), PCB153 (100 ng/mL) respectively as shown in Figure 32, 33 and 34.
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SU5416

Figure 32- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using
MTT assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT assay
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC
vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1 µM) is VEGF receptor
antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed
by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 33- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using
SRB assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC
vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1µM) is VEGF receptor
antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed
by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 34- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using
BrdU assay
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for
SMC vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1µM) is VEGF
receptor antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed
by ANOVA; Tukey HSD test for multiple comparisons.
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Endothelial spheroid assay
In spite of endothelial cells lined the innermost layer of artery grows in monolayer, cells
in plexiform lesions grow in the three-dimension structure resembles spheroid. These
cells do not follow characteristics of the cells, which grow in a monolayer. The cells
derived from tumour tissue alter their both genotype and phenotype characteristics once
they cultured in monolayer (Lee et al., 2006). Therefore, we tried to imitate the
conditions of tumour in vitro. In addition to this, recent data from our laboratory showed
that ID3 induced a molecular stem cell-like signature—CD133+ VEGFR3+ CD34+ in
microvascular ECs. We grew the cells in no FBS DMEM F-12 medium supplemented
with B-27 reduced growth supplement. We used a stem cell sphere-forming assay to
determine the effect of E2 and PCB153 on HPMEC ID3+ cells. HPMEC ID3+ spheroids
were bigger in diameter than HPMEC spheroids. We also found the treatment with
PCB153 (100 ng/mL) was statistically significant (P<0.01) than control HPMEC ID3+
spheroids in terms spheroid size and spheroid number. We found the similar results on
the 10th day, all the treatments the treatment with PCB153 (100 ng/mL) was statistically
significant (P<0.01) than control HPMEC ID3+ spheroids in terms spheroid size and
spheroid number as shown in Figures 35, 36 and 37.
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Fig 28. Schematic diagram of spheroid formation.

Figure 35- PCB153 increases spheroid formation
It shows pictures of spheroid. PCB153 increased the size and number of spheroid
compared to control in lung EC & lung EC ID3+. Scale bar= 10 µm.
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Figure 36- PCB153 increases spheroid number in HPMEC ID3+
In both lung EC & EC ID3+, PCB153 increased the number of spheroids compared to
control. Magnification X200. Graph shows quantification of spheroid number. Error
bars represent the mean sphere number ± SD in 5 wells. PCB153= 100 ng/mL. a
**p<0.01 for lung EC; b **p<0.01 for lung EC ID3+ vs control at day 10 as well as
*p<0.05 for lung EC vs control at day 10. Data were analyzed by ANOVA; Tukey
HSD test for multiple comparisons.
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Figure 37- PCB153 increases spheroid size in HPMEC ID3+
In both lung EC & EC ID3+, PCB153 increased the diameter of spheres compared to
control. Magnification X200. Graph shows quantification of spheroid diameter. Error
bars represent the mean sphere size ± SD in 5 spheres. PCB153= 100 ng/mL.
Representative microphotographs of treatment groups are shown inset. Error bars
represent the mean diameter of 5 spheroids ± SD. a **p<0.01 for lung EC; b **p<0.01
for lung EC ID3+ vs control at day 10 as well as *p<0.05 for Lung EC ID3+ vs control
at day 10. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.

Co-culture of HPMEC ID3+ and SMC ID3+ spheroid assayEarlier, researchers have shown the involvement of SMCs along with lung endothelial
cells in formation of plexiform lesions and tumors (Doran et al., 2008;. Lee et al., 1998).
We decided to culture HPMEC ID3+ cells with SMCs in 1:8 ratio to get the best results
(in press). We seeded and co-culture HPMEC ID3+ cells with SMC ID3+ in 1:8 ratio in an
ultra-low attachment 96-well plate with no FBS DMEM F-12 medium supplemented with
B-27 reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153
(100 ng/mL) in separate wells. We analyzed the data on 5th and 10th day. We found that
all the treatments E2 (100 ng/mL), PCB153 (100 ng/mL) were statistically significant
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(P<0.01) than control spheroids in terms spheroid size and spheroid number as shown in
Figures 38-43.

Figure 38- Images of co-culture of HPMEC ID3+ and SMC ID3+ spheroid at day5
PCB153 and E2 increased the size and number of spheroid compared to control. Scale
bar= 10µm.
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Figure 39- PCB153 and E2 increased the size of spheroid co-culture of HPMEC
ID3+ cells with SMC ID3+ at Day5
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153
(100 ng/mL) in separate wells. E2 and PCB153 increased the diameter of spheres
compared to control. Magnification X200. Graph shows quantification of spheroid
diameter. Error bars represent the mean sphere size ± SD in 15 spheres. E2 &
PCB153= 100 ng/mL. Representative microphotographs of treatment groups are
shown inset. E2 and PCB153= 100 ng/mL. **p<0.01 for Lung EC ID3+: SMC ID3+vs
control at day 5 Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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Figure 40- PCB153 and E2 increased the number of spheroid co-culture of HPMEC
ID3+ cells with SMC ID3+ at Day5
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 (100
ng/mL) in separate wells. E2, PCB153 treatments increased the number of spheroids
compared to control. Magnification X200. Graph shows quantification of spheroid
number. Error bars represent the mean sphere number ± SD in 5 wells. E2 & PCB153=
100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+ vs control at day 5 Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.

Figure 41- It shows pictures of co-culture of HPMEC ID3+ and SMC spheroid at
Day10
PCB153 and E2 increased the size and number of spheroid compared to control. Scale
bar= 10µm.
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Figure 42- PCB153 and E2 increased the size of spheroid co-culture of HPMEC
ID3+ cells with SMC ID3+ at day10
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153
(100 ng/mL) in separate wells. E2 and PCB153 increased the diameter of spheres
compared to control. Magnification X200. Graph shows quantification of spheroid
diameter. Error bars represent the mean sphere size ± SD in 15 spheres. E2 &
PCB153= 100 ng/mL. Representative microphotographs of treatment groups are
shown inset. E2 & PCB153= 100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+vs
control at day 10 Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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Figure 43- PCB153 and E2 increased the number of spheroid co-culture of
HPMEC ID3+ cells with SMC ID3+ at day10
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 (100
ng/mL) in separate wells. E2, PCB153 treatments increased the number of spheroids
compared to control. Magnification X200. Graph shows quantification of spheroid
number. Error bars represent the mean sphere number ± SD in 5 wells. E2 & PCB153=
100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+ vs control at day 10 Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Spheroid assay- MTT, SRB, BrdU assay
Proliferative vascular lesions have been studied extensively using the VEGF─receptor
antagonist, Sugen 5416 (SU5416), plus chronic hypoxia (SuHx) rodent model as shown
in Figure 44. Therefore, the aim of this study was to determine whether SU5416 exposure
of ECs become more sensitive to estrogen-induced cell growth. We exposed human
pulmonary endothelial cell line HPMEC ID3+ to SU5416 to select for a sub-population of
cells, which were then treated with 17β-estradiol and/or PCB153. We observed a
significant increase of 2-3 fold change in cell growth and proliferation as determined by
MTT, SRB, BrdU, analysis when SU5416 treated cells were exposed to estrogenic
chemicals as shown in Figure 45, 46 and 47.

Figure 44- Procedure of formation of spheroid by treatment of ID3+
overexpressing lung endothelial cells with SU5416 and then cultured these cells to
measure survival and growth.
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Figure 45- SU5416 treatment increased the survival and proliferation of HPMEC
ID3+ cells.
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells,
which were then grown with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol
and/or PCB153. Graph of cell survival determined by MTT assay of endothelial
spheroids 24 h after exposure. All the treatment showed significant increase**p<0.01
for HPMEC ID3+ vs control
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Figure 46- SU5416 treatment increased the survival and proliferation of HPMEC
ID3+ cells.
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells
which were then grown with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol and/or
PCB153. Graph of cell survival determined by SRB assay of endothelial spheroids 24 h
after exposure. All the treatment showed significant increase**p<0.01 for HPMEC ID3+
vs control
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Figure 47- SU5416 treatment increased the survival and proliferation of HPMEC
ID3+ cells.
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells
which were then grown with no FBS DMEM F-12 medium supplemented with B-27
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol and/or
PCB153. Graph of cell survival determined by BrdU assay of endothelial spheroids 24 h
after exposure. All the treatment showed significant increase**p<0.01 for HPMEC ID3+
vs control
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Flow Cytometry

Figure 48- Analysis by flow cytometry of cell cycle profiles of HPMEC and HPMEC
ID3+
The distribution of cells in the different phases of the cell cycle was analyzed in absence
(control) or presence of PCB153 in both HPMEC and HPMEC ID3+ cell types.

97

The cell cycle is process in which cell undergo its division and duplication of its DNA
(DNA replication) to produce two daughter cells. The cell cycle consists of four distinct
phases: G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and
M phase (mitosis). G0 is a resting phase where the cell has left the cycle and has stopped
dividing. The cell cycle starts with this phase. G1 is first phase of interphase also called
as growth phase where cell prepares itself to go under cell division. The cell increases its
supply of proteins, increases the number of organelles (such as mitochondria, ribosomes),
and grows in size. The S phase starts when DNA synthesis commences; when it is
complete, all of the chromosomes have been replicated, i.e., each chromosome has two
(sister) chromatids. G2 phase occurs after DNA replication and is a period of protein
synthesis and rapid cell growth to prepare the cell for mitosis.
Our flow cytometry experiments revealed that approximately 82.4% of the DNA content
in HPMEC ID3+ resided in the G0/G1 phase compared to only 78.6% of the wild-type
cells. Thus, HPMEC ID3+ showed a statistically significant 4.7205% of difference and
1.04 -fold increase in G0/G1 phase cells (Fig. 48). The percentage of DNA content in S
phase decreased from approximately 8.1% in HPMEC to 2.1% in HPMEC ID3+. Thus,
ID3 significantly reduced the number of cells in S phase by more than 2-fold (Fig. 48).
The HPMEC ID3+ showed increase in percentage of DNA content in G2/M phase from
approximately 13.3% in wild-type cells to 15.5% in the HPMEC ID3+ population (Fig.
48).Our data suggest that in the HPMEC ID3+ population there is a significant increase in
the number of cells that reside in the G0/G1 phase which is indicative of proliferative
quiescence. Since a higher proliferative capacity may exhaust a stem cell population, this
observed increase in G0/G1 phase by HPMEC ID3+ may help to maintain a stem cell-like
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state by slowing cell cycle progression. Similarly, we found same trend in case of
treatment with PCB153 to HPMEC and HPMEC ID3+. When both the cells treated with
PCB153, we found that cells showed more DNA percentage reside in G0/G1 phase
compared to the control. In case of HPMEC cells, PCB153 exposure increased DNA
percentage from 78.6% to 90.4%. In case of HPMEC ID3+ cells, PCB153 exposure
increased DNA percentage from 82.4% to 95.2%. Since Felty et al. already shown, ID3
overexpression gives stemness character to the cells and stem cells reside longer in the
G0/G1 phase of the cell cycle. Proliferative quiescence is a state observed in stem cells
which reside longer in the G0/G1 phase of the cell cycle; and it has been hypothesized
that quiescence may prevent against the depletion of the stem cell population. Similarly,
we found the same effect in SMC and SMC ID3+ cells. SMC ID3+ cells showed that their
percentage of DNA reside more in G0/G1 phase and cells prepare for synthesis in S
phase. In addition, we found that the exposure to PCB153 increases percentage of DNA
in

G0/G1

phase

in

SMC

ID3+

compared
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to

control

(Figure

49).

Figure 49- Analysis by flow cytometry of cell cycle profiles of SMC and SMC ID3+
The distribution of cells in the different phases of the cell cycle was analyzed in absence
(control) or presence of PCB153 in both SMC and SMC ID3+ cell types.
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Western blot
Aim- To determine the effect of PCB153 on ID3 expression.
We seeded the HPMEC and HPMEC ID3+ cells in four 100 mm petri dishes each. We
added 0.1% DMSO (control), and PCB153 (100 ng/mL) to separate petri dishes. We
analyzed that combination treatment of PCB153 increase 2-3-fold change in ID3
expression in HPMEC ID3+ cells compared to control. PCB153 (100 ng/mL) treatment
showed significant (P<0.01) increased than control as shown in Figure 50. We have also
checked the expression of ID3 protein in SMC and SMC ID3+ cell line in Figure 51.
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Figure 50- PCB153 increases ID3 expression in HPMEC cells.
Detection of ID3 protein 17 KDa and Beta actin as a control 41 KDa in lung EC ID3+
cell line. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and
+

Secondary Ab- 1:10000. PCB153 = 100 ng/mL. HPMEC and HPMEC ID3 cells
treated with 0.1% DMSO (control), PCB153 (100 ng/mL). All the treatment showed
significant increase**p<0.01 for HPMEC ID3+ vs control. Antibody concentration =
0.1 mg
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Figure 51- ID3 expression in SMC and SMC ID3+ cells
Detection of ID3 protein 17 KDa and Beta actin as a control 41 KDa in lung SMC ID3+
cell line. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and
Secondary Ab- 1:10000. SMC and SMC ID3+ cells treated with 0.1% DMSO (control).
Antibody concentration = 0.1 mg.
EndMT markers expression in lung EC ID3+
Endothelial to mesenchymal transition (EndMT) is major event arrive when endothelial
cells dramatically alter their shape and motile behavior as they differentiate into
mesenchymal cells. In this process, cells detached from cell-cell junctions of neighboring
cells and basement membrane (Larue & Bellacosa, 2005). During this transition, cells
express and loose some protein markers. Interestingly, EndMT process is an integral part
of tumor cells metastasis in which cells show alteration in some protein markers.
Expression of VE cadherin, Vimentin, and Matrix metalloproteinase 9 proteins are the
hallmark of EndMT process. VE-cadherin (CD144) is a cell-adhesion protein that
maintains the cell-cell contacts (Kowalski, 2003). Matrix metalloproteinase 9 (MMP9) is
a zinc finger dependent enzyme cuts cell-cell and basement membrane contact and
promotes invasion, metastasis, and angiogenesis. Vimentin is cytoskeletal intermediate
filaments (IFs) protein and is expressed more in mesenchymal transition. It has been
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shown that Vimentin expression is also upregulated in wound healing in vitro culture
system (Hendrix, Seftor, Seftor, & Trevort, 1997; Liu, Lin, Tang, & Wang, 2015).
Moreover, Felty et al. 2014 showed that PCB153 along with ID3 over expression induced
cell migration and endothelial spheroid growth in HUVEC cells. They also showed that
ID3 overexpression regulates the upregulation of VEGFR3, which is marker of
angiogenesis and neovascularization. Hence, we investigated the role of ID3 in case
endothelial to mesenchymal transition of cells in presence of estrogenic chemical.
We seeded the HPMEC and HPMEC ID3+ cells in eight chambered slide and added the
treatments 0.1% DMSO (control) and PCB153 (100 ng/mL). We found that VE cadherin
expressed more in HPMEC cells compared to HPMEC ID3+ in control. Vimentin and
MMP-9 expressed more in HPMEC ID3+ cells compared to HPMEC cells. We also found
that vimentin and MMP-9 expression of HPMEC ID3+ cells was significantly higher in
PCB153 (100 ng/mL) than control as shown in Figure 52. We have also showed the
changes in expression of EndMT markers in ID3 overexpressing HPMEC cell line. We
observed gain of N-Cadherin, Vimentin and loss of VE-Cadherin in Figures 53, 54 and
55.
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Figure 52- Immunofluorescence. ID3 altered expression of VE-cadherin, vimentin,
and MMP-9 in lung endothelial cell line HPMEC ID3+.
Cells were exposed to vehicle or PCB153 100 ng/mL for 24h. (A-B) Stable expression of
ID3 showed a loss of endothelial marker VE-cadherin a characteristic of endothelial-tomesenchymal transition (EndMT). (E-F) ID3 increased expression of mesenchymal
marker vimentin. (I-J) ID3 increased expression of mesenchymal marker matrix
metalloproteinases 9 (MMP9).

Figure 53- Detection of N-Cadherin protein
Detection of N-Cadherin protein 132 KDa in HPMEC and HPMEC ID3+ cell line. Gel
percentage 7.5%. Sample loaded per well = 50 microgram. N-cadherin- (H-63): sc-7939
mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody concentration = 10
µg/50 µl
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Figure 54- Detection of VE-Cadherin protein
Detection of VE-Cadherin protein 130 KDa in HPMEC and HPMEC ID3+ cell line. Gel
percentage 7.5%. Sample loaded per well = 50 microgram. VE-cadherin-2 Antibody (F4): sc-515467 mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody
concentration = 10 µg/50 µl

Figure 55- Detection of Vimentin protein
Detection of Vimentin protein 51 KDa in HPMEC and HPMEC ID3+ cell line. Gel
percentage 10%. Sample loaded per well = 50 microgram. Vimentin Antibody (V9): sc6260 mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody
concentration = 10 µg/50 µl
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Zebrafish model to study role of ID3 in EC proliferation
Our main objective of this research is to investigate the in vivo role of ID3 in the
pathogenesis of proliferative vascular lesions in early stages of zebrafish embryos and in
xenograft tumors. The purpose of this study is to develop a zebrafish xenograft model of
metastasis by injecting Cancer Stem Cells (CSCs), or Tumor Initiating Cells (TICs)
isolated from ID3 positive or negative or ID3 target gene(s) expressing in vitro cultured
lung endothelial cells in early stages of zebrafish embryos. Endothelial cells in plexiform
vascular lesions (a pathological hallmark of PAH) have been characterized as hyperproliferative and apoptosis resistant, which is consistent with a neoplastic hypothesis.
This lesion is a major cause of high morbidity and mortality in severe end-stage IPAH
patients because the pulmonary vascular lesion (PVL) progressively obliterate pulmonary
arterioles and impinge upon the unobstructed vessels resulting in heart failure. Our
research over the past 10 years has uncovered that the disruption of mitochondrial ROS
production and redox signaling to nuclear regulatory pathways by estrogen or its
metabolite, 4- hydroxy-estradiol contribute to the development of vascular lesions. In
addition, our preliminary results in 2D and 3D model showed that ID3 seems to be
essential for generation of stem-like cells and EndMT and cell migration, but the targets
of ID3 gene are unknown. The present research is centered on the concept that activation
of dynamic "rheostat" molecules in CSCs, or TICs regulate gene networks of
chromosomal/genomic instability and they drive vascular lesion in pulmonary arterioles
involving oxidative stress, apoptosis, and stemness. In line with this overall paradigm, we
propose mechanistic studies targeting the redox response, involving ID3 gene shown to
induce oxidative stress, anti-apoptosis, stemness and genomic instability. The
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significance of the use of zebrafish model in this study is to identify the ID3 targets using
both genetic and biochemical analyses for their ability to promote or inhibit nonmalignant vascular lesions in vivo. Zebrafish embryos will be used to develop xenograft
vascular lesions to determine if essential effectors of ID3 and their potential targets are
relevant drug targets that may epigenetically drives the formation of non-malignant
vascular lesions from exposure to PCBs in vivo. Our data showed that HPMEC ID3+
cells after injection show migration through blood vessels to thoracic and head part of the
zebrafish as shown in Figure 56.

Figure 56- Proliferation and migration of a human lung EC ID3+ cell line in
zebrafish
The lung ECs ID3+ of xenotransplantation in zebra fish embryo (2 dpf) showed that
spread of the GFP fluorescent dye labeled lung ECs moved through blood vessels from
the site of injection to the region of secondary target organ for metastasis lesions. The
photomicrographs were captured by Nikon confocal microscopy. The treatment of
PCB153 on lung ECs ID3+ group showed the more migratory cells for adhesion, micro
invasion and metastasis. The red color showed injected all cells stained with the
fluorescent dye, CellTracker™ CM-DiI (stained both GFP and non GFP cells ) which
is well suited for monitoring all live cell movement in the blood vessel of the zebra
fish embryo. 400X).
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Discussion
In the present study, we determined PCB-induced neovascularization with the aim of
elucidating the role of environmental PCBs in lung endothelial dysfunction while focused
on ID3. Enhanced neovascularization has been implicated in the development of
plexiform lesions in idiopathic pulmonary arterial hypertension, and atherosclerotic
lesions in cardiovascular disease. It is evident that humans have been and will continue to
be exposed to PCBs due to deposition of harmful chemical contaminants in the
environment through chemical industries waste, landfills and incinerators (Tanabe, 1988).
PCB153 is included as a persistent non-dioxin-like polychlorinated biphenyl in PCB
congeners, which are abundantly present in the food-chain and the environment. PCB153
may cause deleterious public health effects because of their tendency to bioaccumulate to
high concentrations due to their slow elimination from the human body. In adults, the
estimated elimination half-life for PCB153 is 14.4 years (Ritter et al., 2011b).
Our lab earlier showed that the PCB153 induced ROS formation increases ID3 protein
expression in human microvascular endothelial cell line hCMEC/D3. We also showed in
our earlier studies that the higher expression of ID3 protein increases neovascularization
in human microvascular endothelial cells. The lung endothelial cells come into direct
contact with blood in lung microenvironment. The human blood carries many dissolved
gases, chemicals from environment, and these all directly come in contact with the
innermost layer of lung endothelial cells, which lead to form lesions. Therefore, in
presence of chemical inducers or inhibitors lung endothelial cells may undergo an
alteration in the phenotype. In the study, we investigated the effect of PCB153 on lung
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endothelial cells while focused on ID3. We exposed lung endothelial cells with PCB153
and studied the behavior of cells. In wound healing assay, our results showed that in
presence of PCB153 the rate of cells migration to the wound area was significantly higher
than control. In addition to this, in case of overexpressed ID3 lung endothelial cells
showed higher rate of cell migration when treated with PCB153 compared to wild type
cells. These results showed that overexpressed ID3 lung endothelial cells in presence of
environmental contaminant of PCB153 showed higher cell proliferation behavior than
wild type. To strengthen our claim regarding change in behavior of overexpressed ID3
lung endothelial cells, we did endothelial spheroid assay, which mimics plexiform lesion
formation in vivo model. We found that PCB153 increased the size and number of
spheroid significantly in lung ECs ID3+ compared to wild type lung EC. We also cultured
the spheroid from lung EC ID3+ cells and measured ell growth and proliferation
determined by MTT, SRB, BrdU, analysis. We found that PCB153 increased growth and
proliferation of lung EC ID3+ cells. Our western blot results also demonstrated the
growth and proliferation effect at molecular level. ID3 protein expressed significantly
higher when lung ECs ID3+ cells treated with PCB153. We also observed cell migration
behavior at molecule level with immunofluorescence assay. In this process, cells
detached from cell-cell junctions of neighboring cells and basement membrane (Larue &
Bellacosa, 2005). During this transition, cells express and loose some protein markers.
Interestingly, EndMT process is integral part of tumor cells metastasis in which cells
shows alteration in some protein markers. Expression of VE cadherin, vimentin and
Matrix metalloproteinase 9 (MMP9) proteins are hallmark of EndMT process. When we
exposed lung ECs ID3+ cells with PCB153, we found that higher expression of vimentin
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and MMP9 proteins. These results corroborate our hypothesis that environmental
chemical PCB153 increases proliferation of cells by increasing ID3 expression as well as
instigate stem cells like properties to lung EC cells.
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CHAPTER 3

The genome-wide mapping of ID3 target genes reveals the role of ID3 in the
proliferation and dysregulation of lung endothelial cells.
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Abstract
Background: ID3 is a key gene implicated in maintaining the stemness of embryonic and
adult stem cells, which lacks the basic DNA-binding domain. ID3 appears to re-activate
in several human cancers like NSCLC and in diseases such as PAH. However, the
detailed response programming of ID3 in HPMEC has not yet been defined.
Results: We show that overexpression of the ID3 gene in HPMEC cells increases cell
proliferation. We then comprehensively characterize the ID3 response program by an
integrated analysis using advanced genomic technologies including Chromatin
Immunoprecipitation Sequencing (ChIP-Seq) and RNA sequencing. Using ChIP-Seq
technology, we identified 2336 ID3 binding regions (ChIP peaks) in the HPMEC ID3+
(ID3 overexpressing HPMEC cell line) cells genome. ID3 binding regions with the
highest peak score demonstrated the sequence GAGAGAGAGAGAGAG that occurred a
total of 900 instances in 2493 ID3 binding regions. We then further with the help of
Genomic Regions Enrichment of Annotations Tool (GREAT) assigned biological
meaning to 2493 regions. GREAT associated 2336 regions with 2834 genes. RNA-Seq
analysis identified total of 1061 genes whose expression altered in response to ID3
overexpression in HPMEC cells. Out of 1061 genes, 63 genes showed significant (>1
log2 (FC)) fold change.

RNA Seq data demonstrated HSPA8, SH3BP5L, EEF2K

proteins were down-regulated and proteins like EGR1, TNFAIP3, and KLF10 were upregulated. Furthermore, the combination of ChIP-Seq and transcriptome data analysis
used as a compelling approach to decipher the regulation of gene expression with the help
of Binding and expression target analysis (BETA) software. Integration of ChIP Seq with
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differential gene expression data of RNA Seq to infer direct target genes of ID3 revealed
interesting findings, which includes total of 26 genes significantly regulated by ID3.
Conclusions: We present an integrated analysis of ChIP-Seq and RNA sequencing
representing the ID3 response program responsible for HPMEC cells proliferation. The
insights gained from our integrated analysis further our understanding of the potential
actions of ID3 in carcinogenesis and serve as a useful resource to further develop
pharmaceutical drugs targeting the ID3 protein.
Key words: endocrine disruptors, ID3 Lung endothelial cells, PAH, plexiform lesions.

IntroductionID3 is one of the members of the ID protein family, which consists of four genes (ID1–
ID4). ID3 does not have DNA binding domain and interacts with other proteins via helixloop-helix (HLH) motif. It has been reported that ID3 acts as a transcription regulator
which regulate transcription in a dominant-negative manner by dimerizing with basic
HLH transcription factors like E12, E47, E2-2, and HEB (Benezra, Davis, Lockshon,
Turner, & Weintraub, 1990; Doke, Avecilla, & Felty, 2018; Norton, 2000). ID3 is a
pleiotropic protein involved in the modulation of a variety of biological processes such as
cell differentiation, cell proliferation, cell cycle control, senescence, apoptosis or
angiogenesis, and metastasis (Lyden et al., 1999; Lyden et al., 1999b; Ruzinova &
Benezra, 2003). Previously, we have shown that ID3 overexpression reprograms adult
endothelial cells to acquire vascular stem markers including CD133. ID3 is mostly
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implicated in maintaining the stemness of embryonic and adult stem cells while its
expression is down-regulated as tissues mature (Lyden et al., 1999b). However, research
studies showed reactivation of ID3 expression in mature prostate and breast tissues
involved in aggressive growth of cancer (Gupta et al., 2007; Sharma, Patel, & Chaudhary,
2012). The proliferative ECs have been reported to be an aggressive endothelial
phenotype associated with a poor prognosis in non-small cell lung cancer and severe
idiopathic pulmonary arterial hypertension (Tanaka et al., 2003; Tuder, Groves, Badesch,
& Voelkel, 1994). We have also shown the exposure of E2 and EED like PCB153 to ECs
increases ROS. Since ID3 is redox sensitive gene, it acts an important determinant of
ROS-induced proliferation of E2 and PCB153 exposed ECs (Das & Felty, 2014a, 2014d;
Felty & Porther, 2008b; Mueller et al., 2002). However, little is known regarding the
molecular contribution of ID3 to vascular reprogramming and how it interacts with other
transcription factors (TFs), which bind to DNA and regulate the transcriptional
machinery to activate or repress the expression of target genes. In the current study, we
used ChIP-Seq technology and conducted a genome-wide target identification for ID3
binding in lung EC cells. In addition to this, we used RNA sequencing for accurate
detection and measure of gene expression of differential expressed (DE) genes between
HPMEC and ID3 overexpressed HPMEC. Further, we performed an integrated analysis
of ChIP and RNA Seq data, which revealed key response programs that potentially may
play important role in lung ECs proliferation.
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Materials and Methods
Cell culture and treatment conditions
Primary cells, Human pulmonary microvascular endothelial cells or Human lung
endothelial cells (HPMEC-ST1.6R). HPMEC cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.
Estrogenic chemical treatments
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB
blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in
occupationally exposed individuals (Wassermann et al., 1979). Our unpublished data
showed a significant increase in PCB-induced vascularization with PCB153
concentrations of 10–100 ng/mL. Based on known PCB blood levels from occupational
exposure and our preliminary results; we chose a PCB dose of 100 ng/mL (∼0.3 µM) to
expose endothelial cells. Our previous studies also showed endothelial cell proliferation
and vascular tube formation at physiological doses of 17β-estradiol (Das & Felty, 2014a;
Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+ were exposed
to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′-hexachlorobiphenyl
(PCB153) were purchased from AccuStandard (Newhaven, CT) and dissolved in
dimethyl sulfoxide (DMSO). All other chemicals and reagents were purchased from
Sigma (St. Louis, MO).
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ID3 overexpression
The HPMEC cells were stably transfected with either Precision LentiORF for ID3
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy.
Experiment procedure for Chromatin Immunoprecipitation (ChIP) Sequencing
(ChIP-Seq)
Chromatin-immunoprecipitation followed by sequencing of the immuno-precipitated
DNA is an expeditiously becoming a very important method for understanding the
mechanisms of protein: DNA interactions. It was first introduced and described in 2007
(Robertson et al., 2007). It is a powerful tool for understanding the mechanisms of gene
regulation by transcription factors and modified histones. ChIP-Seq process is very
tedious and time-consuming to perform, involving many steps and variables that must be
optimized by each investigator in their model system. To perform ChIP-Seq, chromatin is
isolated from cells or tissues and fragmented. Specific antibodies against chromatinassociated proteins are used to enrich for specific chromatin fragments. The DNA is
recovered, sequenced and aligned to a reference genome to determine specific protein
binding loci.
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ChIP sequencing makes use of the power of massively parallel or next-generation
sequencing (NGS) which have increased our knowledge of transcription factor biology,
DNA methylation and histone modifications. ChIP- Seq is a counting assay that uses only
short reads to align to the genome, but requires millions of them to provide meaningful
data.
In order to perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP
OneDay Kit, which is designed to isolate and purify high-quality DNA bound to our
protein of interest. The EpiTect ChIP OneDay Kit contains all buffers and components
needed for immunoprecipitation, crosslink reversal, and genomic DNA purification for
detection. To begin with chromatin immunoprecipitation, we seeded the cells and treated
with treatment for 48 hours. Then, we cross-linked cells with formaldehyde. The
chromatin containing covalent complexes between genomic DNA and all nuclear factors
is isolated and sheared by sonication into 100-300 base pair (bp) sizes.
Immunoprecipitation pulls down not only the target nuclear factor of interest but also any
specifically bound genomic DNA sequences. Reversal of the chemical cross-linking and
nucleic acid purification prepare the DNA for detection by sequencing. The sequencing
of ChIP processed DNA is carried out by Center for Genome Technology (CGT) of John
P. Hussman Institute for Human Genomics at University of Miami Miller School of
Medicine. CGT facility used DNA SMART ChIP-Seq Kit (Clontech Laboratories, Inc.)
which generated Illumina-compatible sequencing libraries from 100 pg–10 ng of singlestranded (ss) or double-stranded (ds) DNA resulting from chromatin immunoprecipitation
experiments. Then we performed ChIP-Seq analysis using various tools available at
Galaxy, which is an open source, web-based platform (Afgan et al., 2016). It begins with

121

mapping of trimmed sequence reads to a reference genome. Next, peaks are found using
peak-calling algorithms. To further analyze the data, we performed differential binding
and motif analyses, which are common end points of ChIP-Seq workflows. In order to
perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP OneDay
Kit, which is designed to isolate and purify high-quality DNA bound to our protein of
interest. ChIP samples were prepared from lung EC WT, lung EC ID3+, and lung EC
ID3+ + E2 cells as follows: 80.0 x 106 cells from each of all the three cell lines were
cross-linked with 1% formaldehyde for 10 minutes at room temperature. Cross- linking
was stopped by the addition of harvesting buffer to a final concentration of 125 mM, and
cells were washed twice with PBS. Centrifuged at 2000 rpm, removed supernatant.
Added 800 μL to 1 mL Lysis buffer to ppt. The cell pellet was resuspended consecutively
in ChIP lysis buffers and sonicated for 6 minutes, 12 cycles (30 seconds high frequency
pulsing followed by 30 seconds resting) using the Bioruptor sonicator (Diagenode,
Denville, NJ). In addition to this, added 10 μL of nuclease + 20 μL reaction mixture to
the sample and incubate 20 min at 37 ºC. Added 40 μL Stop buffer to produce chromatin
fragments of 100 – 300 bp on average. Ran 1.2% agarose gel with sample and molecular
marker to check whether the chromatin broken into appropriate sizes. Added 50 μL
Protein A Beads for each IP Fraction. To prepare these beads, 100 μL of protein beads
were incubated overnight with 10 μg SC-490 polyclonal ID3 antibody (SantaCruz
Biotechnology), at 4 °C. The following day, the beads were rinsed and added to the
sheared chromatin and incubated over- night at 4 °C. Samples were then rinsed one time
each with buffer I,II,III,IV and V. The cross-linking of antibody with protein of interestDNA complex was reversed by treating with RNAse A and Proteinase K. Procedure
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controls included an input condition, obtained before DNA-protein complex sonication
and further used during ChIP-Seq assays as normalization sample, and nonimmunoprecipitated DNA (non-IP DNA), which was obtained just prior to ID3
immunoprecipitation. Added 400 μL Column Binding Buffer to each 200 μL IP Fraction
sample. Mixed well by pipetting. Immediately transferred the entire supernatant to its
own DNA Spin Column (in 2 mL Collection Tube) without wetting the rim, close the lid,
and centrifuge at 11,000 × g for 1 min at room temperature. Added 600 μL Column Wash
Buffer, containing ethanol, to each column, without wetting the rim, close the lid, and
centrifuge at 11,000 × g for 1 min at room temperature. Placed the DNA Spin Column
into a clean Elution Tube, and discarded the Collection Tube. Added 100 μL Elution
Buffer to the center of the column membrane. This elution step with another 100 μL of
Elution Buffer carried out for a final elution volume of 200 μL for each ChIP DNA
Sample. The purified ChIP DNA Samples can be stored at -20°C. The purified DNA
further processed with the help of Clean & Concentrator™ from ZYMO RESEARCH
CORP for the rapid purification and concentration of high quality DNA. The ChIP DNA
Clean & Concentrator™ employs a single buffer system that allows for efficient DNA
adsorption to the matrix of the supplied Zymo-Spin™ Column. Then we measured the
concentration of DNA in samples and inputs with the help of BioRad spectrophotometer.
Experimental protocol for Chromatin ImmunoprecipitationAim- To determine genome-wide mapping of ID3 target genes by using ChIP-Seq
experiment. ChIP Ready Chromatin Preparation: This section describes the preparation
of ChIP Ready Chromatin. It covers cell cross- linking, harvesting, lysis, and chromatin
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shearing based on adherent mammalian cell lines. Certain steps may need to be optimized
for experiment-dependent performance. This protocol also provides several stopping
points for the flexibility to optimize those steps.
Things to do before startingIn order to immunoprecipitate the ID3 bound chromatin, we seeded the 20.0 x 106 cells of
lung EC vector, lung EC ID3+, and lung EC ID3+ + E2 cells on each of four 150 mm
petri dishes to achieve 80.0 x 106 cells for all three cell lines.
(i) Lung Vector Control (HPMEC), (ii) Lung ID3, (iii) Lung ID3 + E2.
We treated cells with vehicle or E2 overnight. We did fixing and harvesting of chromatin
from all plates - Total volume per sample = Follow the steps of Cross-Linking Cells with
1% formaldehyde. Add 1 mL cell harvesting buffer and centrifuge at 2000 rpm. Remove
supernatant. Add 800 μL to 1 mL lysis buffer to ppt. We warmed IP Lysis Buffer to room
temperature to prevent precipitation. We thawed Protease Inhibitor Cocktail (PIC) at
room temperature. This product contains DMSO and will remain frozen below 18.4 °C.
Cross-Linking Cells- We prepared following buffers, scale up accordingly if necessary.
i.

1 × PBS Buffer: 3.3 mL 10 × PBS to 29.7 ml ddH2O. Mixed well and placed on

ice.
ii.

FRESH Fixing Buffer (1% Formaldehyde): We added 0.27 mL 37%

Formaldehyde to 9.73 mL 1 × PBS Buffer. Mixed and stored at room temperature in a
fume hood.
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iii.

Cell Harvesting Buffer: We added 15 μL Protease Inhibitor Cocktail (PIC) to 3

mL ice-cold 1 × PBS Buffer. Mix well and place on ice.
We aspirated cell culture medium from the dish. Add 10 mL FRESH Fixing Buffer to the
dish. We incubated at 37 °C for 10 min. We added 1.1 mL Stop Buffer to the dish and
swirl to mix thoroughly. We incubated at room temperature for 5 min. We aspirated
buffer as much as possible. NOTE: From this point forward, keep the samples on ice at
all times. We added 9 mL ice-cold 1 × PBS to wash the fixed cells, rocking the dish for 5
seconds. We poured off the wash buffer. Repeat once more. b. Harvesting Cells- We
added 1.5 mL ice-cold Cell Harvesting Buffer to the dish. We placed dish on ice at an
angle and scrape cells down to one edge of the dish with a silicone cell scraper or rubber
policeman. We centrifuged the Sonication Tube at 800 × g for 10 min at 4 °C to pellet the
fixed cells. Remove the supernatant. Repeat harvesting and centrifugation steps as many
times as necessary to collect all of the cells. Store the cell pellet at -80 °C.
c. Cell Lysis
We added 2.2 μL Protease Inhibitor Cocktail (PIC) to 420 μL IP Lysis Buffer in a
standard 1.5 mL Eppendorf tube. Mix well by pipetting. We added entire volume of IP
Lysis Buffer with PIC to the cell pellet. 100 μL IP Lysis Buffer is recommended to lyse
0.5 to 1.5 million cells. We resuspended cells completely by pipetting. Incubate on ice for
10 -15 min, mixing every 5 min. Continue with next step OR store the lysate at -80 °C.
d. Shearing Chromatin- Chromatin Sonication: 800 μL total chromatin volume per
sample sonicated for 6 min (12 cycles). We aliquot 800 uL volume into two 400 μL vials
per sample. 800 μL = 2 x 400 μL vials per sample.

125

We stored one set of 400 μL samples in -80 ºC freezer. We added 10 μL of nuclease + 20
μL reaction mixture to the sample and incubated 20 min at 37 ºC. The added 40 μL Stop
buffer. We ran 1.2% agarose gel with sample and molecular marker. Chromatin should be
broken down by sonicator into DNA pieces of size ranges from 100 bp to 300 bp as
shown in Figure 57.

Figure 57- The picture of 1.2% agarose gel with sample and molecular marker
by using UVITEC UVidoc instrument.
Chromatin is broken down by sonicator into DNA pieces of size ranges from 100 bp
to 300 bp for HPMEC (Control), HPMEC ID3+, and HPMEC ID3+ + E2 cell
samples.
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Chromatin Immunoprecipitation (ChIP) IntroductionIn order to perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP
OneDay Kit, which is designed to isolate and purify high-quality DNA bound to our
protein of interest. ChIP samples were prepared from lung EC WT, lung EC ID3+, and
lung EC ID3+ + E2 cells as follows: 80.0 x 106 cells from each of all the three cell lines
were cross-linked with 1% formaldehyde for 10 minutes at room temperature. Crosslinking was stopped by the addition of harvesting buffer to a final concentration of 125
mM, and cells were washed twice with PBS. Centrifuged at 2000 rpm, removed
supernatant. Added 800 μL to 1 mL Lysis buffer to ppt. The cell pellet was resuspended
consecutively in ChIP lysis buffers and sonicated for 6 minutes, 12 cycles (30 seconds
high frequency pulsing followed by 30 seconds resting) using the Bioruptor sonicator
(Diagenode, Denville, NJ). In addition to this, added 10 μL of nuclease + 20 μL reaction
mixture to the sample and incubate 20 min at 37 ºC. Added 40 μL Stop buffer to produce
chromatin fragments of 100 – 300 bp on average. Ran 1.2% agarose gel with sample and
molecular marker to check whether the chromatin broken into appropriate sizes. Added
50 μL Protein A Beads for each IP Fraction. To prepare these beads, 100 μL of protein
beads were incubated overnight with 10 μg SC-490 polyclonal ID3 antibody (SantaCruz
Biotechnology), at 4 °C. The following day, the beads were rinsed and added to the
sheared chromatin and incubated over- night at 4 °C. Samples were then rinsed one time
each with buffer I,II,III,IV and V. The cross-linking of antibody with protein of interestDNA complex was reversed by treating with RNAse A and Proteinase K. Procedure
controls included an input condition, obtained before DNA-protein complex sonication
and further used during ChIP-Seq assays as normalization sample, and non-
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immunoprecipitated DNA (non-IP DNA), which was obtained just prior to ID3
immunoprecipitation. Added 400 μL Column Binding Buffer to each 200 μL IP Fraction
sample. Mixed well by pipetting. Immediately transferred the entire supernatant to its
own DNA Spin Column (in 2 mL Collection Tube) without wetting the rim, close the lid,
and centrifuge at 11,000 × g for 1 min at room temperature. Added 600 μL Column Wash
Buffer, containing ethanol, to each column, without wetting the rim, close the lid, and
centrifuge at 11,000 × g for 1 min at room temperature. Placed the DNA Spin Column
into a clean Elution Tube, and discarded the Collection Tube. Added 100 μL Elution
Buffer to the center of the column membrane. This elution step with another 100 μL of
Elution Buffer carried out for a final elution volume of 200 μL for each ChIP DNA
Sample. The purified ChIP DNA Samples can be stored at -20 °C. The purified DNA
further processed with the help of Clean & Concentrator™ from ZYMO RESEARCH
CORP for the rapid purification and concentration of high quality DNA. The ChIP DNA
Clean & Concentrator™ employs a single buffer system that allows for efficient DNA
adsorption to the matrix of the supplied Zymo-Spin™ Column. Then we measured the
concentration of DNA in samples and inputs with the help of BioRad spectrophotometer.
Illumina high-throughput Chromatin Immunoprecipitation -Sequencing (ChIP-Seq)
Chromatin-immunoprecipitation (ChIP) followed by sequencing of the immunoprecipitated DNA is an expeditiously becoming a very important method for
understanding the mechanisms of Protein: DNA interactions and gene regulation by
transcription factors. The sequencing of ChIP processed DNA is carried out by Center for
Genome Technology (CGT) of John P. Hussman Institute for Human Genomics of Miller
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School of Medicine at University of Miami. CGT facility used DNA SMART ChIP-Seq
Kit (Clontech Laboratories, Inc.) which generated Illumina-compatible sequencing
libraries from 100 pg–10 ng of single- stranded (ss) or double-stranded (ds) DNA
resulting from chromatin immunoprecipitation (ChIP) experiments (Nos, 2012).
Clontech’s template switching technology, known as SMART® (Switching Mechanism
at 5’ End of RNA Template), has been used as a basis for cDNA synthesis for nextgeneration sequencing (NGS) applications (Zhu, Machleder, Chenchik, Li, & Siebert,
2001). The CGT facility generated ChIP-Seq libraries with the DNA SMART ChIP-Seq
Kit, a priming site is first added to the 3’ end of the DNA template using the Terminal
Deoxynucleotidyl Transferase. This is followed by annealing of a proprietary DNA
SMART Poly(dA) Primer, which anneals to the T-tail added by the Terminal
Deoxynucleotidyl Transferase. This primer is then used by the SMARTScribe™ Reverse
Transcriptase (RT) to copy the DNA strand. When the SMARTScribe RT reaches the 5’
end of the DNA template, the enzyme’s terminal transferase activity adds a few
additional nucleotides to the 3’ end of the newly synthesized DNA. The carefully
designed DNA SMART Oligonucleotide base-pairs with these additional non-template
nucleotides and creates an extended template, enabling the SMARTScribe RT to continue
replicating to the end of the oligonucleotide. Sequencing libraries are then generated by
PCR-mediated addition of Illumina adapters using primers compatible with regions on
the DNA SMART Poly(dA) Primer and the DNA SMART Oligonucleotide (“Illumina
Adapter Sequences Illumina Adapter Sequences Illumina Adapter Sequences,” 2017).
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Figure 58- The diagrammatic representation of workflow of ChIP-seq experiment
carried out using HPMEC (Control), HPMEC ID3+, and HPMEC ID3+ + E2 cell
samples.
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After elution of DNA sample, we used the Chromatin Immunoprecipitation (ChIP) DNA
Clean & Concentrator™ from ZYMO RESEARCH CORP. for the rapid purification and
concentration of high quality DNA. The ChIP DNA Clean & Concentrator™ employs a
single buffer system that allows for efficient DNA adsorption to the matrix of the
supplied Zymo-Spin™ Column as shown in Figure 59.
Reagent PreparationBefore starting, we added 24 mL 100% ethanol to the 6 mL DNA Wash Buffer
concentrate to obtain the final DNA Wash Buffer solution. In 1.5 mL micro centrifuge
tube, add 5 volumes of ChIP DNA Binding Buffer to each volume of sample (5:1).
Mixed briefly. We transferred mixture to a provided Zymo-Spin™ Column in a
Collection Tube. Centrifuged at ≥ 10,000 x g for 30 seconds.
We added 200 µl Wash Buffer to the column. Centrifuge at ≥ 10,000 x g for 30 seconds.
Repeat wash step. We added 6-100 µl Elution Buffer directly to the column matrix.
Transfer the column to a new 1.5 mL micro centrifuge tube and centrifuge at ≥ 10,000 x
g for 30 seconds to elute the DNA. Ultra-pure DNA is now ready for use for DNA
quantification, sequencing and other molecular applications.

Figure 59- The diagrammatic representation of elution of clean DNA sample using
the Chromatin Immunoprecipitation (ChIP) DNA Clean & Concentrator™ from
ZYMO RESEARCH CORP.
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Then we measured the concentration of DNA in samples and inputs with the help of
BioRad spectrophotometer as shown in Table 3.

Sample details
Input vector
Input ID3 expressing
Input ID3 expressing with
treatment
Sample vector
Sample ID3 expressing
Sample ID3 expressing with
treatment

Sample
Conc.
94.6295
67.155
estrogen 31.844

Units Volume
(uL)
pg
95µl
pg
95µl
pg
95µl

260/280
Ratio
1.8603
1.8065
1.8621

195.9
76.1805
estrogen 53.694

pg
pg
pg

1.8292
1.8706
1.8867

95µl
95µl
95µl

Table 3- The information about the sample like concentration, volume and quality.
Table
DNA sequencingWe performed ChIP sample and input sequencing analysis at Center for Genome
Technology (CGT) of University of Miami Miller School of Medicine. This genomic
facility center used DNA SMART ChIP-Seq Kit (Clontech Laboratories, Inc. A Takara
Bio Company) which generated Illumina-compatible sequencing libraries from 100 pg–
10 ng of single- stranded (ss) or double-stranded (ds) DNA resulting from chromatin
immunoprecipitation (ChIP) experiments.
Clontech’s template switching technology, known as SMART® (Switching Mechanism
at 5’ End of RNA Template), has been used as a basis for cDNA synthesis for nextgeneration sequencing (NGS) applications (Zhu, Machleder, Chenchik, Li, & Siebert,
2001). The CGT facility generated ChIP-Seq libraries with the DNA SMART ChIP-Seq
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Kit, a priming site is first added to the 3’ end of the DNA template using the Terminal
Deoxynucleotidyl Transferase. This is followed by annealing of a proprietary DNA
SMART Poly (dA) Primer, which anneals to the T-tail added by the Terminal
Deoxynucleotidyl Transferase. This primer is then used by the SMARTScribe™ Reverse
Transcriptase (RT) to copy the DNA strand. When the SMARTScribe RT reaches the 5’
end of the DNA template, the enzyme’s terminal transferase activity adds a few
additional nucleotides to the 3’ end of the newly synthesized DNA. The carefully
designed DNA SMART Oligonucleotide base-pairs with these additional non-template
nucleotides and creates an extended template, enabling the SMARTScribe RT to continue
replicating to the end of the oligonucleotide. Sequencing libraries are then generated by
PCR-mediated addition of Illumina adapters using primers compatible with regions on
the DNA SMART Poly(dA) Primer and the DNA SMART Oligonucleotide as shown in
Figure 60 (“Illumina Adapter Sequences Illumina Adapter Sequences Illumina Adapter
Sequences,” 2017).
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Figure 60- The diagrammatic workflow represents addition of adapter sequences at
both ends of ChIP DNA using Clontech’s template switching technology, known as
SMART®
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SAMPLE

Input vector

SAMPLE
ID

20170023101
Input
ID3 201700232expressing
01
Input
ID3 201700233expressing
01
with estrogen
treatment
Sample
201700234vector
01
Sample ID3 201700235expressing
01
Sample ID3 201700236expressing
01
with estrogen
treatment

PF
Clusters

Index Seq

Clontech
TruSeq
DUAL
Index HT
ligated
(Lot#1511520a)
22,746,865 ATTACTCG- R1-F2
D701ATAGAGGC
D502
24,084,017 TCCGGAGA- R2-F2
D702ATAGAGGC
D502
21,705,440 CGCTCATT- R3-F2
D703ATAGAGGC
D502

22,093,845 GAGATTCC- R4-F2
ATAGAGGC
22,999,843 ATTCAGAA- R5-F2
ATAGAGGC
24,738,084 GAATTCGT- R6-F2
ATAGAGGC

D704D502
D705D502
D706D502

Table 4- It illustrates the list of Illumina adapters used to make sequencing
libraries.
These adapters are used for labeling the samples in sequence analyzer machine

After adapter sequences addition at both ends of ChIP-Seq DNA, Illumina sequencing
Table-2
machine at CGT facility processed ChIP-Seq DNA information into computer files as
shown in table 4. We received the raw ChIP-Seq input and sample files (.txt files) in the
paired end sequenced format. Therefore, all the input and sample ChIP-Seq files have
two files each (Part 1 and 2). All Illumina NGS (next-generation sequencing) systems are
capable of paired-end sequencing as shown in Table 5. The paired-end sequencing reads
are very crucial and significant in the case of detection of genomic rearrangements such
as insertions, deletions, and inversions. It also facilitates users to detect the repetitive
sequence elements, as well as gene fusions and novel transcripts. Essentially, it provides
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superior alignment to a reference across DNA regions containing repetitive sequences,
which improves the quality of the entire data set. It also produces longer contigs for de
novo sequencing by filling gaps in the consensus sequence.

Field
STUDY
SPECIES
PREP_TYPE

Description
Official HIHG project name
OR PI name for external
Species
protocol used for sample
preparation

Examples
AUT, PD, jHendrix

h.sapiens
Agilent SS 38Mb exome,
Nimblegen
custom
1.5Mb,
Illumina Multiplexing, whole
genomic, ChIP-Seq, Illumina
mRNAseq, Ribominus Whole
Transcriptome, Nugene Whole
Transcriptome, etc.
PLATFORM
platform
GA, Solid, HiSeq
RUN_TYPE
single-read=1x,
paired- 1x36, 2x50, 2x75, Full 1x50,
end=2x followed by read Octet 1x50
length;
Full, Quad,
Octet Refer to spots on
SOLiD slide
ALIGN_TO
reference used for alignment whole genome, custom, chr3
only
HIHG_ID
HIHG generated sample 200425179-12
number
CONCENTRATION Concentration
10
CONC_UNIT
Concentration unit
ng/µL
METHOD
instrument used to measure nanodrop,
bioA,
qubit,
concentration
picogreen, qPCR
VOLUME
DNA Volume in above 55
concentration unit
VOL_UNIT
Volume unit
µL
Table 5- It illustrates the information about sequencing carried out by Illumina
sequencing machine at CGT facility.
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Methodology to analyze the ChIP-Sequencing data

Figure 61- It shows in pictorial format that what kind of information we get in the
form FASTA format from sequencing machine.
All Sanger format files saves the data in .txt files as shown in Figure 61. These files can
be used as a raw data to process further analyses like peak finding, differential binding of
protein of interest and comprehensive motif analysis (including motif discovery) of ChIPSeq workflows. We analyzed the ChIP-Seq data by using tools available at Galaxy
platform (Afgan et al., 2016). We uploaded the raw .txt files of input and samples in
Galaxy server with the help of FileZilla which a free software, cross-platform file transfer
protocol (FTP) application, consisting of FileZilla Client and FileZilla Server. We have
used FileZilla to upload large sized .txt Sanger files to the Galaxy server as shown in
Figure 62.
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•
•
•

Step 1: Go to the web server, usegalaxy.org
Open a web browser and go to usegalaxy.org
Let’s Register
• Click “User”  “Register”

Figure 62- Diagrammatic representation of workflow of how to use Galaxy platform
to upload the raw FASTA files from computer.
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The FASTQ format files are saved in .txt files in local computers and contains DNA
sequencing trace files. PHRED software evaluates and accredits certain quality value to
the DNA sequences also known as bases (Ewing & Green, 1998). The quality value of
each base is estimated in terms of probability of error. Sanger FASTQ format utilize
ASCII 33–126 to encode PHRED qualities from 0 to 93 (i.e. PHRED scores with an
ASCII offset of 33). In order to understand the file, Sanger FASTQ format restricted the
choices to the ASCII printable characters 32–126 (decimal). The following example
illustrates the application of PHRED score in Sanger FASTQ format files as shown in
Figure 63.
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Figure 63- Diagrammatic illustrates the application of PHRED score in Sanger
FASTQ format files.
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Since the newer machines are in Sanger format 1.9, Galaxy requires 1.8. The uploaded
.txt files converted using FASTQ Groomer within Galaxy in order to make Galaxy
recognize the format (Blankenberg et al., 2010). We also ran FastQC analysis on these
files. FastQC is a Java based quality control tool for raw high throughput sequence data (
Andrews, 2016). The following tables illustrate the FastQC analysis of our pair ended
raw datasets as shown in table 6. FastQC tool produces a basic text and a HTML output
file that contain all of the results, including the following (Andrews, 2010). We have
discussed some of the outputs from the following list:

 Basic statistics- It generates some simple composition statistics for the file
analyzed. The following tables illustrate basic information of the ChIP-Seq files.
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Name

Filename

Encoding

Sample
vector 1

qFelty_ID3chipseq_20170023401_S_8_1.txt

Sample
vector 2

qFelty_ID3chipseq_20170023401_S_8_2.txt

Sample ID3
expressing

qFelty_ID3chipseq_20170023501_S_8_1.txt

Sample ID3
expressing
2
Sample ID3
expressing
with
estrogen
treatment 1
Sample ID3
expressing
with
estrogen
treatment 2

qFelty_ID3chipseq_20170023501_S_8_2.txt

Sanger
Illumina
1.9
Sanger
Illumina
1.9
Sanger
Illumina
1.9
Sanger
Illumina
1.9
Sanger
Illumina
1.9

qFelty_ID3chipseq_20170023601_S_8_1.txt

qFelty_ID3chipseq_20170023601_S_8_2.txt

Total
Sequences

Sequence
length

%GC

/

22093845

35-125

40

/

22093845

35-125

36

/

22999843

35-125

41

/

22999843

35-125

40

/

24738084

35-125

41

Sanger /
Illumina
1.9

24738084

35-125

40

Table 6- It illustrates the quality and information about sequences of ChIP Seq files
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 Per base sequence quality – This output measures the overall range of quality
values across all bases at each position in the FastQ file.

For each position a Box Whisker type plot is drawn. The elements of the plot are as
follows:


The central red line is the median value
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The yellow box represents the inter-quartile range (25-75%)



The upper and lower whiskers represent the 10% and 90% points



The blue line represents the mean quality

The y-axis on the graph shows the quality scores. The higher the score the better the base
call. The background of the graph divides the y-axis into very good quality calls (green),
calls of reasonable quality (orange), and calls of poor quality (red).
 Per sequence quality scores

The per sequence quality score report allows to see if a subset of sequences have
universally low quality values. A warning is raised if the most frequently observed mean
quality is below 27 - this equates to a 0.2% error rate.
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 Per Base Sequence Content- It plots out the proportion of each base position in a
file for which each of the four normal DNA bases has been called.



Per sequence GC content- This module measures the GC content across the whole
length of each sequence in a file and compares it to a modelled normal
distribution of GC content.
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 Per base N content
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 Sequence Duplication Levels

 Kmer content

Out of all the outputs generated from FastQC analysis, per base sequence quality and
sequence duplication levels are the most significant and useful outputs for further
analysis. The sequence quality is calculated and measured on the basis of PHRED score (
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Andrews, 2010; Cock, Fields, Goto, Heuer, & Rice, 2009). The bad quality sequences are
removed from the raw Fastq files as shown in the following Figures by trimming the
sequences. We used Trimmomatic tool to trim the bases in ChIP-Seq file. Trimmomatic
tool is a more flexible, pair-aware and efficient preprocessing tool, optimized for Illumina
NGS data (Bolger, Lohse, & Usadel, 2014). It is also equipped with the identification of
short adapter sequences and quality filtering. It effectively removes the common ‘adapter
read-through’ scenario, whereby the sequenced DNA fragment is shorter than the read
length in both single and paired end data. In order to perform Trimmomatic operation on
adapter sequence on our data, we selected TrySeq2 (paired-ended, for Illumina GAII)
option.
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The following diagrammatic process shows the Trimmomatic trimming tasks as shown in
Figure 64.

Figure 64- Diagrammatic representation of settings used in Trimmomatic software to
trim the pair end adaptor sequences.
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Trimmomatic process the paired end data in specific way and gives out the output of
trimmed forward and reverse paired ended files. The following diagram reprenets process
of Trimmomatic operation on paired end reads as shown in Figure 65 (Bolger et al.,
2014; Usadellab, ). We then used these trimmed forward and reverse paired ended files as
sample input to align with reference human genome –Human Dec. 2013 (GRCh38/hg38)
(hg38) (Miga et al., 2014a).

Figure 65- Flow of reads in Trimmomatic Paired End mode.
Trimmomatic process the paired end data in specific way and gives out the output
of trimmed forward and reverse paired ended files
Read alignment/mapping with BOWTIE2
Bowtie2 is ultrafast read aligner and its algorithm coded by Ben Langmead. It is an
ultrafast and memory-efficient tool for aligning sequencing reads to long reference
sequences. Bowtie2 outputs alignments in BAM format, enabling interoperation with a
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large number of other tools available at this site (Langmead and Salzberg, 2013). It
combines strengths of the full-text minute index with the flexibility and speed of
hardware-accelerated dynamic programming algorithms. We used Bowtie2 to align
trimmed paired reads with hg38 reference genome and used following settings shown in
the Figures 66 and 67.

Figure 66- Paired end sequencing enabled both ends of fragments to be sequenced.
The distance between each paired read is known, alignment algorithms can use this
information to map the reads over repetitive regions more precisely.
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Figure 67- Settings used in Bowtie2 for Paired end sequencing.
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Bowtie2 gives output in the BAM format. The BAM format provides binary versions of
store sequence data, both aligned as well as unaligned, but not in a human readable
format. It is not easy to process by conventional text based processing programs, such as
awk, sed, and python (Genome Analysis, 2013). Therefore, we converted BAM file into
BED format with the help of bedtools, which converts sequence alignments in BAM
format into BED, BED12, and/or BEDPE records as shown in Figure 68. We used
following settings for bedtools.
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Figure 68- Settings used in conversion BAM files from Bowtie2 software into
BED format.
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Peak Finding and Data Analysis
IntroductionPeak calling is a very crucial step in ChIP-Seq workflow and study genome-wide proteinDNA interactions. Peak calling is a computational method used to identify areas in a
genome that have been enriched with aligned reads as a consequence of performing a
ChIP-Sequencing experiment. These areas are those where a protein interacts with DNA
(Pepke, Wold, & Mortazavi, 2009).When the protein is a transcription factor, the
enriched area is its transcription factor binding site (TFBS).We used the powerful novel
algorithm, named Model-based Analysis of ChIP-Seq (MACS), for identifying protein
interest binding sites on DNA. MACS2 is capable of capturing enriched ChIP region and
improves the spatial resolution of binding sites through combining the information of
both sequencing tag position and orientation in spite of genome complexity. MACS2
increases the specificity of callpeak function by comparing with the control. MACS2
estimates reads for a given location by assuming mean of the Poisson from control
experiment (background reads) in 5 Kbp or 10 Kbp around the examined location. If
reads in sample file comes out more than would have expected from the Poisson (p <
0.00005), then MACS2 calls a peak i.e. build model for peaks. ID3 ChIP was performed
using SC-490 polyclonal Anti-ID3 antibody as described above. Two Illumina TruSeq
ChIP libraries were constructed from ChIP and input control DNA and sequenced using
Illumina HiSeq 2500 by Center for Genome Technology (CGT) of John P. Hussman
Institute for Human Genomics of Miller School of Medicine at University of Miami. We
performed ChIP-Seq analysis using various tools available at Galaxy, which is an open
source, web-based platform (Afgan et al., 2016). FASTQ reads were uploaded to the
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galaxy server platform (Afgan et al., 2016) with the help of FileZilla which is a free
software, cross-platform file transfer protocol (FTP) application, consisting of FileZilla
Client and FileZilla Server. We also ran FastQC analysis on these files. FastQC is a Java
based quality control tool for raw high throughput sequence data (Andrews, 2016). Then
FASTQ file trimmed with identification of short adapter sequences and quality filtering
by Trimmomatic software (Bolger et al., 2014). Then these reads mapped to the human
genome –Human Dec. 2013 (GRCh38/hg38) (hg38) (Miga et al., 2014a) using Bowtie2
with default settings (Langmead & Salzberg, 2012). Next, peaks are found using peakcalling algorithms. Peak calling was performed using Model-based analysis for ChIP-Seq
(MACS2 (2.1.0) options gsize 2451960000 --bw 300 --ratio 1.0 --slocal 1000 --llocal
10000 --keep-dup 1 --bdg --qvalue 0.05 ‘‘--tsize=35 --, lower mfold=5, lower mfold= 50,
--pvalue=1e-5’’) on each ChIP-Seq file against the matching input file (Feng, Liu, Qin,
Zhang, & Liu, 2012; Zhang et al., 2008). For the analysis, peaks with a false discovery
rate (FDR) of <5% were selected. MACS2 is very conducive and it yields detailed
information for each peak, such as genome coordinates, p-value, FDR, fold enrichment,
and summit (peak center). For further processing, we converted tabular format file of
MACS2 call peak into interval type by modulating settings. We filtered the data file by
setting cut off value for the fold enrichment of the peaks above 5. The summit of the peak
represent maximum binding probability of transcription factor or protein of interest on
the particular position of DNA. Therefore, we decided to select 200 base pairs region
around summit location which is also called as summit region. In order to get summit
region we subtracted and added 100 base pairs from summit location. Then cut down the
three columns containing chromosome number, start site of summit region of peak and
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end site of summit region of peak. This process resulted into 200 base pairs region of
peak, which signifies most predictable binding sites of our protein of interest ID3. These
peaks with start and end position associated with chromosome number were copied and
pasted in tested region in the Genomic Regions Enrichment of Annotations Tool
(GREAT). GREAT uses ChIP-Seq identified binding events as the TFs binding region on
DNA. GREAT associates the proximal and distal transcription start site (TSS) of target
gene to the genomic region and then annotates these genomic regions with gene
ontologies. GREAT uses statistical algorithm to study enrichment analysis for the
associations between genomic regions with annotations. GREAT requires statistical
significance from binomial test, but also filters on fold enrichment to identify
enrichments of large effect (McLean et al., 2010). GREAT works perfectly to annotate
the peaks (genomic regions) with known genes but it uses Human: GRCh37 (UCSC
hg19, Feb/2009) as a reference genome, which is earlier version of Human reference
genome as shown in Figure 69. In order to annotate the peak regions with genes of
updated version of human genome- Human Dec. 2013 (GRCh38/hg38) (hg38), we used
RnaChipIntegrator. RnaChipIntegrator integrates analyses of genes (or other genomic
feature data) against a set of peaks of ChIP data (Additional file 5), identifying the
nearest peaks to each feature and vice versa (Briggs, Donaldson, 2010 ).
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Figure 69- Diagrammatic representation of Peak finding analysis process of
MACS2 software. (from Zhang et al. Model-based Analysis of ChIP-Seq
(MACS). Genome Biology (2008) vol. 9 (9) pp. R137)
MACS2 empirically models the shift size of ChIP-Seq tags, and uses it to improve
Methodthe spatial resolution of predicted binding sites of protein of interest in this case ID3.
The collections of aligned reads (three ChIP-Seq and three input controls) were
normalized to the same sequencing depth by randomly removing aligned reads.
Duplicated reads were removed before normalization. Peak finding was carried out by
running MACS2 (Zhang et al. 2008; options ‘‘--tsize=35 --bw=110, lower mfold=5,
lower mfold= 50,

--pvalue=1e-5’’) on each ChIP-Seq file against the matching input
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file. For the analysis, peaks with a false discovery rate (FDR) of <5% were selected.
MACS2 is very conducive and yield detailed information for each peak, such as genome
coordinates, p-value, FDR, fold enrichment, and summit (peak center) as shown in Figure
70.

Figure 70- Settings used in MACS2 software for peak finding analysis.
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For further processing, we converted tabular format file of MACS2 call peak into interval
type by modulating settings. We filtered the data file by setting cut off value for the fold
enrichment of the peaks above 5 as shown in Figure 71.

Figure 71- Setting used for sorting the peak data.
The cut off value for the fold enrichment of the peaks above 5 used in MACS2 software.
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From the above table, we selected summit location of each peak region. The summit
location is considered to be the center location of the peak. Each peak region generally
consists of 500-600 base pairs. The above table shows the start and end location of the
peak correspond to chromosome number. The summit of the peak represents maximum
binding probability of transcription factor or protein of interest on the particular position
of DNA. Therefore, we decided to select 200 base pairs region around summit location,
which is also called as summit region. In order to get summit region we subtracted and
added 100 base pairs from summit location. Then cut down the three columns containing
chromosome number, start site of summit region of peak and end site of summit region of
peak. This process resulted into 200 base pairs region of peak, which signifies most
predictable binding sites of our protein of interest ID3. The process is shown in the
following Figure 72.
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Figure 72- Diagrammatic representation of workflow of setting use for selecting
only 200 bp region around summit location of peaks and chromosome number of
peaks.
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These peaks with start and end position associated with chromosome number copied and
pasted in tested region in the Genomic Regions Enrichment of Annotations Tool
(GREAT). GREAT uses ChIP-Seq identified binding events as the TFs binding region on
DNA. GREAT associates the proximal and distal transcription start site (TSS) of target
gene to the genomic region and then annotates these genomic regions with gene
ontologies. GREAT uses statistical algorithm to study enrichment analysis for the
associations between genomic regions with annotations as shown in Figure 73. GREAT
requires statistical significance from binomial test, but also filters on fold enrichment to
identify enrichments of large effect (McLean et al., 2010).

Figure 73- The Diagrammatic representation of workflow of setting used for peak
data in GREAT software.
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Motif discovery
We used MEME-ChIP 4.3.0 (Bailey, 2011; Ma, Noble, & Bailey, 2014) to discover
motifs. We selected 10% of the strongest peaks for each experiment (reads under peak).
The location of the peak was extracted and extended by 100 bp on either side. MEME
was instructed to report the top 10 motifs between 5 and 30 bases in length. We accepted
all motifs that showed significant similarity (S. Gupta, Stamatoyannopoulos, Bailey, &
Noble, 2007) to the reported motif (Mathelier et al., 2014; Sandelin, 2004), MA0074.1,
P-value <1 × 10-5). MEME was instructed to report the top 10 motifs between 5 and 30
bases in length. We accepted all motifs that showed significant similarity motifs present
in HOmo sapiens COmprehensive MOdel COllection (HOCOMOCO) v11 database
(Kulakovskiy et al., 2017). The options were set to perform MEME-ChIP (DREME Evalue ≤0.05, CentriMO score ≥5).
Data Visualization
We used Integrated Genome Browser (IGB) which is an open-source tool for visualizing
of ChIP Seq datasets (Freese, Norris, & Loraine, 2016). To visualize the data, we selected
human genome –Human Dec. 2013 (GRCh38/hg38) (hg38) as a refrence genome and
then uploaded the Bowtie2 mapped aligned sequenced .BAM file and MACS2 generated
ID3 peaks .BED file in the IGB. In order to visualize the peaks, we followed the IGB user
guide instructions. We viewed genomic sequence of peaks with highest peak score and
peaks which fall into the promoter region of gene with the help of IGB Genomic
Sequence Viewer. In order to check the peaks in the promoter region of the gene, we used
RnaChipIntegrator (Briggs, Donaldson, 2010) which shows the information of
overlapping peaks into the promoter region of the gene.
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Results
Global identification of ID3 binding sites in HPMEC and HPMEC cells by ChIPSeq analysis
In order to understand the global binding patterns of ID3, we applied ChIP-Seq
technology, which is a novel approach for identifying transcription factor binding sites
genome-wide (Barski et al., 2007; Johnson, Mortazavi, Myers, & Wold, 2007). We
performed experiment in replicates of HPMEC ID3+ ChIP and HPMEC ChIP samples.
After sequencing analysis, we obtained a total of 45,999,686 and 44,187,690 sequence
tags respectively for HPMEC ID3+ ChIP and HPMEC ChIP that were mapped uniquely
using Bowtie2 to the reference human genome GRCh38 (hg38) by allowing two
mismatches (Miga et al., 2014b; Univeristy of California Santa Cruz, 2013b) (Langmead
& Salzberg, 2012) . Peak calling was performed on HPMEC ID3+ ChIP sample using
Model-based analysis for ChIP-Seq (MACS2 (2.1.0) on each ChIP-Seq file against the
matching input file (Feng et al., 2012; Zhang et al., 2008). The q-value =0.01 (minimum
FDR) cutoff to call significant regions. Using MACS2, we identified a total of 2493 ID3
peaks in HPMEC ID3+ ChIP using control ChIP-Seq data as the negative control. These
mapped regions then associated with gene ontologies with the help of GREAT software
which uses GRCh37 (hg19) as a reference genome (McLean et al., 2010). GREAT
associated 2336 ID3 peak-binding regions (200 base pairs bp) around summit location of
the peak) of HPMEC ID3+ ChIP sample to transcription start site (TSS) of 2834 known
genes (Fig.68B) (Additional file 1). Out of 2834 known genes, 470 genes were associated
with only one binding region, 1589 genes were associated with two regions and 1 gene
was associated with three regions (Fig.75B). Results additionally showed 276 genes were
not associated with any region. We calculated the distance of the ID3 binding regions to
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TSS (transcription start sites) and then tabulated the frequency across the distance
intervals before TSS and after TSS against region-gene association (Fig. 75A). Figure
75A shows that distance of peak around the TSS sites. We found that about 4.19% ID3
(153 of 3651) binding regions were mapped within ±5 Kb of TSS (Figure 68B), and
about 24.92% (910 binding regions) were mapped within ± 50 Kb of TSS. Similarly,
MACS2 identified 3603 ID3 binding regions i.e. peaks in HPMEC ChIP sample using
control ChIP-Seq data as the negative control. GREAT associated 3516 ID3 peaks
binding regions (200 bp around summit location of the peak) that were mapped to TSS
(transcription start site) of 3935 known genes (Fig.76B) in HPMEC ChIP sample
(Additional file 2). Out of 3935 known genes, 782 genes were associated with only one
binding region, 2524 genes were associated with two regions per gene. While 208 genes
were not associated with any region. We calculated the distance of the ID3 binding
regions to TSS (transcription start sites) in HPMEC ChIP sample and then tabulated the
frequency across the distance intervals before TSS and after TSS against region-gene
association (Fig. 3A). Figure 76A shows that the distance of peak around the TSS sites.
We found that about 3.86% ID3 (226 of 5841) binding regions were mapped within ±5
kb of TSS (Figure 76B), and about 22.80% (1332 binding regions) were mapped within ±
50 kb of TSS. Furthermore, we also checked the genome-wide protein-DNA interaction
patterns for HPMEC ID3+ ChIP and HPMEC ChIP data with the help of CEAS (cisregulatory element annotation system) tool which provides summary statistics on ChIP
peaks enrichment in important genomic regions such as individual chromosomes,
promoters, gene bodies or exon (Shin, Liu, Manrai, & Liu, 2009) (Fig.77). Association of
ID3 bound regions with annotated genomic features indicated that ID3 tends to localize
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within intronic regions. A total of 37.4% and 41% peaks were found in HPMEC ID3+
ChIP and HPMEC ChIP samples respectively. Very small percentage of peaks were
found in the coding exons which comprised of 0.6% and 0.5% in HPMEC ID3+ ChIP
and HPMEC ChIP samples respectively. 5'-UTR regulatory regions showed 1.3% and
0.3% of peaks in HPMEC ID3+ ChIP and HPMEC ChIP samples respectively (Figure
77). In addition, ID3 binding sites were found to be localized in the promoter region of
the gene in HPMEC ID3+ ChIP (3.7%) and HPMEC ChIP (3.6%) samples (Figure 77).
We identified ID3 target genes by GREAT and compared the genes between HPMEC
ID3+ ChIP and HPMEC ChIP samples in Fig. 78. We found total of 1240 ID3 gene
targets between both ChIP Seq samples. We found only 22.4% similarity in the genes
associated with binding regions of ID3 in both ChIP Seq samples. These findings may
suggest that ID3-depedent binding to DNA is different in the HPMEC (wild type) and
HPMEC ID3+ cell lines.
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Figure 74- The Diagrammatic representation of workflow of ChIP-Seq experiment
carried out using HPMEC (Control), HPMEC ID3+, and HPMEC ID3 + E2 cell
samples.

Figure 75 A- The graphical representation of MACS2 generated peaks for
HPMEC ID3+ cell sample binned by orientation and distance to TSS. B) The
graphical representation of number of gene associated per ID3 binding peak
regions by GREAT tool.
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Figure 76A) The graphical representation of MACS2 generated peaks for
HPMEC cell sample binned by orientation and distance to TSS. B) The
graphical representation of number of gene associated per ID3 binding peak
regions by GREAT tool.

Figure 77- Diagrammatic representation of MACS2 identified ChIP peaks
characteristics created with the help of CEAS tool. Diagrams show percentage of
peaks overlapping with gene features for ChIP-Seq HPMEC and HPMEC ID3+ cell
samples.
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Figure 78- A Venn diagram showing the overlap of ID3 target genes among
HPMEC and HPMEC ID3+ cell samples.

Snyder et al. recently used ChIP Seq to map binding sites of eGFP-ID3 and other key TFs
on human K562 cell line (ENCSR005NMT) and made data available at ENCODE. We
used GEO accession: GSE91408 data from ENCODE to check ID3 binding regions
(Dunham

et

al.,

2012;

Sloan

et

al.,

2016).

We

GSE91408_ENCFF468VTJ_optimal_idr_thresholded_peaks_GRCh38.bigBed

processed
file

to

annotate the peak or binding regions of ID3 to gene annotation using GREAT. We found
total of 9717 genes were associated with 24336 binding regions of ID3 in ENCODE data.
When we compared the genes generated from HPMEC ID3+ ChIP Seq data with
ENCODE ID3 – K562 ChIP data, 64.60% (1831 out of 2834 genes) of genes of HPMEC
ID3+ ChIP seq data were overlapped with ENCODE ID3 – K562 ChIP data (Fig.79)
(Additional file 3). The difference between numbers of genes associated with ID3
binding region of HPMEC ID3+ ChIP-Seq data and ENCODE ID3 – K562 ChIP data
could be due to the use of different cell line (HPMEC VS K562), different antibodies,
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Snyder et al. used the anti-GFP antibody (11814460001, Roche) or differences in the
analysis pipeline and downstream analysis procedures.

Figure 79- A Venn diagram showing the overlap of ID3 target genes among
ENCODE ID3 – K562 and HPMEC ID3+ ChIP data.

This suggests that there are common sets of genes regulated by ID3 in humans K562 cells
and in HPMEC cells. However, we identified many ID3 binding sites that are only
present in the HPMEC cell line, suggesting that ID3 targets different genes in the context
of lung EC cells. These findings clearly validated ChIP-Seq as an efficient and powerful
technique for mapping ID3 binding sites in HPMEC cells.
Identification of the DNA binding consensus sequences of ID3 and other known TF
binding sites in the ID3 bound regions of the ChIP data. The recognition of
interaction of ID3 protein with TFs found from ChIP-Seq data.
To find out the de novo ID3 binding sequence in the ID3 binding regions (peak regions)
of HPMEC and HPMEC ID3+ cell ChIP samples, we used the MEME-ChIP suite
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program (Bailey, 2011; Ma et al., 2014). We also checked whether other TFs have their
own unique and enriched binding motifs in the ID3 binding regions of HPMEC ID3+ and
HPMEC ChIP sample that we identified. We found a repeated sequence of
GAGAGAGAGAGAGAGAGAGAGAGAGAGAGA with a very high E-value of 2E-62 Enriched
motifs (E-value ≤ 10 using the binomial test) in HPMEC ID3+ ChIP sample. There are
348 instances at which this motif found in 2493 ID3 binding regions. We also manually
checked GAGAGAGAGAGA repeat sequences in peaks with highest peak score and
peaks which fall into the promoter region of gene identified by RnaChipIntegrator
(Briggs, Donaldson, 2010). The data is visualized with the help of Integrated genome
browser (IGB) which is a visual analytics platform for ChIP seq data analysis (Freese et
al., 2016). In addition, we also processed ID3 bound peak regions of HPMEC ChIP
sample

and

found

most

significant,

unknown

motif

TCCCAGCWMYTYGGGAGGCTGAGGCRGGAG sequence with a very high E-value
Enriched motifs (E-value ≤ 10 using the binomial test) of 1.30E-05. There are 45
instances of this motif found in 3603 ID3 binding regions. To identify possible
interactions between ID3 and other TFs, MEME-ChIP suite containing DREME and
Centrimo screening was performed to identify the other most over-represented motifs or
consensus sequences of TFs in the ID3 binding regions identified by MACS2 (Bailey,
2011; Ma et al., 2014). We found IRF1, BC11A, IRF4, PRDM1, FOXJ3, SMAD4,
ZBTB6, GATA1, and STAT2 TFs binding motifs in the binding region of HPMEC ID3+
ChIP sample (Table 7). The consensus sequences with their associated TFs for HPMEC
ID3+ ChIP sample are shown in Table 7. In addtion to this, the consensus sequences with
their associated TFs ZBT7B, NKX28, TGIF1, RFX2, MYOG, ZBT18, MXI1, SOX2,
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MAF, MEIS1, SOX3, SOX9 ,and TBX3 for HPMEC ChIP sample are shown in Table 8.
We have shown all three samples MEME-ChIP generated output in additional file 4.
Since ID3 lacks DNA binding domain, it regulates the transcription machinery in a
dominant negative manner. ID3 binds to basic Helix-loop-helix I (bHLH I) proteins via
the helix loop helix (HLH) motif. ID3 protein interactions block the DNA binding
activity of basic HLH (bHLH) transcription factors (Doke et al., 2018). The molecular
mechanism for the role of ID3 proteins in the transcriptional control was initially thought
to be only dependent on its ability to dimerize with bHLH factors acting as dominantnegative. Nevertheless, in addition to bHLH proteins, researchers have shown the
interaction of ID3 with non-bHLH proteins. Researchers have shown that ID3 interaction
with Pax-5 and ternary complex factor (TCF) subfamily of ETS-domain proteins
(Roberts, Deed, Inoue, Norton, & Sharrocks, 2001; Yates, Atherton, Deed, Norton, &
Sharrocks, 1999). Therefore, it is important to know that TFs could bind to the ID3
binding regions that we identified and act as ID3 cooperators for the regulation of gene
expression. We compared known TFs which were generated using MEME-ChIP suite
analysis from HPMEC ID3+ and HPMEC ChIP samples. We did not find any TFs
overlapped between both HPMEC ID3+ and HPMEC ChIP samples. Although we did
find only one (GATA1) overlap of TF when we compared TFs generated from HPMEC
ID3+ and ENCODE ID3 – K562 ChIP data. Researchers have already shown that
interaction of GATA1 with E47 protein acts as the master regulators of hematopoiesis
and binds to β-globin promoter in Id cDKO bone marrow cells (Zhao et al., 2016). This
data may suggests that ID3 indirectly interacts with GATA1. It is interesting to see that
there is no overlap of any TFs between HPMEC ID3+ and HPMEC ChIP samples. This
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finding corroborates the idea that ID3 gene regulation with copartner TFs is different in
ID3 overexpressed HPMEC than wild type HPMEC. Moreover, we tried to understand
the connection between ID3 and 8 TFs generated from HPMEC ID3+ ChIP data using
STRING database in the Fig. 80 and 81. The STRING netwok showed how this proteins
are interconnected with various pathways (Szklarczyk et al., 2015b; Jensen et al., 2015).
In addition to GATA1, other proteins like STAT2, SMAD4 and IRF1 did not show any
direct connection with ID3 in Figure 82A. But Figure 82B showed indirect interaction of
ID3 with SMAD4 throgh BMP2, as SMAD4 is central component of the BMP signalling
and ID3 is direct target of BMP2 in a variety of cell types (Lim et al., 2015;
O’Shaughnessy, Christiano, & Jahoda, 2004; Voorneveld et al., 2014). In case of STAT2JAK-IRF4 did not show any type of interaction with ID3. But there is evidence of
cytokine-mediated STAT activation directly modulate Id2 expression. Morover.
researchers also suggested possibilty of cytokines indirect regulatation of Id3 expression
through modulation of Id2 expression in memory T cells of mice (Yang et al., 2011).
However, in order to rule out any nonspecific effect of the ID3 antibody on the
recognition of these transcription factors not related to ID3, we compared their amino
acid sequences with the ID3 protein by means of the DNAStar alignment program. No
significant similarities were observed among the considered proteins, thus ruling out any
unspecific binding of the ID3 antibody. Although ID3 ChIP-Seq data demonstrated an
enrichment of genomic regions with overrepresentation of general transcriptional
regulatory TFs, functional experiments should be performed to demonstrate an
interaction of ID3 with these TFs. Our data underscore the importance of synergistic
interactions between ID3 and tissue-specific TFs to ultimately modulate gene expression.
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Gene ID for optimal
Species
peaks

Quality

Consensus

E-value Enriched
motifs (E-value
≤ 10 using the
binomial test)

Region
Width

Region
Matches

2E-62

47

348

8.8E-57

54

475

1.60E-45

54

425

4E-12

81

716

1.9E-11

71

172

GAGAGAGAGAGAGA
GAGAGAGAGAGAGA
GA
GAGAGAGAGAGAGA
GAGAGAG
GAGAGAGAGAGAGA
G
IRF1

HUMAN

A

RAAASNGAAAGTGAAAS
TRR

GGGAGAGA
BC11A

HUMAN

C

RAAAGAGGAAGTGARAV

1.2E-09

72

1014

IRF4
PRDM1
FOXJ3
SMAD4
ZBTB6
STAT2
GATA1

HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN

C
C
A
C
D
B
A

RRRGRGGAASTGARAS
RAAAGTGAAAGTGA
TTGTTTATKKTTW
STGTCTSDCACCT
VGRTGATRGAGCC
TYASTTTCNBTTYCH
CTGBNNVVBRSAGATAAGR

8.7E-09
0.000000031
0.0035
0.0047
0.03
0.005
7.50E-03

81
53
70
90
106
12
76

1061
515
340
891
594
390
251

Table 7- Main TFs binding motifs overrepresented in the ID3 binding regions of
HPMEC ID3+ ChIP data.
Table 1A ID
TCCCAGCWMYTYGGGAGGCTGAGGCRGG
AG
ZBT7B
NKX28
TGIF1
RFX2

Alt ID
MEME-3
HUMAN
HUMAN
HUMAN
HUMAN
DREME6

AGTRGCTG
MYOG

HUMAN

E-value

Region
Width

Region
Matches

1.30E-05

39

45

4.20E-03
7.40E-03
8.40E-03
1.40E-02

12
88
84
5

34
326
620
15

AGTAGCTG

1.60E-02

9

15

CHSCAGCTGYYYB

2.20E-02

94

215

Consensus
TCCCAGCWMYTYGGGAGGCTGAGGCRGG
AG
SSCSGTTGCCATGGVRACSGS
TTCAAGKRC
TGACAGS
CKGTTGCCATGGCRACVS

ACAGGCRTGMGCCACCRYGCC

MEME-5

ACAGGCRTGMGCCACCRYGCC

7.00E-02

48

45

AYTACAGG

DREME3

AYTACAGG

1.50E-01

21

21

KCCAGMTGTKB
SCCACGTGSYB
BBCCTTTGTYYYB
BCCWTTGTYATGYWRA
VAAWBTGCTGASTHWGCMD
GMTGACAGV
BCCWTTGTBYB
YCWTTGKYY
DRAGGTGBSAR

2.10E-01
2.90E-01
4.00E-01
6.20E-01
6.50E-01
6.60E-01
7.10E-01
8.40E-01
9.00E-01

84
100
46
55
86
82
48
38
90

416
457
321
360
483
532
293
317
609

ZBT18
MXI1
SOX2
SOX2
MAF
MEIS1
SOX3
SOX9
TBX3

HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN
HUMAN

Table 8- Main TFs binding motifs overrepresented in the ID3 binding regions of
HPMEC ChIP data.
Table 1B - Main TFs binding motifs overrepresented in the ID3 binding regions of
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HPMEC ChIP data.

Figure 80- A Venn diagram showing there is no overlap of TFs copartners of ID3 in
the ID3 binding regions among HPMEC ChIP and HPMEC ID3+ ChIP data.

Figure 81- A Venn diagram showing the one overlap of TF copartner of ID3 in the
ID3 binding regions among ENCODE ID3 – K562 and HPMEC ID3+ ChIP data.
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Approved
symbol
BCL11A

Approved name

HGNC ID

Location

B cell CLL/lymphoma
11A

HGNC:13221

2p16.1

IRF4

interferon regulatory
factor 4

HGNC:6119

6p25.3

PRDM1
FOXJ3
SMAD4

PR/SET domain 1
forkhead box J3
SMAD family member
4
zinc finger and BTB
domain containing 6

HGNC:9346
HGNC:29178
HGNC:6770

6q21
1p34.2
18q21.2

HGNC:16764

9q33.2

ZBTB6
STAT2

GATA1

signal transducer and
HGNC:11363
activator of transcription
2
GATA binding protein 1 HGNC:4170

12q13.2

Xp11.23

Table 9- A detailed list of TFs binding in the peak regions of ID3 from HPMEC
ID3+ ChIP sample.
Table 2- A detailed list of TFs binding in the peak regions of ID3 of HPMEC ID3+
ChIP sample.

Figure 82- A) STRING protein network illustrates 8 proteins interaction with ID3
protein and p= 0.00495 shows that interactions among the protein is significant. B)
STRING has added a total of 5 proteins to network to show a network around our
earlier 9 proteins
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CHAPTER 4
The whole transcriptome shotgun sequencing (RNA Sequencing) of ID3 target genes
reveals the role of ID3 in the proliferation and dysregulation of lung endothelial
cells.
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IntroductionIn recent years, next-generation sequencing methods, for instance, ChIP-Seq and RNASeq, due to their distinct advantages in increasing specificity and sensitivity of gene
expression, they have become a popular choice in biological studies. Specifically, RNASeq has become an attractive alternative to microarrays in the inference of differential
expression between several conditions or tissues, for it gives more accurate detection and
measure of gene expression. The power of sequencing RNA lies in the fact that the twin
aspects of discovery and quantification can be combined in a single high-throughput
sequencing assay called RNA-sequencing (RNA-Seq). Every RNA-Seq experimental
scenario could potentially have different optimal methods for transcript quantification,
normalization, and ultimately differential expression analysis.

Materials and Methods
Cell culture and treatment conditions
Primary cells, Human pulmonary microvascular endothelial cells or Human lung
endothelial cells (HPMEC-ST1.6R).

HPMEC cells were maintained in Dulbecco’s

modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.
Estrogenic chemical treatments
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB
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blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in
occupationally exposed individuals (Wassermann et al., 1979). Our unpublished data
showed a significant increase in PCB- induced vascularization with PCB153
concentrations of 10–100 ng/mL. Based on known PCB blood levels from occupational
exposure and our preliminary results; we chose a PCB dose of 100 ng/mL (∼0.3 µM) to
expose endothelial cells. Our previous studies also showed endothelial cell proliferation
and vascular tube formation at physiological doses of 17β-estradiol (Das & Felty, 2014a;
Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+ were exposed
to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′-hexachlorobiphenyl
(PCB153) were purchased from AccuStandard (NewHaven, CT) and dissolved in
dimethyl sulfoxide (DMSO). All other chemicals and reagents were purchased from
Sigma (St. Louis, MO).
ID3 overexpression
The HPMEC cells were stably transfected with either Precision LentiORF for ID3
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy.
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The whole transcriptome shotgun sequencing (RNA-Sequencing)
We extracted total RNA from the HPMEC (control), HPMEC ID3+ and HPMEC ID3+ +
PCB153 cells with the help of Invitrogen™ TRIzol™ Reagent RNA extraction method
Pub. No. MAN0001271 (Fisher Scientific Rio, Ares, Hannon, & Nilsen, 2010). The
protocol required using TRIzol™ Reagent. TRIzol™ Reagent maintains the integrity of
the RNA due to highly effective inhibition of RNase activity while disrupting cells and
dissolving cell components during sample homogenization (Chomczynski P, 1983). After
dislodging of growing monolayer of cells from petri-dishes with TRIzol™ Reagent,
chloroform is added to cell sample, and is allowed to separate into a clear upper aqueous
layer (containing RNA), an interphase, and a red lower organic layer (containing the
DNA and proteins). RNA is precipitated from the aqueous layer with isopropanol.
Isolated RNA is then used to prepare as a sample for RNA sequencing analysis. We
performed RNA sequencing analysis at Center for Genome Technology (CGT) of
University of Miami Miller School of Medicine. The CGT facility used Illumina: TruSeq
Stranded mRNA Sample Preparation Guide for RNA sequencing analysis (TruSeq,
2013).
Experiment procedure for RNA Sequencing (RNA-Seq)
IntroductionTo begin with RNA sequencing, we extracted total RNA from the HPMEC (control),
HPMEC ID3+ and HPMEC ID3+ + PCB153 cells with the help of Invitrogen™ TRIzol™
Reagent RNA extraction method Pub. No. MAN0001271 (Fisher Scientific Rio et al.,
2010). The protocol required using TRIzol™ Reagent, which is a monophasic solution of
phenol, guanidine isothiocyanate, and other proprietary components helps the isolation of
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a variety of RNA species of large or small molecular size. TRIzol™ Reagent maintains
the integrity of the RNA due to highly effective inhibition of RNase activity while
disrupting cells and dissolving cell components during sample homogenization
(Chomczynski P, 1983). After dislodging of growing monolayer of cells from petridishes with TRIzol™ Reagent, chloroform is added to cell sample, and is allowed to
separate into a clear upper aqueous layer (containing RNA), an interphase, and a red
lower organic layer (containing the DNA and proteins). RNA is precipitated from the
aqueous layer with isopropanol. Isolated RNA is then used to prepare as a sample for
RNA sequencing analysis.
Method1× 105–1 × 107 cells grown in monolayer in 3.5 cm culture dish (10 cm2). We added 0.3–
0.4 mL of TRIzol™ Reagent per 1 × 105—107 cells directly to the culture dish to lyse the
cells. We did pipet the lysate up and down several times to homogenize. We centrifuged
the lysate for 5 minutes at 12,000 × g at 4–10 °C, then transfer the clear supernatant to a
new tube. We incubated for 5 minutes to permit complete dissociation of the
nucleoproteins complex. We added 0.2 mL of chloroform per 1 mL of TRIzol™ Reagent
used for lysis, then securely cap the tube. We centrifuged the sample for 15 minutes at
12,000 × g at 4 °C. The mixture separates into a lower red phenol-chloroform, and
interphase, and a colorless upper aqueous phase. We transferred the aqueous phase
containing the RNA to a new tube by angling the tube at 45° and pipetting the solution
out.
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We separated phases. We then added 0.5 mL of isopropanol to the aqueous phase, per 1
mL of TRIzol™ Reagent used for lysis. We centrifuged for 10 minutes at 12,000 × g at
4°C.Total RNA precipitate forms a white gel-like pellet at the bottom of the tube. We
discarded the supernatant with a micropipette. We resuspended the pellet in 1 mL of 75%
ethanol per 1 mL of TRIzol™ Reagent used for lysis. Vortex the sample briefly, then
centrifuge for 5 minutes at 7500 × g at 4°C. Vacuum or air dry the RNA pellet for 5–10
minutes. We resuspended the pellet in 20–50 μL of RNase-free water, 0.1 mM EDTA, or
0.5% SDS solution by pipetting up and down. We incubated in a water bath or heat block
set at 55–60 °C for 10–15 minutes. We determined the RNA yield using absorbance
method-Absorbance at 260 nm provides total nucleic acid content, while absorbance at
280 nm determines sample purity. Since free nucleotides, RNA, ssDNA, and dsDNS
absorb at 260 nm, they all contribute to the total absorbance of the sample. We diluted
sample in RNase-free water, then measure absorbance at 260 nm and 280 nm. We
calculated the RNA concentration using the formula A260 × dilution × 40 = μg RNA/mL.
Calculate the A260/A280 ratio. A ratio of ~2 is considered pure.

RNA sequencingWe performed RNA sequencing analysis at Center for Genome Technology (CGT) of
University of Miami Miller School of Medicine. The CGT facility analyzed the quality of
RNA samples by absorption method. The concentration of three RNA samples prior to
use for sequencing are given as follows in table 10-
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Project

Prep

qRNASeq1
TruSeq

volume
(ul)

input
bioA Conc Total RNA input
volume
(ng/ul)
(ng)
(ul)

219.46
245.80
232.01

84.20
102.00
91.1

500
500
500

5.94
4.90
5.49

Table 10- It gives the information about the sample like concentration, volume, and
quality.

The CGT facility used Illumina: TruSeq Stranded mRNA Sample Preparation Guide for
RNA sequencing analysis (TruSeq, 2013). They have used adapter sequence specific to
each samples. The adapter sequences are listed in the following table 11.
Lane Study_Project
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1
1 qFelty_qRNASeq1
2 qFelty_qRNASeq1
3 qFelty_qRNASeq1
4 qFelty_qRNASeq1

Sample
201603252-01
201603252-01
201603252-01
201603252-01
201603252-01_
201603252-01_
201603252-01_
201603252-01_
201603253-01
201603253-01
201603253-01
201603253-01
201603253-01_
201603253-01_
201603253-01_
201603253-01_
201603254-01
201603254-01
201603254-01
201603254-01
201603254-01
201603254-01
201603254-01
201603254-01

Barcode sequence PF Clusters total PF Reads FC_ID
ATCACG
4,551,510
160314_NS500167_0017_AHYF3HBGXX
ATCACG
4,523,244
160314_NS500167_0017_AHYF3HBGXX
ATCACG
4,654,605
160314_NS500167_0017_AHYF3HBGXX
ATCACG
4,582,159
160314_NS500167_0017_AHYF3HBGXX
ATCACG
8,249,593
160325_NS500167_0018_AHY7TMBGXX
ATCACG
8,137,621
160325_NS500167_0018_AHY7TMBGXX
ATCACG
8,342,614
160325_NS500167_0018_AHY7TMBGXX
ATCACG
8,172,774
51,214,120 160325_NS500167_0018_AHY7TMBGXX
TTAGGC
5,029,343
160314_NS500167_0017_AHYF3HBGXX
TTAGGC
4,959,964
160314_NS500167_0017_AHYF3HBGXX
TTAGGC
5,138,406
160314_NS500167_0017_AHYF3HBGXX
TTAGGC
5,047,644
160314_NS500167_0017_AHYF3HBGXX
TTAGGC
9,095,323
160325_NS500167_0018_AHY7TMBGXX
TTAGGC
8,928,221
160325_NS500167_0018_AHY7TMBGXX
TTAGGC
9,219,859
160325_NS500167_0018_AHY7TMBGXX
TTAGGC
9,025,336
56,444,096 160325_NS500167_0018_AHY7TMBGXX
ACTTGA
5,162,332
160314_NS500167_0017_AHYF3HBGXX
ACTTGA
5,110,305
160314_NS500167_0017_AHYF3HBGXX
ACTTGA
5,272,969
160314_NS500167_0017_AHYF3HBGXX
ACTTGA
5,177,994
160314_NS500167_0017_AHYF3HBGXX
ACTTGA
7,523,473
160325_NS500167_0018_AHY7TMBGXX
ACTTGA
7,408,121
160325_NS500167_0018_AHY7TMBGXX
ACTTGA
7,603,456
160325_NS500167_0018_AHY7TMBGXX
ACTTGA
7,437,656
50,696,306 160325_NS500167_0018_AHY7TMBGXX

Table 11- It gives the information about sequencing reads obtained per the sample.
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Methodology to analyze the RNA-sequencing data
Illumina TruSeq RNA libraries were constructed and sequenced using Illumina HiSeq
2000 at CGT. The CGT facility at UM sent us the data in the FASTA format single ended
files. We received FASTA files for HPMEC (control), HPMEC ID3+, and HPMEC ID3+
+ PCB153 samples. The FASTA files were constructed for strand-specific Single-end
cDNA sequencing on the Truseq sequencer (Illumina, UM, Miami). Low-quality
sequences analyzed by FASTQC (Andrew, 2010) and adapter sequences were trimmed
by Trimmomatic, v.0.33 (Bolger et al., 2014; Usadellab, 2013 ), and aligned to the
reference human genome (GRCh38, GENCODE release 23 primary assembly) by the
sequence alignment software Spliced Transcripts Alignment to a Reference, RNA STAR
(Dobin et al., 2013), Bowtie2 (Langmead & Salzberg, 2012), and HISAT (Kim,
Langmead, & Salzberg, 2015). We mapped the sample FASTQ files separately by three
different mapping software to check the mapping efficiency of these various software and
establish optimal pipeline strategy to analyze RNA Seq data to achieve correct
interpretation. Bowtie2 and HISAT are ungapped mapper. In other hand RNA STAR is a
gapped mapper which able detect non-canonical splice junctions (Conesa et al., 2016).
After all filtering and mapping, a high percentage of poor or unaligned reads were
rejected and removed from further analysis. Overall, the mean number of raw reads was
50 million per sample. Of the mean 5.6 million high-quality reads, 24.2% mapped to a
unique location in the reference human genome. RNA STAR, Bowtie2, and HISAT
mapping software aligned millions of short reads to the reference genome and outputs
either SAM file (.sam) is a tab-delimited text file that contains sequence alignment data
or a BAM file (.bam) is the binary version of a SAM file. SAM or BAM file can be used
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as input for a read summarization program suitable for counting reads generated from
RNA. We used featureCounts program which implements highly efficient chromosome
hashing and feature blocking techniques. It is considerably faster than existing methods
by an order of magnitude for gene-level summarization (Liao, Smyth, & Shi, 2014).
FeatureCounts produces a table containing counted reads, per gene, per row. Optionally
the last column can be set to be the effective gene-length. These tables are compatible
with the DESeq2 Galaxy wrapper by IUC. Column names are added as metadata object.
In order to make the expression levels of genes comparable and further conduct
differential expression analysis, normalization is a crucial step in data processing. The
normalization step aims to adjust the systematic technical effects and reduce the noise on
the data as well. Mostly, to compare the transcriptome data, the null hypothesis is being
tested on the logarithmic fold change (LFC) between treatment and control for a gene’s
expression. The null hypothesis for the logarithmic fold change between treatment and
control for a gene’s expression is considered to be exactly zero, i.e., that the gene is not at
all affected by the treatment. The one way to normalize the raw RNA-Seq data by reads
per kilo base of exon model per million reads (RPKM) (Mortazavi, Williams, McCue,
Schaeffer, & Wold, 2008) which is a within-sample normalization method that will
remove the feature-length and library-size effects. RPKM and its subsequent derivatives
fragments per kilo base of exon model per million mapped reads (FPKM), a withinsample normalized transcript expression measure analogous to RPKs acts as a RNA-Seq
gene expression values. Normalization with RPKM method performs poorly when
samples have highly and differentially expressed features (Bullard, Purdom, Hansen, &
Dudoit, 2009; Hansen, Brenner, & Dudoit, 2010). Ranking by fold change, on the other
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hand, is complicated by the noisiness of LFC estimates for genes with low counts.
Furthermore, the number of genes called significantly differentially expressed depends as
much on the sample size and other aspects of experimental design (Boer et al., 2001).
Inferential method is another way that treat each gene separately suffer from lack of
power, due to the high uncertainty of within-group variance estimates and the small
number of samples in typical high-throughput assay experiments – often as few as two or
three replicates per condition. In high-throughput assay analysis, this limitation can be
overcome by pooling information across genes, specifically, by estimating variance-mean
dependence in count data and test for differential expression based on a model using the
negative binomial distribution (Conesa et al., 2016). DEseq2 is software which uses
negative binomial distribution statistics, which gives framework to facilitate gene ranking
and visualization based on stable estimation of effect sizes, as well as testing of
differential expression with respect biological significance. DESeq2, is a method for
differential analysis of count data, using shrinkage estimation for dispersions and fold
changes to improve stability and interpretability of estimates (Anders & Huber, 2010;
Love, Huber, & Anders, 2014) as shown in Figure 83 and 84. This enables more
quantitative analysis focused on the strength rather than the mere presence of differential
expression. DESeq2 takes count tables that generated from the featureCounts as input.
Count tables must be generated for each sample individually. DESeq2 internally corrects
for library size, so it is important to provide un-normalized raw read counts as input. We
used variance-stabilizing transformation to account for differences in sequencing depth.
P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure
(Benjamini & Hochberg, 1995). A false discovery rate adjusted p-value (i.e., q-value) <

193

0.05 was set for the selection of DE genes. A nominal adjusted P value for each
algorithm, which resulted in a median actual precision of 0.9 (FDR = 0.1).
Inputs- The following table gives some examples of factors and their levels:
Factor level
2
Treatment Treated
Untreated
Condition Overexpression Wildtype
Gender Female
Male
Output- DESeq2 generates a tabular file containing the different columns and optional
Factor

Factor level 1

visualized results as PDF.
Column Description
1
Gene Identifiers
2
Mean normalized counts, averaged over all samples from both conditions
3
Logarithm (to basis 2) of the fold change (See the note in inputs section)
4
Standard error estimate for the log2 fold change estimate
5
Wald statistic
6
p value for the statistical significance of this change
p value adjusted for multiple testing with the Benjamini-Hochberg procedure
7
which controls false discovery rate (FDR)

Figure 83- It illustrates the information about the approach of RNA Seq analysis
used in this study.
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Figure 84- It illustrates the setting used for DESeq2 analysis of differentially
expressed genes in ID3 overexpressed sample VS vector control.
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Integrative analysis of ChIP- and RNA- Seq data with Binding and expression
target analysis (BETA)
BETA is a software package that integrates ChIP-Seq data of TF with transcriptome
quantification and then differential gene expression data to infer direct target genes. We
used available open source at http:// cistrome.org/BETA.

We used BETA-minus

software and input only binding data i.e. peak regions bed file generated from MACS2
output which predicted target genes. The purpose of this protocol is to predict genes that
are the direct targets of TFs or chromatin regulators. BT minus defined the targets as the
genes with a high regulatory potential, derived only from TF binding within a specific
region (100 kb default). BETA calculates regulatory potential for each gene using the
equation

. BETA minus is only equipped to predict TF target genes. It

cannot predict whether the factor binding is activating or repressing gene expression (S.
Wang et al., 2013). We checked the potential target genes output from BETA minus with
DESeq2 differential expressed gene list and then sorted them into upregulated or
downregulated genes list on the basis of fold change of ID3 overexpressed count data
over HPMEC control count data.

ResultsTo examine the global changes in the ID3 gene overexpression HPMEC cells by
using whole transcriptome shotgun sequencing.
We performed global transcriptome analysis on HPMEC and HPMEC ID3+ cells. We
isolated RNA from HPMEC and HPMEC ID3+ cells and performed RNA Seq analysis
comparing gene expression. We mapped FASTAQ files to a reference genome an
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ungapped aligner Bowtie2. Mapping with gapped mapper allows for the identification of
novel genes or transcripts. However, we did not require any novel transcript discovery,
therefore we used Bowtie2. Bowtie2 mapped reads, then used for transcript identification
and quantification. We found total of 1061 genes (significantly change over control with
P < 0.05) were differentially expressed in HPMEC ID3+ than HPMEC cells (Additional
file 8A). We then selected only selected differentially expressed genes with at least one
fold change in expression. Therefore, out of of 1061 genes, we finally found 43 genes
that were downregulated and 22 upregulated genes. DESeq2 normalized the gene
expression counts taken from RNA Seq data of HPMEC ID3+ and HPMEC cells. An
MA-plot is used to visualize differences between measurements taken in HPMEC ID3+
and HPMEC cells. An MA-plot is a plot of log-fold change (M-values, i.e., the log of the
ratio of level counts for each gene between two samples) against the log-average (Avalues, i.e., the average level counts for each gene across the two samples) (Love et al.,
2014). The MA-plot is shown in Figure 85. We used volcano plots to show significance
versus fold-change on the y and x axes, respectively. A volcano plot combines a measure
of statistical significance from a statistical test (e.g., a p value from an ANOVA model)
with the magnitude of the change, enabling quick visual identification of genes that
display large magnitude changes that are also statistically significant.The green colour
marked genes detected as differentially expressed and named at Padj<0.001 when
Bonferroni correction testing adjustment is used (Figure 86). The dispersion estimates for
normaized data is given in additional file 7. A representative heat map is shown in Figure
87 (complete image of heat map is given in additional file). The complete list of raw data
of expressed genes is given in additional file 8B. To further examine the biological
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significance of the differentially expressed genes, we used FunRich which is an open
access standalone functional enrichment and interaction network analysis tool (Pathan et
al., 2015, 2017). G-protein NF-Kβ signaling pathway, immune response, DNA
replication, cell proliferation, and MAPK cascade are topmost significant biological
processes network were expressed after ID3 overexpression which shown in Figure 88
(Additional file 9). The top 20 canonical pathways modulated by ID3 are shown in Figure
82. We found that the topmost pathways modulated by ID3 were regulation of cell cycle
checkpoints, oxidative stress response, EGFR dependent signaling network, biological
oxidation and VEGF and VEGFR signaling network (Additional file 10). Further,
analysis of molecular and cellular functions of the differentially expressed genes revealed
that they are involved in protein-metal ion binding, enzyme binding, cadherin binding,
sequence specific DNA binding, and transcription regulator activity (Figure 90)
(Additional file 11). KEGG pathways were significantly enriched in these ID3-regulated
genes, which included DNA/RNA events, cell cycle, cell-cell interactions (focal
adhesions, adherent junctions), cancer-related pathways (MAPK, LKB1, mTOR and
VEGF) signaling events.
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Figure 85- The MA-plot
It visualizes the differences between gene expression in HPMEC ID3+ and HPMEC
(control) cells, by transforming the data onto M (log2 fold changes attributable to a
gene expression in HPMEC ID3+ over the mean of normalized counts for both
HPMEC ID3+ and HPMEC (control) cells. Points have been colored red whose
adjusted p value is less than 0.1.
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Figure 86- Volcano plot
It illustrates fold differences in individual gene expression in HPMEC ID3+ vs HPMEC
(control) cells, and associated P values (negative log10), in RNA Seq experiment.
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Figure 87- HeatMap
Gene expression profiles of
HPMEC ID3+ and HPMEC
(control) cells are illustrated by
heat map. Heat map of
differentially expressed genes
between control and ID3
overexpressed cells is shown.
Increased or decreased mRNA
expression is represented by red
or blue, respectively.

201

Figure 88- FunRich GEO Biological Process
Differentially expressed genes were subjected to FunRich GO enrichment analysis to
elucidate the biological processes and the top 20 biological processes are shown.
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Figure 89- FunRich Molecular Function
Differentially expressed genes were subjected to FunRich GO enrichment analysis to
elucidate the molecular function of DE genes. The top 20 molecular functions in
which DE genes involved are shown.
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Figure 90- FunRich Biological Pathways
Differentially expressed genes were subjected to pathway analysis using
FunRich enrichment analysis and the top 20 biological pathways are shown.
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Understanding ID3 gene regulatory mechanisms by integrating ChIP-Seq and RNASeq data in HPMEC cells.
To answer the question whether ID3 binding to the genomic regions has functional
consequences through changes in the expression level of target genes, the ChIP-Seq data
were integrated with the RNA Seq data. High-throughput technologies like, RNA-Seq
and ChIP-Seq are widely used to measure gene expression and to obtain genome-wide
maps of transcription factor occupancies (Angelini & Costa, 2014; Park, 2009; Wang,
Gerstein, & Snyder, 2009). The interplay between transcriptomics and epigenomics is
very important to understand the chromatin accessibility to the transcription machinery
which regulates gene expression and, vice versa, some non-coding RNAs can affect local
chromatin states (Wang et al., 2011) In the pipeline process of ChIP Seq data, MACS2
and SICER10 are some of the peak caller tools uses to identify precise TF-binding sites
called peak regions. These peak regions then associated with nearest gene. This peakbased method to identify targets is to assign the proximal nearest gene or the gene
containing peaks in its promoter region (Boyer et al., 2005; Rougemont & Naef, 2012).
Researchers have shown that most of the TF ChIP-Seq data contain only a small
percentage of binding at the promoter region. In addition the use of nearest peaks to
assign target genes is very unreliable (Hua et al., 2008). Therefore, it is very important to
integrate ChIP-Seq and RNA-Seq data to predict gene expression during various cellular
and metabolic pathways (Angelini & Costa, 2014). We used BETA to predict precise
gene targets of ID3 in HPMEC cells. We used BETA minus on Cistrome Galaxy
platform, which predicted ID3 direct gene targets by using .BED peaks file of ID3
binding regions. We gave two ranks (R) to every gene target predicted by BETA minus
(g): one is based on decreasing regulatory potential (Rgb), such that is Rgb = 1 for the
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gene with the largest regulatory potential score, and the other is based on the increasing
of the P value (Rge), that is, Rge = 1 for the most strongly differentially expressed gene.
Then the rank product of the gene (g), RPg = (Rgb/n)*(Rge/n). The RP can be interpreted
as a P value; because it shows the probability that the gene has a regulatory potential rank
≤Rgb and a differential expression changed rank ≤Rge. On the basis of RP, we judged the
targets with an RP less than 10−3 will be more likely to be the true target genes of ID3
(Breitling, Armengaud, Amtmann, & Herzyk, 2004). We found total of 27 most
significant genes (RPg <0.001), which is supposed to be regulated by ID3 (Additional file
13). We then further analyzed by using gene ontology–based tools such as STRING and
FunRich to link functions to this set shown table 12, Figures 91 and 92. If we decrease
the significance level up to RPg <0.05 then list increased to 493 genes. We also identified
19 genes whose promoter region bound by ID3 and also differentially expressed in RNA
Seq data. These data shows that 19 gene were directly regulated by ID3 (additional file
14) (Thomas et al., 2003).
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GO biological process complete

Homo sapiens REFLIST (21042)

(fold
Enrichment)

(raw Pvalue)

cellular response to zinc ion (GO:0071294)

19

47.13

1.25E-08

cellular response to cadmium ion
(GO:0071276)
response to zinc ion (GO:0010043)

31

24.07

3.89E-06

54

16.58

2.91E-06

cellular response to metal ion
(GO:0071248)
cellular response to inorganic substance
(GO:0071241)
positive regulation of RNA metabolic
process (GO:0051254)
regulation of transcription, DNA-templated
(GO:0006355)
regulation of nucleic acid-templated
transcription (GO:1903506)
regulation of RNA biosynthetic process
(GO:2001141)
regulation of RNA metabolic process
(GO:0051252)

154

8.72

1.49E-06

178

7.55

4.62E-06

1504

2.48

2.46E-05

3680

1.87

1.74E-05

3704

1.85

1.85E-05

3712

1.85

1.90E-05

3909

1.79

2.98E-05

(FDR
)
1.93E
-04
1.51E
-02
1.51E
-02
1.16E
-02
1.43E
-02
4.24E
-02
4.51E
-02
4.11E
-02
3.69E
-02
4.62E
-02

Table 12- A detailed list of GO biological processes associated with most
significant genes identified by BETA software.
Table 3- A detailed list of GO biological processes associated with most significant
genes identified by BETA software.
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Figure 91- FunRich GO enrichment analysis of ID3 regulated significant genes
involved in molecular functions
ID3 regulated significant genes were subjected to FunRich GO enrichment analysis to
elucidate the molecular function. The top 10 molecular functions in which these genes
involved are shown.
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Figure 92- FunRich GO enrichment analysis of ID3 regulated significant
genes involved in biological pathways
ID3 regulated significant genes were subjected to FunRich GO enrichment
analysis to elucidate the biological pathway. The top biological processes in
which these genes involved are shown.
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A)

B)
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C)

Figure 93- A,B,C ID3 regulated significant genes involved in EGFR, mTOR and
Focal adhesion signaling biological pathway are shown using KEGG pathway
database.

Figure 94- The cell signaling biological pathways shown in diagram are involved in
cell proliferation.
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Discussion
We applied ChIP-Seq technology to identify global ID3 binding regions in HPMEC and
HPMEC ID3+ cells. To our best knowledge, this is the first global analysis of ID3’s
binding regions in HPMEC cells. ID3 belongs to a family of HLH proteins identified and
named over two decades ago for its dual role as both inhibitors of the differentiation
process and inhibitors of DNA binding. We show here for the first time that ID3 is part of
a more general mechanism of transcriptional regulation than was at first thought. Our
ChIP Seq data show that ID3 binds to a subset of 1240 target genes shared by both
HPMEC ChIP and HPMEC ID3+ ChIP samples (Figure 78). However, only a minor
fraction (3.5-3.7%) of the ID3 binding sites identified which are close to TSSs. This
moderate percentage may be explained by the ID3 binding site distribution, where most
of the binding sites are related with orphan intergenic regions. In this regard, our study
demonstrates ID3 binding sites in regions distal to TSSs, preferentially in distal
intergenic regions, which highlights a potential role as a distal or alternative
transcriptional regulator, although this does not rule out indirect regulation.
MEME-ChIP showed that ID3 binds to statistically significant GAGAGAGAGA motif
sequence on the genomic DNA. Researchers have not been confirmed yet any ID3
binding sequences. However, Zaragoza et al. showed in genome wide mapping
experiment that Id2 binds to individually as well as along with E2F4 on c-myc promoter
of mouse liver cells (Ferrer-Vicens et al., 2014). Id2 is one of the members of the ID
family proteins, which lacks DNA binding domain similar to ID3. In addition, genome
wide mapping (ChIP on chip) and then MEME analysis showed overrepresentation of
similar GAGAGAGA motifs also known as GAF motif for polycomb/trithorax response
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elements in Drosophila melanogaster (Ringrose, 2017; Ringrose, Rehmsmeier, Dura, &
Paro, 2003). These evidences support the hypothesis of ID3 binding to the DNA. There is
another possibility that ID3 may be regulating gene expression by interacting with other
known TFs and then binding to DNA as a protein complex. This type of protein complex
binding is also known as cofactor based targeting binding. Targeting of non-DNAbinding cofactors to DNA was earlier viewed solely via protein–protein interactions with
DNA-bound TFs. This is known as indirect interaction with DNA through the TFs.
However, several studies have described a provocative alternative mechanism in which
recruited cofactors interact directly with DNA when part of a larger, multi-protein
complex (Babb, Huang, Aufiero, & Herr, 2001; Siggers, Duyzend, Reddy, Khan, &
Bulyk, 2011). The non-DNA-binding cofactors mediate sequence-specific interactions
that preferentially stabilize the binding to composite DNA sites containing specific
auxiliary motifs. This represents yet another mechanism to enhance the DNA sequence
specificity of multi-protein regulatory complexes. The regulation of sulfur metabolism
genes in yeast involves a multi-protein complex composed of a sequence-specific TF
Cbf1 and two non-DNA-binding cofactors Met28 and Met4 (Blaiseau & Thomas, 1998;
Kuras, Cherest, Surdin-Kerjan, & Thomas, 1996). Cbf1 is a bHLH protein and binds as a
homodimer to E-box sites with a consensus 5′-CACGTG-3′ core (Kuras et al., 1996).
Therefore, we predict it may be possible that ID3 regulating gene expression by
interacting with TFs like BCL11A, IRF4, PRDM1, FOXJ3, SMAD4, ZBTB6, STAT2,
and GATA1. Researchers have already shown that loss of SMAD4 and overexpression of
IRF4 increases the cell proliferation in Non-small cell lung cancer (NSCLC) (Haeger et
al., 2016; Qian et al., 2017). In addition, our lab and other researchers have shown ID3
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involvement in EC proliferation acts as a disease phonotype for NSCLC (Castañon et al.,
2013). The regulation of ID3 through interaction with other TFs proteins enhances the
cooperation in the modulation of transcription of other genes. Taking into account this
complete transcriptional scenario, our data describe potential interactions of ID3 with
both common TFs and core elements, which could cooperate in chromatin remodeling for
transcriptional regulation in lung endothelial cells.
Identification of biological processes controlled by overexpressed ID3 in HPMEC has
been mainly associated to lung EC proliferation and checking at cell cycle phases through
its transcriptional role in key EC proliferation-related genes (Al-husseini et al., 2015; Das
& Felty, 2014b; Felty, Yoo, & Kennedy, 2010). At this regard, we observed a
downregulation of Cell division protein kinase 6 (CDK6), which is an enzyme encoded
by the CDK6 gene. It is important for the G1 phase progression and G1/S transition of
the cell cycle (Meyerson et al., 1992). Researchers have shown that deregulation of
CDK6 has been shown to be important in lymphoid malignancies by increasing
angiogenesis, a hallmark of cancer (Diaz-Moralli, Tarrado-Castellarnau, Miranda, &
Cascante, 2013). Interestingly, we observed four fold downregulation of EGR1. EGR1
acts as a tumor suppressor in NSCLC (Zhang et al., 2013). Our data showed that ID3
significantly downregulated EGR1 which could result into HPMEC hyper proliferation.
Intriguingly, ID3 modulates the expression of several genes involved in carcinogenesis
and lung malignancies in Figures 93 A, B, C and 87 (insulin signaling, mTOR signaling,
EGFR signaling and MAPK pathways), inflammatory response and angiogenesis
(VEGFR signaling). We observed VEGFA overexpression in RNA Seq data, which is
angiogenesis marker. Moreover, we found upregulation of gene HSPA8 that is a heat
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shock family protein 70. Its functions contribute to biological processes including signal
transduction, apoptosis, autophagy, protein homeostasis, and cell growth. It codes for the
protein HSP72 which is shown to be over expressed in gastric cancers, colon cancers,
breast cancers, and lung cancers (Wang et al., 2013a) (Mayer & Bukau, 2005; Wang et
al., 2013b). We also observed EEF2K gene upregulation which codes for
calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase enzyme (Ryazanov
et al., 1997). Researchers have shown upregulation EEF2K gene in various cancers
(Leprivier et al., 2013).
Moreover, MyCancerGenome has compiled database on molecular profiling of lung
cancer which is comprised of oncogenes associated with two main histologic subtypes:
non-small cell lung cancer and small cell lung cancer (SCLC) (Lovly, Horn, 2016). The
database has identified the total of 23 oncogenes known to be important for lung cancer
pathogenesis. We compared this list of genes with DE gene list from RNA Seq data that
resulted into 11 common oncogenes. Similarly, comparison has been done between the
lists of lung cancer oncogenes with BETA integrative analysis list, we found MAP2K1,
and MET oncogenes were common. We also used pulmonary arterial hypertension
knowledgebase (PAHKB), which provides 341 human PH-related genes (293 protein
coding and 48 non-coding genes) to compare with DE genes and BETA integrative
analysis data (Zhao, Austin, Hemnes, Loyd, & Zhao, 2014). We found common 69 genes
and 30 genes in DE genes and BETA integrative analysis data respectively. This evidence
shows that potential involvement of ID3 in regulation of genes, which are responsible in
lung endothelial cells proliferation. This endothelial cell hyper proliferation is disease
phenotype for both PAH and lung cancer (additional file 15).
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Conclusion
State-of-the-art cis-regulatory sequencing studies have been combined with RNA
sequencing to further characterize the functional relevance of TF- interacting DNA
regions and thus to define their transcriptional output. In our study, we describe ID3 as a
master regulator of key cellular processes for lung cells biology, including cell cycle
regulation, DNA repair, replication and metabolism, and cell polarity, and define a large
set of genes whose expression is modulated by ID3.
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CHAPTER 5
Determination of ID3 targeted genes resulted from the integrative analysis involved
in endothelial cell proliferation
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Abstract
PAH is an incurable end-stage lung disease that is often fatal and characterized by the
presence of plexiform vascular lesions in pulmonary arterioles. ECs in plexiform vascular
lesions (a pathological hallmark of PAH) have been characterized as hyper-proliferative
and apoptosis-resistant, which is consistent with a neoplastic hypothesis. Epidemiological
studies have reported that women are up to four times as likely to present with severe
PAH as men while animal studies have implicated endogenous estrogen as a contributing
factor for PVL. The impact of exogenous estrogen or estrogenic PCBs is growing as an
environmental risk factor, particularly exposure to PCBs, in the development of PAH that
clearly justify the need for further studies to determine the contribution of the
environment to PVLs. The integrative analysis of ChIP- and RNA-Seq data from our lab
resulted in ID3 specific targeted genes, which are associated with vascular
reprogramming. Out of these ID3 target genes, some of the genes have been shown
involved in vascular reprogramming and EC proliferation. The objective of the research
is to investigate the interaction of ID3 with these genes and elucidate molecular
pathogenesis of a highly disordered or neoplastic-like endothelial vascular lesion to more
accurately address the clinical reality of short survival and no cure for IPAH patients with
PVLs. Our aim is to generate mechanistic data of this interaction in our cell model with
ID3 in order to identify target genes involved in promoting the growth of a tumor-like
vascular lesion.
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IntroductionThe integrative ChIP and RNA Seq data of ID3 targeted gene demonstrated that DNAJC2
and MALAT1 genes were significantly expressed. Therefore, we decided to check the
DNAJC2 and MALAT1 genes epigenetically regulate ID3 and PCB-induced vascular
lesions in vitro. DNAJC2 is a gene in Homo sapiens codes for the protein which is an
officially named as DnaJ heat shock protein family (Hsp40) member C2 (Entrez Gene:
ZRF1 zuotin related factor 1, ; Matsumoto-Taniura, Pirollet, Monroe, Gerace, &
Westendorf, 1996). DNAJC2 gene is also known as MPHOSPH11, MPP11, MIDA1, and
Zuotin-related factor 1, ZRF1 (Gray, Yates, Seal, Wright, & Bruford, 2015). DNAJC2
gene belongs to the family of the M-phase phosphoprotein (MPP), which encodes a
phosphoprotein with a J domain and a Myb DNA-binding domain, which localizes to
both the nucleus and the cytosol. The protein acts as a molecular chaperone for nascent
polypeptide chains as they exit the ribosome (Matsumoto-Taniura et al., 1996). It has
been shown that DNAJC2 protein is related to pathways like a cellular response to heat
stress and cellular Senescence (Gray et al., 2015). Researchers have also shown the
evidence of involvement of DNAJC2 as leukemia-associated antigen and in primary head
and neck squamous cell tumors (Demajo et al., 2014; Resto et al., 2000). The DnaJ
domain of DNAJC2 protein, which is part of the amino-terminal part of the protein is
conserved ubiquitously from yeast to mammals. This amino part mediates interactions
with heat shock proteins and is mainly implicated in protein-chaperone functions
associated with ribosomes (Yan et al., 1998). In addition to this, DNAJC2 can bind to
nucleic acids through its DnaJ domain (Wilhelm, Reinbolt, Gangloff, Dirheimer, &
Wilhelm, 1994; Zhang, Lockshin, Herbert, Winter, & Rich, 1992) and has been suggested
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to have a role in transcriptional regulation (Eisenman & Craig, 2004; Yoshida, Inoue,
Shoji, Ikawa, & Obinata, 2004). Inou et al. have showed that MIDA1 i.e. DNAJC2
protein is associated with ID1 protein which regulates cell growth. They have also shown
that DNAJC2 can directly bind to DNA through amino acid sequence contains
tryptophan-mediated repeats (Tryp-med repeats) similar to the DNA binding region of
the c-Myb oncoprotein (Inoue, Shoji, & Obinata, 2000; Shoji, Obinata, 1999). Recently,
researchers have shown that DNAJC2 protein is a regulator of the expression of
polycomb targets - polycomb repressive complexes 1 and 2 (PRC1 and PRC2), which
play a crucial role in several processes including cell proliferation, and senescence in
stem cells and cancer (Sauvageau & Sauvageau, 2010). In humans, the protein structure
of DNAJC2 contains an additional C-terminal extension with 2 SANT domains. SANT
domains are similar to the Myb-DNA binding motif, (Boyer, Latek, & Peterson, 2004)
which is required for Myb proto-oncogene to bind DNA as shown in Figure 95. Indeed,
the researchers have shown that DNAJC2 can directly bind to DNA. Researchers have
shown the evidence of binding of DNAJC2 to monoubiquitinated histone H2A (H2Aub1)
protein through its ubiquitin-binding domain (UBD). In proliferating conditions of cells,
polycomb proteins occupy H2Aub1 mark. In vitro studies have shown that DNAJC2
displaces PRC1 from chromatin during differentiation stage by competing for the
H2Aub1 mark. Once DNAJC2 protein attached to the chromatin by DnaJ binding
domain, it induces transcriptional activation of differentiation genes (Richly et al., 2010).
In addition to this, DNAJC2 protein is also responsible for self-renewing, the pluripotent
state of endothelial stem cells (ESC). Researchers have shown that DNAJC2 protein
directly interacts with ID1 protein to maintain a self-renewing state of ESCs. Similar to
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H2Aub1 protein, DNAJC2 protein interacts with ID1 through its UBD domain (Aloia,
Gutierrez, Caballero, & Di Croce, 2015; Ruzinova & Benezra, 2003). ID1 protein
regulates the cell differentiation through DNAJC2 protein since ID1 protein belongs to
the family of ID proteins- ID1, ID2, ID3, and ID4. ID proteins are helix-loop-helix
(HLH) proteins also known as inhibitors of differentiation function as dominant negative
regulators of basic HLH (bHLH) transcriptional regulators that drive cell lineage
commitment and differentiation of cells. Earlier researchers and our lab have shown that
ID3 regulates cell differentiation, stemness to the cells and angiogenesis (Das et al., 2015;
Morisaki et al., 2016). With this background information, we checked whether proteins
ID3 and DNAJC2 also interact with each other.

Figure 95- Representative Map Reads from ID3 ChIP-Seq shows
immunoprecipitated chromatin containing DNA regions corresponding to genes
DNAJC2-AS1 and MALAT1
226

Experiment –
Western BlotIn order to determine the interaction between ID3 and DNAJC2 protein, we first checked
the expression of DNAJC2 protein in HPMEC ID3+ cell line with control, E2, PCB153
and co-treatment E2 +PCB153 treatments. We seeded the HPMEC ID3+ cells in four
100mm petri dishes each. We added 0.1% DMSO (control), E2 (100 ng/mL), PCB153
(100 ng/mL) and combination treatment of E2 +PCB153 to separate petri dishes. We
analyzed that combination treatment of E2 +PCB153 increase 2-3-fold change in
DNAJC2 protein expression in HPMEC ID3+ cells compared to control. E2 (100 ng/mL),
PCB153 (100 ng/mL) treatment showed significant (P<0.01) increased than control as
shown in Figure 96.
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Figure 96- Western Blot analysis of DNAJC2 protein
Detection of DNAJC2 protein 71 KDa and beta actin as a control 41 KDa in Lung EC
ID3+ cell line. Gel percentage 7.5%. Dilution of DNAJC2 antibody (1: 2000) i.e. 5 µL
in 10 mL of blocking buffer- Primary antibody is rabbit Ab (polyclonal). Incubation
time overnight at 4 oC for Primary antibody. Secondary Ab is anti-rabbit Ab.
Dilution of Secondary antibody (1: 50000). E2 & PCB153 = 100ng/mL

Immunoprecipitation
ID3 co-immunoprecipitation of DNAJC2Background- In vivo, the mouse homolog to DNAJC2 known as MIDA1 (mouse Id
associated 1) has been shown to bind to ID1 and positively regulate cell growth. Hence,
our aim is to generate mechanistic data of this interaction in our cell model with ID3 in
order to identify target genes involved in promoting the growth of a tumor-like vascular
lesion. We postulate that ID3 is a novel co-activator of DNAJC2 and ID3-DNAJC2
protein-protein interaction is critical in driving the growth of tumor-like vascular lesions.
Procedure- For immunoblots of immunoprecipitated (IP) lysate the following method was
used. ID3 protein was pulled down using magnetic beads (Dynabeads protein G). In
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Brief, the lysate was incubated with 10 mg of antibody and 50 mL (1.5 mg) of Dynabeads
(Invitrogen) in microcentrifuge tubes with rotation for 10 minutes at room temperature.
Samples were then placed on a magnetic particle concentrator (DynaMagTM-2,
Invitrogen) and the supernatant was discarded. Dynabeads–Ab–Ag complex was washed
3 times with washing buffer and tubes were placed on magnetic particle concentrator to
remove the supernatant. The magnetic Dynabeads–Ab–Ag complex was suspended with
20 mL of Elution Buffer and boiled in SDS sample buffer for 5 min. Samples were
placed on the magnetic particle concentrator and the supernatant containing protein were
separated by SDS-PAGE and immunoblotted as described above as shown in Figure 97.
Experimental Design: ID3 and DNAJC2 cross-linked to DNA (chromatin) will be
measured by Western blot using lung EC ID3+ and/or lung EC WT.
Using approved ChIP protocol:
Step 1: Fix cells to cross-link DNA to protein.
Step 2: Sonicate to lyse cells and shear chromatin. Note: run a DNA gel to determine
optimum conditions for shearing DNA.
Step 3: Immunoprecipitated DNA bound by ID3 and/or DNAJC2.
Experiment 1 (ID3 bound DNA)
Sample 1: IP chromatin cross-linked proteins with polyclonal ID3 Ab.
Sample 2: IP chromatin cross-linked proteins with IgG Ab (negative control).
Sample 3: Whole cell lysate (Lung EC ID3+ positive control)
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We loaded the immunoprecipitated lysate in SDS-PAGE and detected ID3 using
antibody. We ran three samples: (i) ID3 IP lysate; (ii) IgG IP lysate (negative control);
and (iii) whole cell lysate 100 µg (positive control).
Experiment 2 (DNAJC2 bound DNA)
Sample 1: IP chromatin cross-linked proteins with polyclonal DNAJC2 Ab
Sample 2: IP chromatin cross-linked proteins with IgG Ab (negative control).
Sample 3: Whole cell lysate (Lung EC ID3+ positive control)
We loaded the immunoprecipitated lysate in SDS-PAGE and detected DNAJC2 using
antibody. We ran three samples: (i) DNAJC2 IP lysate (ii) IgG IP lysate (negative
control) and (iii) whole cell lysate 100 µg (positive control).
ProcedureExperiment-1 - Dilution of ID3 antibody (1: 1000) i.e 10 µL in 10 mL of blocking bufferBSA (0.5g +10 mL TBST). Primary antibody is rabbit Ab (polyclonal). Incubation time
overnight at 4 degrees Celsius for Primary antibody. Secondary Ab is anti-rabbit Ab.
Dilution of Secondary antibody (1: 5000) i.e. 2 µL in 10 mL of blocking buffer.
Molecular weight of ID3 is 17 KDa. Separating Gel percentage- 15% DNAJC2 (abcam)
ab134572 Rabbit polyclonal used for IP. ID3 (CalBioReagent) monoclonal used for
western blot.
Experiment-2 - Dilution of DNAJC2 antibody (1: 2000) i.e 5 µL in 10 mL of blocking
buffer. Primary antibody is rabbit Ab (polyclonal). Incubation time overnight at 4 oC for
Primary antibody. Secondary Ab is anti-rabbit Ab. Dilution of Secondary antibody (1:
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50000). Molecular weight of DNAJC2 is 71 KDa. Separating Gel percentage- 7.5%.
DNAJC2 (abcam) ab134572 Rabbit polyclonal used for western blot. ID3 (Santacruz
Biotechnology sc- 490) monoclonal antibody.
Results-

Figure 97- Immunoprecipitation of ID3 and DNAJC2
ID3 protein was isolated by immunoprecipitation (IP) technique using magnetic beads
and detected by immunoblot. ID3 protein of immunoprecipitated DNAJC2 protein was
determined with anti-ID3 antibody. ID3 bands detected from immunoprecipitated cell
lysate corresponded with the molecular weight of 17 KDa for ID3.
Electrochemiluminescence (ECL) band intensity for phosphorylated ID3 was imaged
with a Bio-Rad Versa Doc instrument. Similarly, DNAJC2 protein detected from
immunoprecipitated ID3 protein lysate at 71 KDa.
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Figure 98- Co-localization of ID3 and DNAJC2
Confocal microscopy of the co-localization of ID3 (blue) with DNAJC2 (Red) in
lung EC ID3+ cells. Cells were treated with DMSO (Left) or PCB153 (0.3 µM)
(Right) for 24h. ID3 was determined by immunofluorescent labelling with rabbit antiID3 polyclonal antibody (Alexa Fluor 566-conjugated secondary antibody). DNAJC2
was determined by immunofluorescent labelling with mouse monoclonal IgG (Alexa
Fluor 633-conjugated secondary antibody).
Immunofluorescence and immunoprecipitation experiments showed that ID3 and
DNAJC2 interact with each other as shown in Figure 97 and 98.
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CRISPR/Cas9 experiment

Hypothesis: The CRISPRCas9 MALAT1/DNAJC2 (ZRF1) epigenetically regulate
the phenotypic expression like spheroid size and numbers in lung EC ID3+.
Background: Our aim is to generate mechanistic data of this interaction in our cell
model with ID3 in order to identify target genes involved in promoting the growth of a
tumor-like vascular lesion. We postulated that ID3 is a novel co-activator of DNAJC2
and ID3-DNAJC2 protein-protein interaction is critical in driving the growth of tumorlike vascular lesions. In order to determine the interaction between ID3 and DNAJC2
proteins, we did a co-immunoprecipitation experiment in two ways. In the first
experiment, we used an ID3 polyclonal antibody to pull own ID3 bound proteins from
Lung EC ID3+ protein sample and then immunoblotted with the monoclonal DNAJC2
antibody. We found the expression of DNAJC2 protein at 71 KDa, which is confirmed by
using standard protein ladder for molecular weight determination on western blots. In
another similar experiment, we used the DNAJC2 antibody for immunoprecipitation from
the sample and then immunoblotted with the monoclonal ID3 antibody. We found the
expression of ID3 protein at 17 KDa, which is confirmed by using standard protein ladder
for molecular weight determination on western blots. Moreover, we did mRNA
sequencing experiment with lung EC ID3+ cells and analyzed the data. We found out that
Metastasis Associated Lung Adenocarcinoma Transcript1 (MALAT1) mRNA was
expressed higher folds in lung EC ID3+ cells compared to the control wild type HPMEC
cells.
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Therefore, to check whether MALAT1 and DNAJC2 proteins co-regulate with ID3
protein, we decided to silence the expression of MALAT1 and DNAJC2 proteins and
study the effect of silencing on the stem like property of lung EC ID3+ cells.
MALAT1 gene is non-protein coding gene which is also known as Nuclear Paraspeckle
Assembly Transcript 2 (Ji, Diederichs, Wang, Böing, et al., 2003; Kryger, Fan, Wilce, &
Jaquet, 2012; Zhang et al., 2017). Noncoding RNAs (ncRNAs) are defined as
untranslated regulatory RNA molecules. In humans, at least 98% of the total genome
does not get translated into protein. Only 2% of total DNA sequences responsible for
non-protein coding regions (Yin, Hamblin, & Chen, 2014). So, the non-protein coding
part of genome consists of Noncoding RNAs which include microRNAs, and long
noncoding RNAs (Bartel & Chen, 2004). MALAT1 gene produces non-long coding RNA.
In addition to this, More than 8000bp sequence present in MALAT1 gene is highly
conserved in 33 mammalian species and the highest expression of MALAT1 mRNA is
found to be in pancreas and lung (Chen, Li, Lodish, & Bartel, 2004; Ji, Diederichs,
Wang, Boïng, et al., 2003). MALAT1 gene transcribes into a precursor transcript. This
transcript resides in the nucleus, which is thought to form molecular scaffolds for
ribonucleoprotein complexes. Then, RNase P cleaves of a tRNA-like small ncRNA
(known as mascRNA) from the 3' end of transcript and extract a long non-coding RNA (
Ma et al., 2015; Rinn & Chang, 2012). Primarily, MALAT1 gene is identified by
subtractive hybridization in stage I NSCLC (non-small cell lung cancer) tumors
(Hutchinson et al., 2007; Ji, Diederichs, Wang, Boïng, et al., 2003).
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At the beginning, many researchers have been originally identified lncRNA MALAT1 as
a prognostic marker for non-small cell lung cancer, in the cerebrovascular pathogenesis
of ischemic stroke. Researchers have done several experiments to prove the elevated
level of lncRNA MALAT1 responsible for NSCLC. In one of the experiments, scientist
tested increasing levels of MALAT1 expression in cultured NSCLC cell lines (A549 and
HTB58) via qPCR analysis (Ma et al., 2015). Gutschner et al. 2013 showed in vivo and in
vitro experiments that NSCLC cell lines transfected with MALAT1- shRNA proliferate
(Gutschner et al., 2013). Moreover, another group of researchers in the literature showed
that inhibition of MALAT1 forces cells to switch its gears from anti-proliferative to
impaired endothelial cell proliferation in vitro and in vivo and reduced retinal vessel
growth. They have also showed that when siRNA transfected for MALAT1 treated with
HUVECs reduces the expression of MALAT1 induces angiogenic sprouting and
migration but represses proliferation. These researchers have also found out that when
HUVECs exposed to hypoxia environment, the expression MALAT1 increased
substantially (Michalik et al., 2014). Similarly, when we treated with lung EC ID3+ cells
to SU5416 which is a selective synthetic inhibitor of the Flk-1/KDR vascular endothelial
growth factor (VEGF) receptor tyrosine kinase in presence of hypoxia environment in our
lab, we found the expression of stem cell markers Oct-4, Sox-2, and Nanog by cell
cytometry and immunohistochemistry analysis. At the same time, surprisingly we found
the elevated expression of VEGFR3 markers on lung EC ID3+ cells (Doke & Felty,
2016). We proposed these stem likes cells, which are pluripotent cell that gives rise to a
clonal pulmonary vascular lesion that supports the aggressive growth of NSCLC.
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Looking at the close relation of lncRNA MALAT1 and ID3 protein to metastatic growth
of NSCLC, therefore, we studied the effect of lncRNA MALAT1 on the lung EC ID3+.
ExperimentsSpheroid AssaysQuestion: Does the long noncoding RNA (lncRNA) MALAT1 and DNAJC2 regulate the
growth of ID3 expressing lung endothelial spheroids (lung EC ID3+)?
Purpose: Small noncoding RNAs (i.e. microRNAs), >200-nucleotide long transcripts,
namely lncRNAs, can interfere with gene expressions and signaling pathways at various
stages. ID3 may be epigenetically regulated by the long-noncoding RNA MALAT1 based
on the following evidence: MALAT1 expression is augmented by hypoxia in endothelial
cells (a contributing factor in the rodent model of PAH) and MALAT1 supports the
proliferative response of endothelial cells both phenomena are correlated with ID3. Thus,
the purpose of this experiment is to determine whether lncRNA MALAT1 regulates the
formation of ID3 expressing endothelial spheroids. It is unclear whether endothelial- or
smooth muscle-based lesions have a similar impact on the course of PAH.
Experimental Design:
We followed the protocol for endothelial spheroid and 3-D cell culture as described in
Das JK et al. Microvascular Research (2015). In brief, cells were suspended in serum-free
stem cell medium containing DMEM/F12 (1:1) supplemented with B27®. For EC
spheroid generation, approximately 100-150 cells per well were seeded in an ultra-low
attachment 96-well plate (Corning Inc, Lowell, MA).
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2.

Experiment 2 Design:


Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with MALAT1 sgRNA
CRISPR/Cas9 All-in-One Lentivector set (Human) Applied Biological Materials
(ABM) K1258505.



Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with DNAJC2 sgRNA
CRISPR/Cas9 All-in-One Lentivector set (Human) Applied Biological Materials
(ABM) K0614705.



Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with Scrambled sgRNA
CRISPR/Cas9.

After 24-48 h transfection, seed cells in triplicate (100-150 cells per well) in ultra-low
attachment 96-well plates as described previously and recorded phenotype changes.
Results: We found that knockdown of lncRNA MALAT1 resulted in the following
phenotype changes- decreased endothelial spheroid number, decreased endothelial
spheroid size when compared to the control endothelial spheroids transfected with
Scrambled sgRNA CRISPR/Cas9. The nuclear transcript MALAT1 has been functionally
associated with gene regulation and alternative splicing and its regulation has been shown
to impact proliferation, apoptosis, migration and invasion. Therefore, these results
showed ID3 may be epigenetically regulated by the long-noncoding RNA MALAT1
(metastasis-associated lung adenocarcinoma transcript 1) as shown in Figure 99, 100 and
101.
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Figure 99- It shows pictures of spheroids with CRISPR/CAS9 MALAT1 /ZRF1
treatment.
CRISPR/CAS9 MALAT1 /ZRF1 treatment decreases spheroid size and number in the
PCB153 treated wells. The decrese in the size and number of spheroid in
CRISPR/CAS9 MALAT1 /ZRF1 treated wells are significantly lower compared to
scrambled sgRNA control. Scale bar= 10µm.
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Figure 100- CRISPR/CAS9 MALAT1 /ZRF1 knockdown reduced spheroid number
CRISPR/CAS9 MALAT1 /ZRF1 knockdown ID3 expression in lung EC ID3+ and result
in a decrease in spheroid number compared to spheroid with scrambled sgRNA
CRISPR/Cas9. (*)PCB153 treatment in CRISPR/CAS9 MALAT1 /ZRF1 significantly
different from PCB153 treatment in scrambled sgRNA (P<0.01) at day 10. Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Figure 101- CRISPR/CAS9 MALAT1 /ZRF1 knockdown reduced spheroid size
CRISPR/CAS9 MALAT1 /ZRF1 knockdown ID3 expression in lung EC ID3+ and result
in a decrease in spheroid diameter compared to spheroid with scrambled sgRNA
CRISPR/Cas9. (*)PCB153 treatment in CRISPR/CAS9 MALAT1 /ZRF1 significantly
different from PCB153 treatment in scrambled sgRNA (P<0.01) at day 10 Data were
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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PCR experiment
Purpose: To investigate how non-coding RNAs regulate ID3 when exposed to PCBs.
RNA Isolation and Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated and purified using the RNeasy Mini Kit from Qiagen (Valencia,
CA). RNA sample quality was verified by electrophoresis on a denaturing agarose gel
and then reverse transcribed into cDNA using the RT² First Strand Kit from SuperArray
Bioscience Corporation (Frederick, MD) according to the manufacturer's protocol. The
PCR reactions using cDNA were performed in an Applied Biosystems 7300 Real-Time
PCR System using RT2 SYBR Green/ROX qPCR Master Mix and the manufacturer's
thermal cycler protocol (95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, 60 °C
for 1 min). The threshold cycle (CT) from each well was determined using ABI 7300
SDS software.
MALAT1-set siRNA/shRNA/RNAi Lentivector (Human)
The siRNA specifically targeting MALAT1 was constructed by abm Company (USA),
HPMEC and HPMEC ID3+ cells were transfected with siRNA targeting MALAT1 using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Cells
transfected with Scramble was used as the negative control, the Scramble siRNA
sequence was as follows: sense, AACAUCUCUUGGGCUUUUAUU, antisense,
GAGAAUUAAGUAAAUGCCCUU. Cells were collected after transfection for RNA
extraction
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Target Sequence

1762: GACCTTGAAATCCATGACG

5374: TCAGAAGAGTTGCTTCATTTCATCTGGGA
5427: ACAGATAAGTTTAACTTGCATCTGCAGTA
5605: TGGGCTTCAGTGATGGGATAGTACACTTC
Sequencing Primers TACGTCCAAGGTCGGGCAGGAAGA
Mammalian Selection - Puromycin. Direct non-viral plasmid transfection for immediate
expression. Package into Lentiviral particles for high efficiency transduction and stably
integrated expression. RNA interference lentiviral vectors contain siRNAs. We employed
a dual convergent promoter system where the sense and antisense strands of the siRNA
are expressed by two different promoters rather than in a hairpin loop to avoid any
possible recombination events that can occur.
LncRNA MALAT1 polymerase chain reaction (PCR) array
PCR analysis of cDNA from RNA isolated from HPMEC ID3+ treated with vehicle
control (0.1% DMSO), PCB153, or 17β-estradiol for 24h was performed in triplicate
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using RT2. RT² lncRNA qPCR Assay for Human MALAT1 (LPH18065A) and RT²
lncRNA qPCR Assay for Human HIF1A-AS2 (LPH00171A) from Qiagen Inc. were used
to compare the relative expression of genes. Relative changes in gene expression between
the treated and untreated HPMEC ID3+ RNA were calculated by the ΔΔCT method as
previously described (Livak & Schmittgen, 2001). First, target genes in were normalized
to the endogenous control or housekeeping genes: RPL13A, GAPDH, or ACTB. Next,
each treatment group was normalized to the untreated group (vehicle control, 0.1%
DMSO). Using the SA Biosciences PCR Array Data Analysis Web Portal, fold changes
in gene expression were analyzed between groups using the equationΔΔCT= [CT target gene−Avg.CT housekeeping genes] treated group−CT target gene−
Avg. CT housekeeping genes] control group. Each value is a repeat of three independent
experiments. ANOVA and Fisher's least significant difference test were used for multigroup comparisons, with a P value of less than 0.05 considered significant.

Results and ConclusionTo validate our results from RNA Seq studies, we did RT-qPCR analysis. We validated
the expression of lncRNA MALAT1 in HPMEC ID3+ cells. When we treated the cells
with E2 and PCB153, the MALAT1 showed 4-5 fold higher expression compared to
control as shown in Figure 102. These results signify the interaction between ID3
overexpression and MALAT1 is significant. Researchers have already shown a critical
role for MALAT1 in NSCLC cancer metastasis, which is the major cause of cancer
recurrence and tumor-related death. Therefore, we hypothesized that MALAT1 and ID3
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might be a potential therapeutic target to inhibit endothelial cell proliferation due to
exposure to PCB.

Figure 102- MALAT1 expression in HPMEC ID3+ cells.
Upregulation of lncRNA MALAT1 mRNA expression when treated with E2 and
PCB153. HPMEC ID3+ cells were treated with either vehicle or E2 or PCB153 for 24 h,
and the mRNA expression of MALAT1 was validated by using RT-qPCR. Data are
represented as mean ± SE. * p<0.01.
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Figure 103- Knockdown of MALAT1 in HPMEC ID3+ cells measured by qRT-PCR
HPMEC and HPMEC ID3+ cells were transfected with siRNA targeting MALAT1, QRTPCR assay was employed to detect the endogenous expression of MALAT1 to confirm
the knockdown efficiency. The HPMEC cells transfected with Scramble was used as the
negative control.*P < 0.01 vs. the control.

245

ReferencesAloia, L., Gutierrez, A., Caballero, J. M., & Di Croce, L. (2015). Direct interaction
between Id1 and Zrf1 controls neural differentiation of embryonic stem cells. EMBO
Reports, 16, 63–70. http://doi.org/10.15252/embr
Bartel, D. P., & Chen, C.-Z. (2004). Opinion: Micromanagers of gene expression: the
potentially widespread influence of metazoan microRNAs. Nature Reviews
Genetics, 5(5), 396–400. http://doi.org/10.1038/nrg1328
Boyer, L. A., Latek, R. R., & Peterson, C. L. (2004). Opinion: The SANT domain: a
unique histone-tail-binding module? Nature Reviews Molecular Cell Biology, 5(2),
158–163. http://doi.org/10.1038/nrm1314
Chen, C., Li, L., Lodish, H. F., & Bartel, D. P. (2004). Lineage Differentiation. Science,
303(5654), 83–6. http://doi.org/10.1126/science.1091903
Das, J. K., Voelkel, N. F., & Felty, Q. (2015). ID3 contributes to the acquisition of
molecular stem cell-like signature in microvascular endothelial cells: Its implication
for understanding microvascular diseases. Microvascular Research, 98, 126–138.
http://doi.org/10.1016/j.mvr.2015.01.006
Doke, M., & Felty, Q. H. (2016). Abstract 3274: VEGF─receptor antagonist, Sugen
5416, sensitizes pulmonary endothelial stem-like cells to estrogens: A microvascular
model for the progression of lung cancer. Cancer Research, 76(14 Supplement).
Retrieved from http://cancerres.aacrjournals.org/content/76/14_Supplement/3274
Eisenman, H. C., & Craig, E. A. (2004). Activation of pleiotropic drug resistance by the
J-protein and Hsp70-related proteins, Zuo1 and Ssz1. Molecular Microbiology,
53(1), 335–344. http://doi.org/10.1111/j.1365-2958.2004.04134.x
Entrez Gene: ZRF1 zuotin related factor 1. (). Retrieved from
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&Term
ToSearch=27000
Gray, K. A., Yates, B., Seal, R. L., Wright, M. W., & Bruford, E. A. (2015).
Genenames.org: the HGNC resources in 2015. Nucleic Acids Research, 43(Database
issue), D1079-85. http://doi.org/10.1093/nar/gku1071
Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., … Diederichs,
S. (2013). The non-coding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. February, 1(733), 1180–1189.
http://doi.org/10.1158/0008-5472.CAN-12-2850
Hutchinson, J. N., Ensminger, A. W., Clemson, C. M., Lynch, C. R., Lawrence, J. B., &
Chess, A. (2007). A screen for nuclear transcripts identifies two linked noncoding
RNAs associated with SC35 splicing domains. BMC Genomics, 8(1), 39.
http://doi.org/10.1186/1471-2164-8-39

246

Ji, P., Diederichs, S., Wang, W., Boïng, S., Metzger, R., Schneider, P. M., … MuïlerTidow, C. (2003). MALAT-1, a novel noncoding RNA, and thymosin b4 predict
metastasis and survival in early-stage non-small cell lung cancer. Oncogene, 22,
8031–8041. http://doi.org/10.1038/sj.onc.1206928
Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P. M., … MüllerTidow, C. (2003). MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer. Oncogene, 22(39),
8031–41. http://doi.org/10.1038/sj.onc.1206928
Kryger, R., Fan, L., Wilce, P. A., & Jaquet, V. (2012). MALAT-1, a non protein-coding
RNA is upregulated in the cerebellum, hippocampus and brain stem of human
alcoholics. Alcohol (Fayetteville, N.Y.), 46(7), 629–34.
http://doi.org/10.1016/j.alcohol.2012.04.002
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using
real-time quantitative PCR and the 2-ΔΔCT method. Methods, 25(4), 402–408.
http://doi.org/10.1006/meth.2001.1262
Ma, X. Y., Wang, J. H., Wang, J. L., Ma, C. X., Wang, X. C., & Liu, F. S. (2015). Malat1
as an evolutionarily conserved lncRNA, plays a positive role in regulating
proliferation and maintaining undifferentiated status of early-stage hematopoietic
cells. BMC Genomics, 16, 676. http://doi.org/10.1186/s12864-015-1881-x
Matsumoto-Taniura, N., Pirollet, F., Monroe, R., Gerace, L., & Westendorf, J. M. (1996).
Identification of Novel M Phase Phosphoproteins by Expression Cloning. Molecular
Biology of the Cell Nurse, 7, 1455–1469. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC275994/pdf/mbc00016-0138.pdf
Michalik, K. M., You, X., Manavski, Y., Doddaballapur, A., Zörnig, M., Braun, T., …
Dimmeler, S. (2014). Long noncoding RNA MALAT1 regulates endothelial cell
function and vessel growth. Circulation Research, 114(9), 1389–1397.
http://doi.org/10.1161/CIRCRESAHA.114.303265
Morisaki, Y., Niikura, M., Watanabe, M., Onishi, K., Tanabe, S., Moriwaki, Y., …
Misawa, H. (2016). Selective Expression of Osteopontin in ALS-resistant Motor
Neurons is a Critical Determinant of Late Phase Neurodegeneration Mediated by
Matrix Metalloproteinase-9. Scientific Reports, 6(January), 27354.
http://doi.org/10.1038/srep27354
Richly, H., Rocha-Viegas, L., Ribeiro, J. D., Demajo, S., Gundem, G., Lopez-Bigas, N.,
… Di Croce, L. (2010). Transcriptional activation of polycomb-repressed genes by
ZRF1. Nature, 468(7327), 1124–1128. http://doi.org/10.1038/nature09574
Rinn, J. L., & Chang, H. Y. (2012). Genome Regulation by Long Noncoding RNAs.
Annual Review of Biochemistry, 81(1), 145–166. http://doi.org/10.1146/annurevbiochem-051410-092902

247

Ruzinova, M. B., & Benezra, R. (2003). Id proteins in development, cell cycle and
cancer. Trends in Cell Biology, 13(8), 410–8. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/12888293
Sauvageau, M., & Sauvageau, G. (2010). Polycomb Group Proteins: Multi-Faceted
Regulators of Somatic Stem Cells and Cancer. Cell Stem Cell, 7(3), 299–313.
http://doi.org/10.1016/j.stem.2010.08.002
Wilhelm, M. L., Reinbolt, J., Gangloff, J., Dirheimer, G., & Wilhelm, F. X. (1994).
Transfer RNA binding protein in the nucleus of Saccharomyces cerevisiae. FEBS
Letters, 349, 260–264. Retrieved from http://ac.els-cdn.com/0014579394006830/1s2.0-0014579394006830-main.pdf?_tid=b4a7df8a-6fe0-11e7-803e00000aacb35e&acdnat=1500839836_dfa5266605a2cda5b7e0558f94ab383a
Yan, W., Schilke, B., Pfund, C., Walter, W., Kim, S., & Craig, E. A. (1998). Zuotin, a
ribosome-associated DnaJmolecular chaperone. The EMBO Journal, 17(16), 4809–
4817. http://doi.org/10.1093/emboj/17.16.4809
Yin, K.-J., Hamblin, M., & Chen, Y. E. (2014). Non-coding RNAs in cerebral endothelial
pathophysiology: Emerging roles in stroke. Neurochemistry International, 77, 9–16.
http://doi.org/10.1016/j.neuint.2014.03.013
Yoshida, M., Inoue, T., Shoji, W., Ikawa, S., & Obinata, M. (2004). Reporter gene
stimulation by MIDA1 through its DnaJ homology region. Biochemical and
Biophysical Research Communications, 324(1), 326–332.
http://doi.org/10.1016/j.bbrc.2004.09.059
Zhang, L., Niyazi, H. E. X. D., Zhao, H. R., Cao, X. P., Abudula, M. N. S., Ye, W. J., …
Bao, Y. X. (2017). Effects of miRNA-143 and the non-coding RNA MALAT1 on
the pathogenesis and metastasis of HeLa cells. Genetics and Molecular Research :
GMR, 16(1). http://doi.org/10.4238/gmr16019269
Zhang, S., Lockshin, C., Herbert, A., Winter, E., & Rich, A. (1992). Zuotin, a putative ZDNA binding protein in Saccharomyces cerevisiae. The EMBO Journal, 11(10),
3787–96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1396572

248

CHAPTER 6
The ID3 Protein: A Novel, Potential Target for Therapy to Inhibit the Proliferative
Plexiform Lesion in PAH and NSCLC.
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Introduction
The proliferative vascular lesion is a major cause of high morbidity and mortality in
severe end stage IPAH patients because the pulmonary vascular lesion progressively
obliterate pulmonary arterioles and impinge upon the unobstructed vessels resulting in
heart failure. The prognosis of these patients remains poor because the current treatment
modalities rely on vasodilators, which are not designed to control the growth of PVL,
which has become a major clinical barrier for the treatment of end stage PAH. We have
earlier shown that PCB-induced ROS upregulated ID3 levels and this re-programmed
adult human ECs into iPSCs. Furthermore, we have demonstrated that ID3 signals
VEGFR3 expression in vitro (Das et al., 2015). Hence, our findings support the idea that
ID3 re-programs the adult ECs through inducing VEGFR3 to induce pluripotent
endothelial stem cells. This is consistent with the fact that VEGFR3 knockout mice are
embryonically lethal and display defects in remodeling the primary vascular plexus.
Recently, the expression of VEGFR3 has been shown in non-malignant orbital vascular
lesions (Atchison et al., 2016). Based on these evidences, we hypothesize that ID3VEGFR3 signaling act to drive stemness by enhancing proliferation and inhibiting
differentiation. Therefore, we propose that blocking this signaling pathway will suppress
stem cell–related cell proliferation. We postulate the following signaling pathway:
PCBs → ID3 → VEGFR3 and/or PCB → ROS → ID3→ VEGFR3
Our preliminary data have shown that PCB-induced ROS contribute to cell proliferation
and endothelial spheroid growth. Using the previously published data, we decided to use
BNC420 drug to check whether epigenetic regulation of ID3 is affected in the presence
and absence of PCBs.
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Materials and Methods
Cell culture and treatment conditions
Primary cells, Human pulmonary microvascular endothelial cells or Human lung
endothelial cells (HPMEC-ST1.6R.).

HPMEC cells were maintained in Dulbecco’s

modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.

Estrogenic chemical treatments
Stock solutions of PCB153 was prepared in DMSO. The same amount of DMSO as in
PCB and estradiol-treated cells were added to control cultures. The level of DMSO in
experimental media was less than 0.1%. PCB blood levels have been reported to reach
approximately 1000 ng/mL (∼3 μM) in occupationally exposed individuals (Wassermann
et al., 1979). Our unpublished data showed a significant increase in PCB- induced
vascularization with PCB153 concentrations of 10–100 ng/mL. Based on known PCB
blood levels from occupational exposure and our preliminary results; we chose a PCB
dose of 100 ng/mL (∼0.3 µM) to expose endothelial cells. Our previous studies also
showed endothelial cell proliferation and vascular tube formation at physiological doses
of 17β-estradiol (Das & Felty, 2014a; Felty, 2006; Felty & Porther, 2008b) therefore,
HPMEC and HPMEC ID3+ were exposed to estradiol at 100 ng/mL (∼3.6 nM). PCB
congeners

2,2′,4,4′,5,5′-hexachlorobiphenyl

(PCB153)

were

purchased

from

AccuStandard (NewHaven, CT) and dissolved in dimethyl sulfoxide (DMSO). All other
chemicals and reagents were purchased from Sigma (St. Louis, MO).
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BNC420 Treatment
Stock solutions of BNC420 was prepared in dimethyl sulfoxide (DMSO). The same
amount of DMSO as in PCB and estradiol-treated cells were added to control cultures.
The level of DMSO in experimental media was less than 0.1%. BNC420 is a novel
VEGFR3 selective inhibitor provided by Bionomics Limited via approved Material
Transfer Agreement (Leske et al., 2015). The single oral dose of BNC420 used in mice is
at 75 mg/kg, which is well below the IC50 value. This dose is equivalent to 0.15 mM
(Mol. Wt. = 501.55). We treated the cells with lower dose than 0.15 mM. Therefore,
BNC420 is dissolved in DMSO at a stock conc. of 10 mM and further to achieve working
concentration of 0.1 mM stock solution was diluted in culture medium for in vitro use as
per Bionomics suggestions.
ID3 overexpression
The HPMEC cells were stably transfected with either Precision LentiORF for ID3
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy.
Western blot
Whole cell lysates were prepared with lysis buffer containing 25 mM Tris-HCl buffer
(pH 8.0), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 8 mM b-glycerophosphate, 2.5 mM
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sodium pyro- phosphate, 10 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and 10 ml/ml
protease inhibitor cocktail (Sigma-Aldrich) followed the published protocol of our
laboratory (Das & Felty, 2014a). Proteins were quantified using the Bradford Assay
Reagent (Bio-Rad) according to the manufacturer’s instructions. Proteins (35–75 mg)
were separated by 15% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore). Membranes were blocked with 5% nonfat milk and incubated
with the following antibodies: ID3 (Cal BioReagent) and b-actin (Cell Signaling). Antibody dilutions used were according to manufacturer’s recommendations for detection by
immunoblot. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and
Secondary Ab- 1:10000. Membranes were then incubated with horseradish peroxidaseconjugated secondary IgG antibodies and visualized with ECL Plus Western blot reagents
(GE Healthcare, Amersham). The membranes were re-probed for b-actin as a loading
control. Electrochemiluminescence (ECL) intensity of detected target proteins was
imaged and quantified with a Bio-Rad Versa Doc instrument. All immunoblots have
completed a minimum of three times for each experiment.
Immunofluorescence
The cells will be fixed with methanol and incubated at −20 °C for 15 min.
Immunofluorescence staining was performed according to standard procedures. Briefly,
the cells were blocked with 3% normal goat serum at 4 °C for 1 h and then incubated
with antibodies: anti-ID3 overnight at 4 °C. After washing with 1× phosphate buffered
saline (PBS), cells were incubated with anti-mouse-IgG Alexa Fluor® 633 for ID3 (Santa
Cruz Biotechnology Inc.). Cells were washed with PBS mounted with Fluoromount-
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GTM re- agent. The spheroids with GFP or RFP were photographed and analyzed using a
Nikon C1 laser SCANNING confocal microscope.
Endothelial spheroid assay
HPMEC ID3+ cells were suspended in serum-free DMEM/F12 (1:1) culture medium
supplemented with B27. For EC spheroid formation, approximately 100–150 HPMEC
ID3+ cells were seeded separate well in an ultra-low attachment 96-well plate (Corning
Inc. Lowell, MA) followed the published protocol of our laboratory (Das & Felty,
2014a). The effect of estrogenic chemical PCB153 was determined by pre-treating the
cells with 100 ng/mL E2 2h prior to exposure with 100 ng/mL (∼0.3 µM) PCB153 on the
day of seeding cells. Endothelial spheroids were grown for 10 days in liquid culture in the
absence or presence of PCB153. A total of 15 endothelial spheroids with a minimum
diameter of 50 µm were counted in each experimental group. Pictures were taken on 10d
after seeding. We counted number and size of spheroids on 10d. Data were analyzed by
ANOVA; Tukey HSD test for multiple comparisons
MTT assay
To determine the effect of extra estrogen environmental pollutant PCB153 on the
metabolic activity of lung endothelial cells, we performed some cell viability and cell
proliferation assays. For cell viability measurement, we performed MTT assay which is
colorimetric assay and measures the metabolic activity of cells. Actually, MTT is a
tetrazolium dye known as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
NAD(P)H-dependent oxidoreductase enzymes present in mitochondria of metabolically
active and dividing cells. This enzyme catalyses tetrazolium dye and converts into
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insoluble formazan, which gives a purple colour (Berridge & Tan, 1993; M. V. Berridge
et al., 2005). The intensity of the purple colour which can be measured at an optical
density (OD) of 590 nm and its proportional to a number of metabolic active cells. We
seeded HPMEC and HPMEC ID3+ cells with 50% confluence in 96 well clear-walled
plate. We allowed the cells to grow for 24h in 5% FBS culture medium. After 24 hours,
we gave treatments, 0.1% DMSO (control), PCB153 (100 ng/mL) to make total volume
100 µL in each well. We measured the metabolic activity of cells after 48h with the
addition of MTT dye and evaluating the purple colour intensity at 590nm.
SRB assay
The sulforhodamine B (SRB) assay is used for measurement of the total cellular protein
content of adherent cells in a 96-well format. This assay is useful in the determination of
cellular proliferation and growth. We seeded HPMEC and HPMEC ID3+ cells with 50%
confluence in 96 well clear-walled plate. We allowed the cells to grow for 24h in 5%
FBS culture medium. After 24 hours, we gave treatments, 0.1% DMSO (control),
PCB153 (100 ng/mL) to make total volume 100 µL in each well. After an incubation of
48h, cell monolayers were fixed with 10% (wt/vol) trichloroacetic acid and stained for 30
min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol)
acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD
determination at 590 nm using a microplate reader (Vichai & Kirtikara, 2006).
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BrdU assay
BrdU assay is a direct method for evaluation of cell proliferation. In this rapid method,
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic nucleoside and
analogue of thymidine gets incorporated into DNA synthesis of proliferating cells. It is a
suitable method for detection and quantification of the stimulatory effect of
environmental chemicals (Russo et al., 1984). For BrdU assay, we used Roche’s kit and
followed the manual instructions.
We seeded HPMEC and HPMEC ID3+ cells in 5% FBS DMEM F-12 media with 50%
confluence and cultured with addition of BrdU in 96 well clear-walled plate. After 24
hours, we gave treatments, 0.1% DMSO (control), PCB153 (100 ng/mL) to make total
volume 100 µL in each well. After an incubation of 48h, cell monolayers fixed with
FixDenat. Followed by fixation we added anti- BrdU-POD, which binds to BrdU in
newly synthesized DNA. This immune complex detected by a plate reader at 450 nm.
STATISTICAL ANALYSIS
All experiments were performed at least three times and data are expressed as mean ±
standard deviation Graphpad prism version 5.01 was used to perform graphics and the
two-tailed student’s t-test was used to compare statistical significance. P<0.05 was set as
a statistical significance. Data were analyzed by ANOVA; Tukey HSD test for multiple
comparisons.
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ResultsSelection of optimum BNC420 Treatment dose
BNC420 is a novel VEGFR3 selective inhibitor made by company Biogenomics. It has
been shown in mouse model that angiogenesis specially inhibited by BNC420. In every
protein targeted molecular drug treatment research revolved around ensuring cellular
protein homeostasis. The efficacy of drug treatment is based on assessment of how it
affects cellular viability, that is, their cytotoxic effect. Investigations of cytotoxicity often
require testing several different concentrations and drug exposure times using cells in
culture. Therefore, we used colorimetric tetrazolium salt assay to test putative cytotoxic
effects associated with exposure to a BNC420. MTT assay monitors metabolic activity of
cultured cells, was adapted to analyze the viability of cells exposed to BNC420. It was
found that 24h exposure to increasing concentration of BNC420 reduced the viability of
lung EC ID3+ cells, with the most severe effect observed at 10 µM dose of 24 h exposure
with MTT reductions approaching 30% of non-exposed cells as shown in Figure 104. For
a series of incubations for 24 h, it was found that concentration 0.1 µM did not affect the
viability, and BNC420 concentrations of 0.5 µM reduced the MTT reduction rate to
approximately 20% the level displayed by cells receiving vehicle alone. Generally, less
than 10 µM concentration of a drug in plasma is accepted because higher than 10 µM of a
drug inhibit necessary enzymes. The most of the drugs on the market have less than 10
µM therapeutic plasma concentrations. In most cases, the IC50 of the best candidate
compound should be lower to 10 µM, which is acceptable for NIH to screen the NCI60
program. Therefore, lower dose the IC50 of candidate drug was, the higher potentially it
become the new drug for any diseases. (Hansen & Bross, 2010; Hughes, Rees,

257

Kalindjian, & Philpott, 2011; Wang, Newton, Liu, Atkins, & Lu, 2000; Williams et al.,
2002). We decided to use the dose of 0.1 µM to treat the lung cell and measure the
changes at molecular level in the expression level of ID3 protein as well as phenotypic
changes. The single oral dose of BNC420 used in mice is at 75 mg/kg by Biogenomics
Company, which is well below the IC50 value. This dose is equivalent to 0.15 mM (Mol.
Wt. = 501.55). We tried to mimic similar drug concentration in Lung EC ID3+ cells with
lower dose than LC50 value. We treated the cells with lower dose than 0.15 mM.
BNC420 inhibited Lung EC ID3+ cells with 50% survival at 15 µM.

Effect of BNC420 on Lung EC ID3+ cells survival
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Figure 104- Graph of cell cytotoxity assay for BNC420 drug
Graph of cell survival was determined 24 h after exposure to BNC420. LC50∼15 µM by
using MTT assay. Results shown are averages of triplicates ± SD (<10%).
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BNC420 inhibits PCB153-induced lung endothelial cell proliferation
We have earlier tested the lung endothelial cell proliferation in presence of estrogenic
chemicals by MTT, SRB and BrdU assay. In this experiment, we tested the effect of
BNC420 drug on the cell proliferation of HPMEC ID3+ cells in presence or absence of
PCB153. The PCB153 induced cell proliferation measured by MTT, SRB and BrdU
assay. We tested range of BNC420 concentration starting from 10 µM to 0.1 µM (Figure
105 A,B,C). Our data revealed that in presence of treatment PCB153 (100 ng/mL) with
addition of different concentration of BNC420 drug ranges from 10 µM to 0.1 µM
showed a significant gradual inhibition in cell proliferation. We measured the growth in a
number of cells in terms increase in OD value. Our MTT assay results were corroborated
by SRB and BrdU assay. The data from SRB and BrdU assays reported that treatment
PCB153 (100 ng/mL) showed a significant gradual inhibition in cell proliferation. In
terms of SRB assay, the total protein content of treated cells was inhibited. The BrdU
assay data results showed the synthesis of new DNA in proliferating cells was
significantly inhibited in treatments than control. These results prove that PCB153 (100
ng/mL) is an estrogenic chemical drives the endothelial cells proliferation. These data
shows that BNC420 with dose of 0.1 µM and 1 µM effectively inhibits PCBindcued
cellulr proliferation without having any cellular toxicity effects.
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260
PCB153 (100ng/ml)

BNC420(0.1µM)

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

BNC420(0.1µM)

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

PCB153 (100ng/ml)

control

Absorbance OD at 590 nm

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

BNC420(0.1µM)

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

PCB153 (100ng/ml)

control

Absorbance OD at 590 nm

Lung EC ID3 MTT assay

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

PCB153 (100ng/ml)

Treatments

Lung EC ID3 SRB assay

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

BNC420(0.1µM)

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

BNC420(0.1µM)

BNC420(0.5µM)

BNC420(1µM)

BNC420(5µM)

BNC420(10µM)

PCB153 (100ng/ml)

0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

control

Absorbance OD at 450 nm

Lung EC ID3 BrdU assay

PCB153 (100ng/ml)

Treatments

Figure 105 A, B, C- BNC420 inhibits the PCB153 induced cell proliferation
A, B, C- BNC420 inhibits the PCB153 induced cell proliferation measured using
MTT, SRB and BrdU assay 24 h after exposure to BNC420. Results shown are
averages of triplicates ± SD (<10%).
BNC420 inhibits PCB153-induced lung EC spheroid formation
The endothelial cells lines the innermost layer of artery maintains the balance between
vasoconstriction and vasodilation of pulmonary artery. When endothelial dysfucntion
happens, the cells undergo proliferation and form plexiform lesions, which grow in the
three-dimension structure resembles spheroid. These cells do not follow characteristics of
the cells, which grow in a monolayer. The cells derived from tumour tissue alter their
both genotype and phenotype characteristics once they cultured in monolayer (Lee et al.,
2006). Therefore, we tried to imitate the conditions of tumour in vitro. In addition to this,
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recent data from our laboratory showed that ID3 induced a molecular stem cell-like
signature—CD133+ VEGFR3+ CD34+ in microvascular ECs. These spheroid also form
angiogenic sprouting network. We grew the cells in no FBS DMEM F-12 medium
supplemented with B-27 reduced growth supplement. We used a stem cell sphereforming assay to determine the effect of BNC420 drug on HPMEC ID3+ cells spheres.
We treated spheroid-containing wells with 0.1 µM BNC420 in presence or absence of
estrogenic chemicals like E2 and PCB153 as shown in Figure 106. We checked whether
BNC420 inhibits spheroid growth of HPMEC ID3+ cells. We found that BNC420
significantly inhibited the growth of spheroids in terms of spheroid number and spheroid
size compare to E2 and PCB153 treated spheroid-containing wells as shown in Figures
107 and 108.

Figure 106- shows pictures of spheroids with BNC420 treatment.
BNC420 treatment decreases Spheroid size and number in the PCB153 and E2 treated
wells. The decrease in the size and number of spheroid in BNC420 treated wells are
significantly lower compared to respective control. Scale bar= 10µm.
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Figure 107- BNC420 treatments decreased the size of spheroids compared to control.
Graph shows quantification of spheroid diameter. Error bars represent the mean sphere
size ± SD in 5 spheres. E2 & PCB153= 100 ng/ mL. Representative microphotographs of
treatment groups are shown inset. E2 & PCB153= 100 ng/mL. BNC420= 0.1 μM
Measurements were performed from a representative experiment repeated three times in
triplicate. (*a) BNC420 treatment significantly different from vehicle control at (P<0.01).
(**) PCB & E2 treatment significantly different from vehicle control at (P<0.01). (*)
BNC420 treatment significantly different from PCB153 + BNC420 & E2 + BNC420
(P<0.05) at day 10 Data; Tukey HSD test for multiple comparisons. Magnification X200.
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Figure 108- BNC420 treatments decreased the number of spheroids compared to
control.
Graph shows quantification of spheroid number. Error bars represent the mean sphere
number ± SD in 5 wells. E2 & PCB153= 100 ng/mL. BNC420= 0.1 μM Measurements
were performed from a representative experiment repeated three times in triplicate. (*a)
BNC420 treatment significantly different from vehicle control at (P<0.01). (**) PCB &
E2 treatment significantly different from vehicle control at (P<0.01). (*) BNC420
treatment significantly different from PCB153 + BNC420 & E2 + BNC420 (P<0.05) at
day 10 Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
Magnification X200.

BNC420 inhibits PCB153-induced ID3 expression
We performed immunoblot and fluorescent microscopy experiment after detecting
change in spheroid and cell viability assay due to the treatment of BNC420. The
immunoblot and fluorescent microscopy results revealed that BNC420 significantly down
regulated ID3 protein expression in lung EC ID3+ cells compared to control as shown in
Figure 109, 110 and 111.
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Control

BNC420

PCB153

BNC420 +PCB153

Figure 109- Representative images of fluorescent microscopy to study the effect of
BNC420 drug on ID3 expression
Fluorescent microscopy experiment was used to compare the effect of BNC420 0.1 µM
on PCB153 treated lung EC ID3+ cells. The experiment showed that BNC420 treatment
decreased the expression of ID3. BNC420= 0.1 μM, PCB153 = 100 ng/mL (∼0.3 µM).
Scale bar= 50 μm

Figure 110- Western blot analysis of inhibition of PCB-induced ID3 expression
by BNC420
The experiment shows inhibition of ID3 protein by 0.1 µM BNC420 dose with or
without exposure to PCB153. BNC420= 0.1 μM, PCB153 = 100 ng/ mL (∼0.3 µM).
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Figure 111- The relative expression level of ID3 protein in BNC420 drug treated
lung EC ID3+ cells
Shows the relative expression level of ID3 protein in lung EC ID3+ cell line when
treated with PCB153, BNC 0.1 μM and PCB153 + BNC 0.1 μM. PCB153 = 100 ng/
mL
(∼0.3 µM). (*) PCB513 treatment significantly different from PCB153 +
BNC420 (P<0.05) at day 10 Data were analyzed by ANOVA; Tukey HSD test for
multiple comparisons.
Conclusion
Using a novel VEGFR3 selective inhibitor BNC420 (provided by Bionomics Limited via
approved Material Transfer Agreement), we determined BNC420 treatment of hiPSCs
controls the epigenetic regulation of ID3 and regression of PCB-induced vascular lesions
in vitro. These results are very promising can give impetus for further development of
BNC420 drug and can used as a molecular target against ID3 protein. Molecular targeting
overexpreesed ID3 expression can regress angiogenesis and lung EC cell proliferation
which are markers of NSCLC and PAH.
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Overall summary

Stable ectopic expression of ID3 in lung endothelial cells contributed to endothelialmesenchymal transition (EndMT) and cell proliferation. ID3 overexpressing cells showed
the loss of VE-cadherin and gain of N-Cadherin and vimentin, which are markers of
EndMT. Using an endothelial spheroid assay, an established method to measure aberrant
hyper-proliferation of endothelial cells in PAH patients, we show that stable ectopic
expression of ID3 increased the number and size of vascular spheres.
We investigated ID3 transcriptional reprogramming using ChIP-seq and RNA-seq
technology. We show here for the first time that ID3 is part of a more general mechanism
of transcriptional regulation. Our ChIP-Seq data show that ID3 binds to a subset of
approximately 1200 target genes. Comprehensive motif analysis of ChIP-seq data using
the MEME Suite software toolkit revealed that ID3 bound to the GAGAGAGAGA motif
sequence on genomic DNA. We also show a significant preference of ID3 binding to
motifs associated with transcription factors IRF1, ZRF1, BC11A, IRF4, PRDM1, FOXJ3,
SMAD4, ZBTB6, GATA1, and STAT2. Using an integrative approach of ChIP-Seq and
RNA-Seq data, we identified 27 genes was bound by ID3 and RNA was differentially
expressed in ID3 overexpressing cells.
Our data demonstrated that PCB153 and/or ID3 induces proliferation of lung endothelial
cells via transcriptional reprogramming. Discoveries from these findings will lay the
necessary groundbreaking work for testing the efficacy of ID3 antagonists for the
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prevention and treatment of pathological vascular remodeling as well as provide a new
paradigm by which PCBs may contribute to lung vascular toxicity.
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